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South Africa has the highest vwrld prevalence of porphyria 
cutanea tarda (PCT)(?O), a disorder of haem metabolism. The disease 
presents as a purely cutaneous disorder, with excessive fragility of 
the skin, which results in considerable disability especially in man~ 
ual vwrkers. PCT is one of the hepatic porphyrias, as classified 
in recent reviews< 193 , 219 ), and occurs "in many thousands of patients 
in South Africa(74). Thus in spite of relatively infrequent occur-
rence on a world-\'iide basisC1 93), this disorder constitutes a major 
health problem in this country. 
The disease occurs mostly as an unusual accompaniment of com-
man hepatic disorders e.g. alcoholic liver disease. However, there 
have been reports of epidemics of PCT in groups of people when they 
were exposed to porphyrogenic hepatotoxins( 2l, 57 , 251 ). One of these 
toxins is hexachlorobenzene (HCB), which caused an outbreak of PCT 
ii1 Turkey when seed wheat treated with a fungicide containing HCB 
was used for human consumption<57 ). The disturbance of haem meta-
bolism in PCT biochemically manifests itself as a unique pattern of 
porphyrin overproduction and excretion. In particular, there is a 
marked increase of urinary URO and heptacarboxylic porphyrin ex-
cretion<74), which reflects the accumulation of these porphyrins 
in the liver< 23 ,64 , 65 >. In addition, there is a significant quan-
tity of porphyrin P1 fraction (isocoproporphyrin and de-ethyliso-
coproporphyrin) excreted in the faeces< 79 ). 
The main purpose of this thesis is to study the derangement 
of haem metabolism in PCT. In order to amplify necessarily 
limited data from humans, experimental data was obtained from 
2 
rats treated with HCB, so that data from both sets of observations 
could be correlated. It has been shown that experimental porphy-
ria develops in rats treated with HCB( 2lO, 252 ,253 ,255 ), and 
. furthermore,there are certain similarities between idiosyncratic 
PCT and HCB-induced rat porphyria. Firstly, there is the character-
istic urinary pattern of porphyrin excretion both in PCT and in HCB-
treated rats, including large amounts of porphyrins with 8,7 ,6 ··and 
5 carboxyl groups( 74 ,210 , 246 ). Secondly, the isocoproporphyrins 
are present in the faeces( 77 ,7s, 79 ), and thirdly, livers are morpho-
1 ogi ca lly abnormal in both situations {l 43'l44'186 ,250,253' 307 ~~l l). 
Differences between PCT and HCB-induced rat porphyria are principally 
in the isomer composition of excreted porphyrins and liver porphyrins, 
these being mainly of the III series in the rat( 246 ), whereas in PCT 
URO is mainly of the isomer I series, with other porphyrins being mix-
tures of both series of isomers{G5). 
Because of the biochemical similarities between human PCT and 
HCB-induced rat porphyria, it was decided to determine whether bio-
chemically the HCB-rat 11model 11 resembled the human disease on more 
detailed studies. If this were to be borne out, then some basic 
aspects of the metabolic disorder in the HCB-intoxicated rat might 
point the way to finding a similar defect in PCT which may allow for 




THE PORPHYRIAS - WITH SPECIAL REGARD TO PCT AND HCB-INDUCED PORPHYRIA 
2. l Definition and Classification of the Porphyrias 
The porphyrias may be defined as a group of acquired or in-
herited clinical illnesses, characterised by porphyrin and/or porphy-
rin-precursor overproduction, accumulation and excretion. Classifi-
cation of the porphyrias is based on clinical manifestations and 
unique patterns of p9_rphyrin and porphyrin-precursor excretion in 
urine and faeces. (Fig. I). 
Porphyrins are haem precursors( 3B), haem being the prosthetic 
group of haemoproteins, whose major functions are transport and utili-
sation of oxygen. The major sites of haemoprotein synthesis in 
mammals are the liver and bone marrow, so that in the porphyrias, 
metabolic derangement of haem biosynthesis manifests principally in 
the liver or bone marrow or both. In 1954, Schmid et a1(
257
) 
proposed a classification of the porphyrias into 2 groups, viz. 
hepatic and erythropoietic. A third group, the erythrohepatic 
porphyrias, was proposed(83,219) because of increasing evidence 
of liver involvement in erythropoietic protoporphyria. A 
working classification of the porphyrias is given in Table l. 
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Bi osyntheti c pathway of haem i 11 ustrati ng the pattern 
of precursor excretion in the hepatic porphyrias and 
the regulation of ALA-S by the end product, haem. 
ALA= 6-Aminolaevulinic acid; PBG = porphobilinogen; 
URO'GEN = uroporphyrinogen; COPRO'GEN = coproporphyri-
nogen; URO = uroporphyrin; COPRO = coproporphyrin; 
PROTO = protoporphyrin IX; AIP = acute intermittent 
porphyria; PCT = porphyria cutanea tarda; HCP = 
hereditary coproporphyria; VP = variegate porphyria. 
TABLE l 
Classification of the Porphyrias~ together with Synonyms 
I. Erythropoietic Porphyria 
Congenital erythropoietic porphyria (congenital 
photosensitive porphyria, Gunthe~s disease). 
II. Hepatic Porphyria 
A. Genetic autosomal dominant porphyrias 
l. Acute intermittent porphyria (intermittent 
acute porphyria, acute porphyria, Swedish 
porphyria, pyrroloporphyria). 
2. Variegate porphyria (porphyria variegata, 
South African genetic porphyria, mixed 
hepatic porphyria, porphyria cutanea 
hereditaria, protocoproporphyria). 
3. Hereditary coproporphyria. 
B. Porphyria cutanea tarda (symptomatic porphyria, 
acquired porphyria, constitutional porphyria, 
idiosyncratic porphyria, toxic porphyria, uro-
coproporphyria, porphyria cutanea tarda sympto-
matica, porphyria cutanea chronica, Bantu porphyria). 
1. Idiosyncratic 
2. Toxic 
3. Porphyrin-producing hepatic neoplasms. 
I I I. Erythrohepati c protoporphyri a ( erythropoieti c protoporphyri a, 
protoporphyri a). 
4 
A secondary type of coproporphyrinuria can occur in other condi-
tions and does not in itself produce symptoms or classic signs of cutan-
t h . ( 219). eous or acu e porp yr1a · . 
A number of reviews on the porphyrias have appeared(l6,57,68, 70 
72~83,107,193,219,293,303) in which the clinical manifestations and 
diagnosis of the different types of porphyria have been well documented. 
5 
2.2 PCT - Historical Considerations 
Gunther(llB) in 1911 described for the first time in the litera-
ture the disease now known as PCT. At the time the disease was 
designated "haematoporphyria chronica 11 , although he later considered 
this disease a mild and late form of porphyria congenita(ll 9), now 
known as congenital (erythropoietic) porphyria. Waldenstrom{ 315 ) 
introduced the term "porphyria cutanea tarda" (PCT) in place of 
Gunther's "chronic porphyria" to describe a group of patients who 
developed a cutaneous form of porphyria after puberty. This term 
clearly differentiated "chronic porphyria 11 from congenital erythro-
poi et_i c porphyri a, which was present from birth, and from acute 
intermittent porphyria, in which cutaneous symptoms do not occur. 
It was established by reports subsequent to that of Waldenstrom that 
PCT was principally a disease of men over the age of 40, who frequently 
gave a history of alcoholism and showed evidence of impairment of 
liver function. Furthermore, these patients suffered no attacks of 
acute porphyri a and a family history of porphyri a was uncommon (35' .36' 
292) 
Much confusion has arisen out of the term 11 porphyria cutanea 
tarda". The term impl·ies a slow or late onset of cutaneous porphy-
ria, although cases of PCT have been reported in children{ll ,?O), and 
furthermore, the outbreak of PCT in Turkey was primarily a disease of 
children and adolescents( 57). Until 1958, the hereditary porphyria 
now known as variegate porphyria was included with PCT(l32,l88). Thus 
in earlier reports(42,63,ll3,132,188,239,3l9,325)cases of PCT were 
described where skin lesions and acute attacks occurred but the 
patients were, in general, younger than 40, and there was familial 
evidence of porphyria. In the United States of America these cases 
were described as 11 mixed porphyria 11 ( 320 ) and the term 11 porphyria 
cutanea tarda 11 was used only for cutaneous "middle-aged alcoholic" 
porphyria. l~aldenst;om( 316 ) in 1957 recognised that the disease 
6 
that had hitherto been referred to as 11 porphyri a cutanea tarda" ~ms in 
fact a mixed group of two diseases. Patients with skin lesions and 
acute attacks were reclassified as 11 porphyria cutanea tarda heredi-
taria 11 • Those patients in whom the disease manifested by skin 
lesions only and in whom there was an onset of porphyria later in 
life, were reclassified "porphyria cutanea tarda symptomatica". 
. ( 58) 
Dean and Barnes in 1958 described cases of "porphyria cutanea 
tarda hereditaria 11 in South Africa as "porphyria variegata" 
because of variety of presentation of this disease. Porphyria 
variegata or variegate porphyria was shown to have an autosomal 
dominant pattern of inheritance( 56 ,69 ). It was later showJ.75,288) 
that the porphyrin excretion patterns in "porphyria variegata" and 
"porphyria cutanea tarda symptomatica" were quite distinct, so that 
the existence of a purely cutaneous form of hepatic por~hyria became 
established. 
In recent years, the condition has been called "symptomatic 
cutaneous hepatic porphyria 11 ( 33 ) or "symptomatic porphyria( 69 ). 
With( 327) has proposed "porphyria cutanea chronica" for the disease. 
I propose to use "porphyria cutanea tarda" (PCT) because I feel there. 
has been no general agreement on terminology to describe the disease. 
However, the term porphyria cutanea tarda (PCT) is to be construed in 
its strictest sense, i.e. to describe a purely cutaneous form of par-
phyria, usually with evidence of liver disease, and clinically with no 
clear-cut pattern of inheritance and with attendant biochemical abnorm-
alities. 
2.3. PCT - Clinical Considerations 
Manifestations of PCT appear as a sporadic reaction to a 
variety of liver diseases. PCT presents as a purely cutaneous 
disorder, indistinguishable clinically from purely cutaneous varie-
gate porphyria (VP) in remission,and excessive fragility of sun-
exposed skin is characteristic~in both. f,ven slight trauma leads 
to erosion formation and the development of blisters or bullae{fil, 
7 
70,219) Patients with PCT develop no acute attacks with accompany-
ing abdominal pain and neurological complications however, and reaction 
to drugs, which in patients with VP or acute intermittent porphyria 
can precipitate acute attacks, is normal( 293 ). Further, there is .. 
almost invariably evidence of hepatocellular disease, and on analysis 
a unique pattern of porphyrin excretion is found. There appears to 
be no evidence of PCT being a hereditary disease. 
As shown in Table l, PCT can be subdivided into 3 categories: 
(a) Idiosyncratic PCT occurs as an unusual accompaniment of 
liver disease, frequently alcoholic liver disease with 
siderosis. PCT may follow Bantu siderosis, ingestion of 
oral contraceptives and immunopathic disorders usually 
involving connective tissue. The fact that only a mino-
rity of patients with these relatively common liver ail-
ments have coexisting PCT might be indicative of an 
occult genetic abnormality( 321 ). However, there is 
little unequivocal evidence that idiosyncratic PCT is 
a purely inherited form of porphyria( 74 ,219 ). 
Idiosyncratic PCT in South Africa occurs mainly in 
the Bantu population(9,70, 164) but there are many cases 
in the Cape Coloured and White population groups( 69 ). 
PCT manifests mainly after the age of 45, but EalesVO) 
has reported two unrelated children of ages 8 and 15 
years with the disease. · Alcohol appears to play an im-
portant role in the genesis of PCT in about 90% of the 
cases(lO), but other factors need ~o be taken into 
account, viz. iron overload, malnutrition and protein 
deficiency( 74 ). A factor of great importance, and one 
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which should be taken into account when considering the 
development of PCT in the Bantu of South Africa, is that 
members of this population group frequently partake of 
illicitly brewed "Kaffir Beer" which can contain porphyrogenic 
toxins(lSl). 
In a study of 42 patients with PCT, histopathology revealed 
changes associated with alcoholic liver disease( 3ll). These 
changes reflected the whole range of alcoholic liver disease9 
with liver damage in the mildest form being fatty change. 
Siderosis was found to be invariably present. This finding 
has been substantiated by other authors(l 43 , 144 , 186, 250, 
307): Timme( 298) has described lesions, thought to be 
typical of PCT, on electron microscopy of liver from patients 
with this disease. 
Oral contraceptives have been imolicated in the precipita-
tion of idiosyncratic PCT( 168,193 ) , but although liver 
damage is present on histological examination, siderosis is 
unusual in these cases~ 
Immunopathic diseases which occur in association with PCT 
have been well described( 219 ). 
(b) Toxic PCT results usually from exposure to chemicals which 
can cause porphyria. The first clear instance of toxic 
PCT in man was the Turkish "epidemic 11 which has been well 
documented by Schmid( 251 ) and DeaJ57 ). ·This disease affected 
several thousand individuals, predominantly children and 
adolescents, in 3 south-eastern provinces in Turkey, between 
1955 and 1959. The children had blisters and sores on the 
hands and face, with dark pigmentation and particularly pro-
nounced hairiness of the face. Hepatomegaly was present, and 
liver function tests showed impairment of liver function. 
Urine was dark red or brown, containing ether-soluble and 
ether-insoluble porphyrins, but no porphobilinogen (PBG) 
was present( 57 ). These findings were virtually identical 
to those in Bantu PCT{lo, 44 ), Epidemiological studies in-
dicated that the toxin causing the PCT was a fungicide 
( c) 
containing HCB, used in the treatment of wheat(Sl, 251 ). 
No new cases of porphyria have been reported from Turkey 
since 1960, which coincides with the HCB-treated wheat 
having been withdrawn in 1959. An additional factor 
which pointed to the HCB being the toxic agent was that 
rats when treated with this toxin developed experimental 
porphyria (210,252,253,255). 
Toxic PCT has been reported in workers in a chemical 
factory \.'1here the herbicide 2 ,4 ,5-tri ch l orophenoxyaceti c 
acid was manufactured( 2l). The most likely causative 
agent in this outbreak of PCT would have been 2,3,7,8-
tetrachlorodibenzo-p-dioxin(223a), a porphyrbgenic contami-
nant which is frequently formed during the synthesis of 
2 ,4 ,5-tri ch 1 orophenoxyaceti c acid. 
A porphyrin-producing hepatic neoplasm, associated with 
a PCT-like syndrome has been reported by Tio et al( 3oo). 
The tumour fluoresced, and appeared to be the source of 
the increased porphyrin excretion, since removal of the 
neoplasm resulted in remission of the syndrome in the 
patient. 
2.4. PCT - Biochemical Considerations 
As has been stated, the porphyrias can be distinguished 
biochemically by virtue of the fact that in each of the porphyrias 
there is a characteristic pattern of porphyrin excretion (Fig. I). 
In patients with idiosyncratic PCT, there is a markedly increased 
urinary excretion of ether-insoluble porphyrins, principally URO 
(8-COOH) and heptacarboxylic porphyrin (7-COOH) and smaller amounts 
of hexa- and penta-carboxylic porphyrins (6-COOH and 5-COOH)( 74 ). 
Urinary quantities of 6-aminolaevulinic acid {ALA) and PBG in this 
condition are normal(9, 69, 164}. Faecal porphyrins are normal or 
9 
moderately increased, but generally the COPRO (4-COOH) fraction exceeds 
10 
the PROTO (2-COOH) fraction{69,73,75,83,288). Probably 
as much porphyrin is excreted by this route as in the urine{288 ), 
URO is a minor component of faecal porphyrins in PCT and is of 
little diagnostic value{ 74 ). Elder( 77 )showed that much of the 
faecal COPRO fraction in PCT consisted of a mixture of tetracarboxy-
lated porphyrins, designated as Pl, P2 and P3. Tentative identi-
fication showed Pl was a mixture of isocoproporphyrin and de-
ethyl isocoproporphyrin, P2 was hydroxyisocoproporphyrin and P3 
was a hydrophillic conjugate of isocoproporphyrin{ 78 ). The main 
porphyrins of this type present in the faeces were found to be iso-
coproporphyrin and de-ethylisocoproporphyrin{ 79 ), i.e. the Pl 
fraction. 
Of the urinary porphyrins excreted in PCT, URO is about 70% 
isomer I, 7-COOH and 6-COOH porphyrins almost all isomer III, with 
5-COOH porphyrin and COPRO 50% isomer I( 65 ). The large quantity 
and the isomer composition of URO in PCT is in contrast to that found 
normally, where URO I is produced and excreted in very small amounts. 
In addition to the excretion of URO and 7-COOH porphyrin, 
there is an accumulation of these porphyrins in the liver, as might 
be expected. Liver biopsy samples from patients with PCT, viewed 
under ultra-violet light, show an intense red fluorescence{8B,3llJ. 
On microscopic study, the fluorescence attributable to the porphyrins 
was found in the cytoplasm of the liver cells, but in a freely dif-
fusible form(BB). An interesting, but unexplained phenomenon is 
that increased amounts of porphyrin can persist within the hepato-
cyte after complete clinical and biochemical remission( 88 ). On 
analysis of porphyrins present in PCT liver, mainly URO and 7-COOH 
. ( 23 ,64 ,65) . h . . l . h . I porphyr1n are found ' wit URO pr1nc1pa ly 1n t e isomer 
form. The large quantity of porphyrin present in the liver, 
11 
especially URO, underlies the unique ~esponse of patients with 
PCT to chloroquine administration. In therapeutic doses, chloro-
quine produces transitory liver damage associated with nausea, 
vomiting and fever. This is accompanied by massive uroporphyrin-
uria {291) because chloroquine forms a water soluble complex with 
URO, which is readily excreted in the urine{ 261 ). 
2.5. PCT - Treatment 
Treatment resulting in clinical and biochemical remission 
of this condition has been well documented~3 ,21 9 ). Withdrawal 
of the offending agent in the specific PCT syndromes may lead to 
clinical and biochemical improvement although the syndrome may per-
sist in toxic PCT and in alcoholic liver disease with idiosyncratic 
PCT, if underlying liver disease has been established. The removal 
of storage iron by repeated venesection over a period of a few 
months produces a clinical and biochemical remission in the majority 
of patients with idiosyncratic PCT. 
2.6 HCB Porphyria in the Rat 
As has been stated in section 2.3.(b), experimental porphyria 
developed in rats treated with HCB{210,252,253,255). Experi-
mental porphyria has been induced also with HCB in guinea pigs, 
mice, rabbits{ 62 ), in chick embryo liver cultures(lOS) and in 
bi rds ( 286 ) . 
Rats treated with HCB for a prolonged period of time (4 - 8 
weeks) have hepatomegaly, tremor, ataxia, weakness and paralysis( 290 ), 
and show a high mortality rate{ 2lO). There is a marked increase in 
the excretion of urinary porphyrins in these rodents( 2lO). The 
relative urinary excretory pattern of porphyrins in rats treated 
12 
with HCB is URO>COPR0>7-COOH>5-COOH>6-COOH, with these porphyrins 
being of the isomer III series. There is accumulation of porphyrin 
in the livers, the major porphyrins are URO III and 7-COOH porphyrin 
(246) 
i.e. 
Faeces have been shown to contain the porphyrin Pl fraction 
isocoproporphyrin and de-ethylisocoproporphyrin(?B). 
Livers of rats that have been treated chronically with HCB, 
show fluorescence in islands of tissue surrounding the central 
veins, when viewed under a fluorescent microscope( 290). Liver 
damage is apparent on light microscopy, with focal necrosis and 
increased size and number of Kupffer cells( 2 ~ 3). An increase in 
smooth endoplasmic reticulum is shown on electron microscopy( 290 ). 
Marked induction of hepatic cytochrome P450 has been reported in 
t ft t t t "th HCB(23~175,231 ,282,290,308) · ra s a er rea men w1 • 
.. CHAPTER 3 
3.1. ··Aims· of the Study 
The aims of this investigation were threefold: 
(a) To study disordered haem biosynthesis in patients with 
PCT. Parameters studied were: 
(i) Hepatic ALA-synthetase (ALA-S) activity. 
(ii) Hepatic cytochrome P450 levels. 
(iii) Hepatic cytochrome P450-dependent enzyme systems 
which metabolise aminopyrine and 3,4-benzpyrene. 
-(fv) Liver ultrastructure by electron microscopy. 
(v) Degree of liver damage and liver fluorescence by 
light and ultraviolet microscopy. 
{b) To study disordered haem biosynthesis in HCB-induced rat 
porphyria. Parameters studied were: 
(i) Urinary, faecal and hepatic porphyrins. 
(ii) Hepatic cytochrome P450 levels. 
(iii) Hepatic cytochrome P450-dependent enzyme 
systems whiCh metabolise aminopyrine and 
3,4-benzpyrene. 
(iv) Hepatic uroporphyrinogen (UROGEN) I decarboxy-
1 ase. 
(v) Effects of iron on hepatic UROGEN I decarboxy-
lase and the effects on faecal and hepatic 
porphyri ns. 
(c) To study the activity of UROGEN I decarboxylase in red 
13 
blood cells from patients with PCT and their relatives to determine 
whether measurement of this enzyme provides a sensitive means of 
testing any genetic predisposition for development of PCT. 
14 
3.2. Rationale for the Study 
Haem formation is regulated (Fig. l) by the activity of the 
first and rate-limiting enzyme in the haem biosynthetic pathway, 
ALA-S(lOB,lll,l 92 ). This is repressed by haem, the end product, 
probably at a level of translation( 248 ,284 , 309 ). The unique 
porphyrin excretory pattern in PCT (Fig. l) suggests impaired de-car~ 
boxyl ati on of UROGEN to PROTO The increased porphyri n production 
in PCT is not clearly understood and conflicting data has been pub-
lished relating to the activity of hepatic ALA-s( 66 ,149,1 68,204,283, 
285,328) For this reason, the activity of this enzyme was re-
investigated, using a highly specific method of assay. 
Further to the suggestion that the biochemical defect in PCT 
would relate to a partial block in the conversion of UROGEN to PROTO 
in the haem biosynthetic pathway, a more direct assessment of hepatic 
haem synthesis in this syndrome was attempted by measurement of levels 
of hepatic cytochrome P450. Cytochrome P450 is a rapidly turning-
over microsomal haemoprotein, and its synthesis would be expected to 
require a considerable quantity of haem and its precursors. Thus, 
by measurement of hepatic cytochrome P450 in patients with PCT, it 
might be anticipated that any partial block in haem synthesis would 
be reflected by the levels of this haemoprotein. Furthermore, it 
was important to measure hepatic cytochrome P450 in PCT in view of 
its regulatory role in haem biosynthesis (Fig. 1, Section 4.5.). 
Evidence obtained early in this investigation indicated that an 
·alternative form of cytochrome P450 might be present in the livers 
of patients with PCT. Cytochrome P450 is an integral component of 
the microsomal drug metabolising system, which catalyses a series of 
widely diverse reactions(l05, l90) It has been shown that in rats 
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there are at least 2 forms of cytochrome P450, one form inducible 
with phenobarbital and the other, cytochrome P448, inducible with 
3-methylcholanthrene(lSG,lB9)_ The administration of phenobarbital 
to rats has been reported to enhance almost all reactions catalysed 
by cytochrome P450, including the metabolism of ethylmorphine, 
hexabarbital, aminopyrlne, acetanilide and 3,4-benzpyrene(lOS). 
However, administration of 3~methylcholanthrene enhanced relatively 
few reactions; the metabolism of acetanilide and 3,4-benzpyrene was 
enhanced, but not that of ethylmorphine, hexabarbital and aminopyr-
ine(lOS). An investigation of the functional capacity of hepatic 
cytochrome P450-dependent enzyme systems to metabolise aminopyrine 
and 3,4-benzpyrene in patients with PCT may therefore reveal the 
presence of a different type of cytochrome P450, if the situation as 
regards cytochrome P450 and cytochrome P448 with respect to microsomal 
drug metabolism in rats wereextrapolated to man. It was considered 
impractical to determine spectrally whether another form of cyto-
chrome P450 was present in liver of patients with PCT, owing to 
the limited quantity of t·issue available. 
Data obtained and published during the course of this study 
indicated that levels of hepatic cytochrome P450 were significantly 
elevated in PCT( 222 ) but not in other hepatic porphyrias or in 
non-porphyries with alcoholic liver disease( 22 ). It was therefore 
important to attempt to correlate levels of hepatic cytochrome P450 
seen in PCT with liver ultrastructure in the same tissue. Light 
and fluorescent microscopic observations were included in the investi-
gation to corroborate findings of other authors(BB,l 43 ,lG4, 279 ,299 , 
307 ,311) 
A correlative investigation was attempted in HCB-induced 
rat porphyria in view of the similarities to PCT. Urinary, 
faecal and hepatic porphyrins were investigated in HCB-treated 
rats to verify the porphyric state of the animals and to corro-
borate published findings(so, 2io,z46 , 252 , 253 , 255 )· Levels of 
hepatic cytochrome P450 and the ability of the hepatic microsomal 
drug metabolising system to metabolise aminopyrine and 3,4-benz-
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pyrene were determined. Furthermore, an attempt was made by spectral 
measurements to ascertain whether a different form of cytochrome 
P450 might be present in the livers of rats treated with HCB. 
Accumulation of URO and 7-COOH porphyrin in the livers of rats 
made porphyri c with HCB may be i ndi ca ti ve of a decrease in the 
activity of UROGEN-I decarboxylase, the enzyme which catalyses the 
stepwise decarboxylation of 4 acetate side chains of UROGEN III to 
give COPROGEN III. The possibility of a decrease in activity of 
this enzyme in HCB-treated rats was investigated by study of UROGE.N-I 
decarboxylase. The UROGEN-I decarboxylase system was selected for 
this investigation since it has been shown that the kinetics for 
UROGEN-I and UROGEN III as substrates are virtually identical, using 
a decarboxylase from mouse spleen( 242 ). 
Hepatic iron appears to play an important role in the genesis 
of the porphyric process, especially in PCT complicating alcoholic 
liver disease(l43,144,161,164,l86,250,265,307,311). This prompted 
an investigation as to the effects of iron in HCB-induced rat par-
phyria. The in vivo effect of iron on UROGEN-I decarboxylase and 
on urinary and hepatic porphyri ns was studied by treating rats with 
HCB and iron simultaneously. Further, the in vitro effect of divalent 
iron on UROGEN-I decarboxylase was investigated. 
There has been speculation as to the possibility of PCT 
being a genetically determined disease. There has been no docu-
mented evidence of an hereditary basis for PCT( 219 ). However, 
investigations as to this possibility have been directed to the 
study of urinary and faecal porphyrins of patients: with PCT and 
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those of their families(?O). Data has been obtained which suggests 
that diminished UROGEN I decarboxylase activity is the basic metabolic 
defect in PCT(lSB,l 59 ), Reduced levels of this enzyme have been de-
monstrated in hepatic tissue llSS,l 59 , 160 )and in red blood cells 
(l 53 ,l 50) of patients with PCT. Furthermore, diminished red cell 
UROGEN I decarboxylase has been recorded in clinically non-porphyric 
relatives of these patients, suggesting that the enzyme deficiency 
was inherited as an autosomal dominant trait (l 5o, 158). It was 
considered pertinent to determine the activity of red cell UROGEN I 
decarboxylase in patients with PCT and their families to determine 
whether an autosomal dominantly inherited defect in this enzyme does 
indeed play a role in the genesis of PCT in South Africa. 
CHAPTER 4 
HAEM BIOSYNTHESIS AND THE RELATIONSHIP OF CYTOCHROME P450 
TO THIS BIOSYNTHETIC PATHWAY 
The biosynthesis of haem for haemoprotein formation has been 
extensively reviewed by a number of authors (l 4,68 ,71 ,83,193,302). 
It is my intention to give a broad overview of haem biosynthesis, 
pinpointing some uncertainties in this pathway, then to discuss in 
greater depth those areas which form the core of this work. 
4.1. Haem Biosynthesis 
·The general pathway for haem biosynthesis is shown in Fig. 2. 
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Initially, ALA is formed as a result of the combination of glycine 
and succinyl CoA which is derived from the citric acid cycle. This 
reaction, which occurs in the presence of pyridoxal phosphate as co-
factor, is catalyzed by the enzyme ALA-S, after which ALA dehydratase 
catalyzes the condensation of 2 molecules of ALA to form the mono-
pyrrole PBG. The enzymes UROGEN synthetase and UROGEN III cosynthe-
tase, catalyze the formation of l molecule of UROGEN III from 4 mole-
cules of PBG. UROGEN III subsequently undergoes a stepwise decarboxy-
lation through 7-,6- and 5-COOH porphyrinogens to COPROGEN III, the 
enzyme involved being UROGEN III decarboxylase. Coproporphyrjnogenase 
catalyses the formation of PROTOGEN IX from COPROGEN III, then PROTOGEN 
IX is oxidised to PROTO IX by protoporphyrinogen oxidase. Haem is 
formed from PROTO IX and Fe2+, this reaction being catalyzed by ferro-
chelatase. The haem thus formed can combine with various apoproteins 
(TCA Cyde) lntra-mitochond rial 
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to yield haem proteins, including haemogl_obin, catalases and cyto-
chromes. 
Only those porphyri nogens of type I II isomer are intermediates 
in the biosynthesis of haem. In the pathway UROGEN III can undergo 
oxidation to result in URO III, which is a side product and does not 
serve as a substrate for UROGEN decarboxylase. . Further, it has been 
demonstrated that UROGEN III can be oxidised to URO III by photo-
catalytic auto-oxidation, a reactio~ accelerated by the product(llO). · 
In addition, COPROGEN III may be oxidised to COPRO III, which again 
cannot be utilised in haem synthesis. Since the amount of porphyrins 
excreted by normal healthy individuals is small when compared to the 
overall magnitude of haem synthesis, it may be reasonable to assume 
that the fraction of porphyrinogens which is oxidised is relatively 
insignificant. In addition, the presence of antioxidants such as 
glutathione and cysteinein the cells, as well as the exclusion of 
light, are factors which are important in keeping most of the tetra-
pyrroles in a reduced form( 198). 
Another side reaction of importance in the haem biosynthetic 
pathway is the production of UROGEN I (Fig. 3). This can undergo 
oxidation to URO I, which cannot be further utilised, or may undergo 
an enzymatic decarboxylation through 7-, 6-, and 5-COOH porphyrinogens 
to COPROGEN I. COPROGEN I does n.ot serve as a substrate for copro-
porphyrinogenase, but can be oxidised to COPRO I. As a result of 
this side pathway, normal human urine will contain URO and COPRO of 
both type I and type III isomers, but the ratio varies considerably 
(48,323) 
There is uncertainty as to the mechanism for the formation of 
UROGEN III. It has been demonstrated that when PBG is incubated 
together with enzyme systems obtained from either Chlorella< 31 ), 
. SUCCINYL CoA 
+ URO fil COPRO m HAEM 
GLYCINE 
l i l l 
ALA --:;i..psG --7-UROGEN m ~ COPROGEN lll --7 PROTOGEN m ~ PROTO IX 
Figure 3 
UROGEN I COPROGEN I 
1 1 
URO I COPRO I 
The production of UROGEN I and COPROGEN I, which may 
be oxidised to URO I and COPRO I, as side products of 
haem synthesis. 
R. spheroides(125 ), red. blood cell haemolysates( 32 ,176 ) or 
mouse spleen0 69 ' l?O), porphyrins of the type III isomer series 
are obtained. However on heating the enzyme systems to 6o0c 
it was found that only· type I isomers were formeJ3o,32 ), which 
indicated that at least two enzymes were involved in the formation 
of UROGEN I I I. Two separate enzyme fractions, viz. UROGEN I 
synthetase, which is relatively heat stable, and UROGEN Ill co-
synthetase, which is heat-labile, were prepared from plants( 26 ,27 ) 
and bacteria( 129), and more recently UROGEN III cosynthetase was, 
prepared from haematopoietically active mouse spleen0 69 ). It was 




), that UROGEN I synthetase together with UROGEN III cosynthetase 
converted PBG to UROGEN II~27 ) but UROGEN III cosynthetase alone did 
not react with either PBG or UROGEN I. 
More than 20 different mechanisms have been proposed to explain 
the formation of UROGEN II I, where the acetate and propionate sub-
stituents are reversed in ring Das compared with UROGEN I. One 
attractive proposal is the "zipping up 11 theory of Frydman et a1(95 ). 
It is envisaged that UROGEN I synthetase and UROGEN III cosynthetase 
act as a dual enzyme system. Four units PBG can be polymerised head-
to-tail to yield UROGEN I on the surface of the UROGEN I synthetase, 
or the way in which PBG condenses can be modified if there is an 
association between the synthetase and cosynthetase. In this latter 
case, a head-to-head condensation of 2 PBG units occurs to yield 
finally UROGEN III. In this way UROGEN III cosynthetase acts as a 
"specifier protein 11 of UROGEN I synthetase. 
Until recently, uncertainty existed over the conversion of COPRO-
GEN III to PROTO IX. It was unclear as to whether coproporphyrino-
genase was responsible for the entire conversion of COPROGEN III 
to PROTO IX. However, there is mounting evidence that the con-




By 1952, from the work of Shemin and Rittenberg( 269 )and 
Shemin and Kumin( 268 ), it became clear that the primary precursors 
for haem synthesis were glycine and succinyl coenzyme A. It was 
subsequently deduced that ALA might be a further intermediate in 
haem biosynthesis and it was shown that {s-14c} ALA yielded proto-
haem. with an identical labelling pattern to that of {2-14c} glycine, 
when these substrates were incubated with haemolysates of duck red 
·blood cells( 270 ). It was further demonstrated that glycine con-
succinyl 
densed with/coenzyme A to form ALA in vitro using preparations from 
avian red blood cells (167 ,2?0) and from mammalian liver(lll). How-
ever, this condensation did not occur when mature mammalian erythro-
cytes were used (167 , 177 ). The condensation reaction is catalyzed 
by the enzyme ALA-S. 
The formation of ALA in the intact mammalian cell occurs within 
the mitochondria (lll,l 67 ,3o6) since it is here where the major frac-
tion of ALA-Sis located(lll ' 122 ), and where succinyl coenzyme A is 
generated. ALA-S has also been detected in the cytosol fraction in 
the livers of rats treated with AIA( 122 ,211 ). It has been suggested 
that the cytosol ALA-S, which has a higher molecular weight than the 
mitochondr-ial enzyme(l 23 ,l 53 ) may be converted to the smaller mito-
chondria 1-type ALA-S and subse·quently transferred into the mito-
chondrion. However, the physiological mechanism by which the 
cytosol ALA-S is converted to the mitochondrial ALA-S is as yet 
unknown. 
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ALA-S has been purified from bacterial and mammalian sources 
(122,123,153,211 ,260,3lB)but whatever the source of enzyme, there is 
an absolute requirement for pyridoxal phosphate for thereaction to 
proceed~ 84 , 259 , 262 ). From various studies it appears likely that 
this cofactor is bound to the ALA-S, and furthermore, kinetic studies 
have shown that pyridoxal phosphate is always bound more strongly to 
the enzyme than succinyl coenzyme A or glycine( 92 ,100,l52,167,259). 
A scheme for the mechanism of formation of ALA has been sug-
gested by Battersby and McDonald{l 4) (Fig. 4). It is postulated 
that the ALA-S, glycine and pyridoxal phosphate form a complex. 
An anion generated from th·is complex undergoes acylation by succinyl 
coenzyme A. It is not known whether succinyl coenzyme A acylates a 
functional group on the enzyme, which then transfers the acyl group, 
or whether the thiol ester is bound to ALA-S in a non-covalent manner. 
It might be expected that the initial product of the enzymatic re-
action would be 2-amino-3-oxoadipic acid, which undergoes spontaneous 
decarboxylation, since it is known that this compound is extremely 
labile{lOO,l 66 ). Alternatively the decarboxylation may be enzyme 
catalized. Analysis of the sterochemistry of {5 - 3H} ALA produced 
enzymatically from the 25 {2 - 3H} glycine enantiomer(l) would seem to 
support this. However, it is not known whether there is a specific 
2-amino-3-oxoadipate decarboxylase present in the cell, or whether 
ALA-S itself is responsible for the decarboxylation. 
The activity of ALA-S is regulated in both bacterial and animal 
cells(4l,l 46 ). Thus there exists a control mechanism determining the 
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Figure 4 Proposed mechanism for the biosynthesis of ALA from 
glycine and succinyl coenzyme A, with the reaction 
ca~alysed by ALA-S. ENZYME = ALA-S. 
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in sectiori 4.5. 
4.3. UROGEN Decarboxylase 
UROGEN decarboxylase catalyzes the decarboxylation of the four 
acetic acid side chains of UROGEN to yield COPROGEN. This enzyme 
has been identified in extracts of bacteria( 125 ), avian red cells( 30l), 
mammalian reticulocytes( 198), mouse spleen( 242 ), rat liver( 23 ' 245 ), 
pig liver(162), human erythrocytes( 22 ,23 ,158) and human liver( 159 ). 
The decarboxylation is a stepwise process so that intermediate por-
phyrinogens with 7-, 6-, and 5-carboxyl groups are formed(l 5,25 ,96 , 
136,_198,240,244) It appears that a single enzyme rather than several 
closely related enzyme systems is responsible for the four successive 
decarboxylations(96 ' 30l) and as such can utilise as substrates por-
phyrinogens which have fewer than 8 carboxyl groups. URO cannot 
replace UROGEN as a substrate for UROGEN decarboxylase and neither 
are ALA and PBG affected by the enzyme(llO). 
It was thought originally that the removal of four carboxyl 
groups from UROGEN III was a random process, but this does not appear 
to be the case. From the studies of Jackson et a1( 136 ) and Smith 
et a1( 276 ), UROGEN III is decarboxylated sequentially in a clockwise 
direction starting at pyrrole ring D via rings A and B to ring C 
I 
(~ig.5). These workers chemically synthesised a number of isomers 
of 7-, 6-,( 136 ) and 5-( 276 ) carboxylated porphyrinogens and investi-
gated the conversion of these isomers to PROTO using chicken erythro-
cyte haemolysates. All these isomers were converted to PROTO, but at 
different rates. The conclusion drawn was that the findings were in 




Figure 5 The clockwise sequence of decarboxylation of UROGEN-III 
to COPROGEN III, starting at ring D, via rings A and B 
to_ ring c. 
24 
as well as another slow route, where the sequence of decarboxylation 
was starting at ring B, through C and D and finishing at ring A, 
to yield COPROGEN III. 
Under normal physiological circumstances, only very small 
concentrations of polycarboxylated intennediates are found in the 
body fluids, tissues or excreta, which can be attributed to the 
rapid transformation of these intermediates to COPROGEN through 
PROTO IX to haem. This is in accordance with the reported low ~ 
(< 5 x l0-6M) and a high turnover number of UROGEN decarboxylase (l 9B) 
In contrast, relatively large amounts of 7-, 6- and 5-carboxylated 
intermediates are present in the excreta of PCT patients(65 ) 
and rats treated with HCB( 246 ), 
The UROGEN decarboxylase enzyme is capable of converting the 
I, II, III and IV isomers of UROGEN to COPROGEN(l 4 )~ Kinetic 
studies on mouse spieen UROGEN decarboxylase have ,revealed that 
the ~ and Vmax values for UROGEN I and UROGEN III are virtually 
identical( 242 ). This seems to indicate that the same decarboxy-
lase enzyme is responsible for the decarboxylation of both naturally 
occurring isomers. 
Studies on UROGEN decarboxylase from avian erythrocytes(96 ) 
indicate that the elimination of the first carboxyl group from 
UROGEN III is not rate-limiting in the multiple decarboxylation 
because large amounts of 7-carboxyl porphyrinogen accumulated. The 
decarboxylation of UROGEN III to COPROGEN III by UROGEN decarboxy-
lase could thus be regarded as occurring in two stages, firstly the 
elimination of the first carboxyl group and secondly the removal of 
the further three carboxyl groups. It was further shown( 96 ) that 
UROGEN III and 7-carboxyl porphyrinogen concentrations affected the 
UROGEN decarboxylase in that UROGEN III inhibited its own de-
carboxylation, that 7-carboxyl porphyrinogen inhibited its own 
decarboxylation, that 7-carboxyl porphyrinogen inhibited the 
decarboxylation of UROGEN III, and that UROGEN III might inhibit 
the decarboxylation of 7-carboxyl porphyrinogen. 
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It has . : been demonstrated that mercury, copper, manganese 
and oxygen inhibit UROGEN decarboxyl ase ( 28 ' 198 ). · However, oxygen 
probably enhances the auto-oxidation of UROGEN to URO. When iron 
was added to mitochondria-free crude extracts of normal porcine 
liver, the activity of UROGEN decarboxylase was inhibited(162). 
4.4. Cytochrome P450 and its Relationship to Haem Synthesis 
and Drug Metabolism 
Cytochrome P450 is a rapidly turning-over microsomal haem 
protein. Measurement of the rate of turnover of cytochrome P450 
shows a biphasic curve with apparent half-lives of 8 and 40 hours 
(171) If this is taken to be indicative of two forms of cytochrome 
P450, then it might be expected that considerable quantities of haem 
and its precursors would be required in the .syn thesis of the cyto-
chrome, and in particular in the synthesis of the cytochrome with . 
the shorter half life( 193 ). 
Cytochrome P450 was originally reported as a carbon monoxide 
binding pigment by Klingenberg( 154 )and Garfinkel(97 ) and evidence 
for its haemoprotein nature came from the work of Omura and Sato( 212 ). 
Cytochrome P450 is so-called because the carbon monoxide compound of 
the reduced pigment has an intense absorption band at 450 nm. It 
was later established( 5o,9o,214 ) that _cytochrome P450 was an 
integral component of a nonspecific enzyme system, located in 
the endoplasmic reticulum, which metabolises a wide variety of 
drugs and steroids( 33 ,5l,l 9o). 
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The haemoprotein is found not only in abundance in hepatic 
microsomes but also in the microsomes and mitochondria of the 
adrenal cortex, where it is involved in the metabolism of steroids 
(90,214) It is found also in the kidney and intestinal mucosa, 
although less abundantly{l 9o). The presence of cytochrome P450 
has been detected in liver microsomes in several types of mammals, 
a bird( 20l), a frog and a fish(l 90), as well a~ in bacteria(l 4B) 
and bacteroids( 7). 
The enzymes catalyzing oxidative reactions in the hepatic 
endoplasmic reticulum are frequently called "mixed function oxi-
dases11 according to the nomenclature of Mason( 197 ) or 11mono-
oxygenases 11 according to that of Haya i sh i ( 124). It was shown, 
using 180-labelled oxygen that during oxidation reactions in the 
hepatic endoplasmic reticulum, the first atom of oxygen was incor-
porated into the substrate, and the second was reduced to water( 197 ). 
The mixed function oxidases of the hepatic endoplasmic reticulum 
catalyse widely diverse reactions: deamination; 0-, N- and S-de-
alkylation; hydroxylation of alkyl and aryl hydrocarbons; epoxida-
tion; formation of alkyl derivatives; N-hydroxylation; N- and S-
oxidation; and dehalogenation (l 90) It was pointed out by Brodie 
and associates( 34 ) that these reactions could be visualised as hydr.o-
',/ 
xylations. It was suggested( 34) that NADPH reduced the component 
in liver microsomes which reacted with molecular oxygen to form an 
"active oxygen 11 complex, which in turn hydroxylated the various sub-
strates by a group of nonspecific enzymes. The reaction was 
formulated by Gillette(l02)as follows: 
l. NADPH + A + H+ + AH2 + NADP+ 
2. AH2 + · o2 + "Active oxygen" complex. 
3. "Active oxygen" complex +· drug+ oxidised drug 
.The overall reaction can be considered as: 
+ NADPH + o2 + drug + NADP + H20 + oxidised drug. 
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It was established(SO) that cytochrome P450, a carbon mono-
xide-sensitive haem protein, was the moiety reduced by NADPH .. 
Further evidence indicated that NADPH-cytochrome C reductase was 
responsible for the reduction of cytochrome P450 by NADPH(l06). 
The spectral characteristics of cytochrome P450 and its deriva-
tive, cytochrome P420, have been extensively investigated and docu-
mented(l90,2l2,213'2i4,235). Hepatic cytochrome P450 appears to 
be very strongly bound to the endoplasmic reticulum, and early 
attempts to isolate the haemoprotein resulted in loss of both spec-
tral characteristics and activity( 2l3). Later(lB0, 20l), it was 
shown that a solubilised form of cytochrome P450 could be obtained 
with retention of spectral and enzymatic properties. 
The first stage in the oxidative metabolism of various drugs 
by liver microsomes is the formation of a complex of the drug and 
oxidised cytochrome P45d238), resulting in changes in the difference 
spectrum i.e. the absorbance spectrum of liver microsomes in the pre-
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sence of substrate (sample cuvette) minus the spectrum of 
liver microsomes in the absence of substrate (reference cuvette). 
It became clear that drugs and other foreign compounds combine 
with cytochrome P450 to produce difference spectra of two general 
types, type I and type II(133 ,238). Compounds giving type I 
spectra with. hepatic microsomes, exemplified by hexobarbital ,result 
in a difference spectrum with an absorption maximum in the general 
range of 385 to 390 nm and an absorption minimum in the general 
range 418 to 427 nm. Compoundsgiving type II spectra, for example 
aniline, give a difference spectrum with an absorption maximum at 
425 to 435 nm and an absorption minimum at 390 to 405 nm( 272 ). The 
compounds which result in type II spectra usually contain nitrogen, 
and it is thought that the spectral change is due to ferrihaemochrome 
formation caused by direct interaction between the basic nitrogen 
and the haem iron(l 3o). Furthermore, there is no evidence that a 
type II spectral change reflects the formation of a metabolically 
active,cytochrome P450-substrate complex(l 3o). Aminopyrine and 
' ) 
3,4-benzpyrene, which were used as substrates for cytochrome P450 
mediated reactions in the present work, both combine with cytochrome 
P450 to result in type I spectra<238 ,247,271,272). 
Variable enzyme activities attributed to liver microsomal 
cytochrome P450 after treatment of animals with various inducing 
agents has suggested that more than one form of cytochrome P450 
b . . l d . . l d h d l t" (49,98,103,104) may e , nvo ve rn m1 crosoma rug y roxy a , ons • 
However, kinetic data obtained using microsomal suspensions( 243 ' 
297 ,314)and with a reconstituted enzyme system< 182 ) showed that a 
number of substrates act as mutually competitive inhibitors, in-
dicating that they may be acted upon by a single enzyme. Spectral 
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evidence was reported which suggested that two forms of cyto-
chrome P450,induced either by phenobarbital or polycyclic aromatic 
hydrocarbons, were present in liver microsomes(6,128 ,139 ,207,274). 
The genetic regulation also supported the involvement of a separate 
enzyme system for aryl hydrocarbon hydroxylation(lOl). Fraction-
ation procedures have been applied to liver microsomes following 
the administration of different inducing agents to animals(47 ), 
and it has been shown th_at different substrate specificity, as 
tested in reconstituted systems, is found in the different cyto-
chrome fractions '(l?9, 180 ,208 ). Multiple forms of cytochrome 
P450 have been separated and purified from rabbit liver micro-
somes and it has been demonstrated that these different forms vary 
in their catalytic properties( 121 ). It was suggested that the 
individual forms of hepatic P450 could bind many or all of the 
potential substrates but there may be a difference in their rela-
tive efficiencies in the hydroxylation of such compounds{ 121 ). 
The hydroxylation mechanism by the cytochrome P450 enzyme 
system of liver microsomal membranes is only partly understood. 
A mechanism has been postulated by Nordblom et al( 209)as shown in 
·Fig. 6. As envisaged by these workers, the following occurs:-
The substrate initially reacts with the oxidised form of cytochrome 
P450. Under anaerobic conditions, two electrons are transferred from 
NADPH to the cytochrome P450 substrate complex via NADPH cytochrome 
reductase, one electron to the iron atom and the other to an as yet 
unidentified acceptor(8,116 ). Molecular oxygen is then bound to the 
ferrocytochrome and together with protonation, a ternary peroxide 
complex is formed( 9l ,ll?,l 35 ). Electron transfer to the oxygen occurs 
with the production of an "activated oxygen 11 capable of attacking the 
substrate, with the possible involve~ent of superoxide( 287 ). The 
.. · p 450 (Ff>3') 
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ternary peroxide complex undergoes further protonation, and the 
subsequent loss of a molecule of water leaves an activated oxygen 
species which rapidly inserts an oxygen atom in a favourably posi-
tioned C-H bond of the substrate. The hydroxylated product then 
dissociates with regeneration of the free oxidised cytochrome P450. 
It has been further shown that in cytochrome P450 mediated 
reactions, molecular oxygen, NADPH and NADPH cytochrome reductase 
could be replaced by hydrogen peroxide, alkyl hydroperoxides or 
peracids( 209). 
A number of compounds are capable of inducing microsomal 
haem~proteins with an associated proliferation of hepatic micro-
somes, when administered to experimental animals. Furthermore, 
the pretreatment can result in a stimulation of the metabolism of 
steroids and foreign compounds bythe mixed function oxidase system 
of the hepatic endoplasmic reticulum(45 ,49 ,a1,93,140,141 ,142,215,236}. 
The mechanism by which induction of drug metabolising enzyme systems 
occurs has been reviewed ,in detail by Ge 1 boi n(99 ). Conney ( 49 ) has 
divided the inducers into two major groups, firstly a small group 
of polycyclic hydrocarbons such as 3-methylcholanthrene which stimu-
lates the metabolism of only a limited number of compounds, and second-
ly, a large group, exemplified by phenobarbital, which is characterised 
by its ability to stimulate the metabolism of a large variety of 
compounds. The inducers of drug metabolism can affect any of the 
components of the mixed function oxidases of the hepatic endoplasmic 
reticulum. Thus phenobarbital increases the amounts of NADPH cyto-
chrome reductase and cytochrome P450( 127 ,215 ,237 ). In contrast, 
3-methylcholanthrene increases the amount of a spectrally distinct 
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haemoprotein, cytochrome P448( 156 ,189 ),· but not the activity of 
NADPH cytochrome reductase{l 27). It has been reported that 
pregnenolone - 16 - a - carbonitrile pretreatment of rats resulted 
in an increase in cytochrome P450 content and NADPH-cytochrome re-
ductase in the hepatic microsomes, yet the specificity of the in-
duction effect on the oxidative metabolism of benzphetamine, ethyl-
morphine and 3,4-benzpyrene differed from the specificity of either 
phenobarbital or 3-methylcholanthrene{lBl). It was suggested that 
the pregnenolone - 16 - a - carbonitrile-induced cytochrome P450 
might be catalytically different from phenobarbital induced cyto-
chrome P450, this being responsible for the varying substrate 
specificities{lSl). 
There is a wide variation in the metabolism of drugs among 
animal species, strains and individuals, and in rats and mice be-
tween the sexes. Furthermore, drug metabolism may be altered by 
the removal of various endocrine glands(lOS). The demonstration 
that multiple forms of cytochrome P450 exist,may explain the specific 
effects of enzyme inducers on catalytic activities as well as species, 
strain and sex differences observed indrug metabolism( 172 ). 
4.5. Regulation of Haem and Haemoprotein Biosynthesis 
The control of haem and haemoprotein biosynthesis has been dis-
d . . t . (193,219) d t . t t" 1 . cusse in recen reviews · an a ·in erna iona symposia 
(226;227,228) However controversy exists over some aspects of 
the regulatory mechanism, in particular the role of cytochrome P450, 
and close examination is warranted. The primary and rate-controlling 
enzyme in haem biosynthesis in the liver is ALA-s( 193 ). Haem, the 
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end product of the pathway, appears to tegulate the activity of 
this enzyme possibly through a negative feedback mechanism( 259 ). 
That is, if the model of Jacob and Monod( 138) for bacterial cells 
in invoked, haem would react with an aporepressor to form a repres-
sor which in turn impedes the synthesis of m-RNA coding for ALA-S. 
This model will not necessarily hold true for animal cells and the 
mechanism of regulation of ALA-S by haem is still an open question( 20). 
However it has been shown that when haem is administered to rats(l 94 , 
322
) or added to the incubation medium of cultured chick embryo 
liver cells (l08,248 ,284 ), the induction of ALA-S by agents such 
as AIA or phenobarbital is blocked. The biologic half life of 
hepatic ALA-Sis of the order of 72 min.( 192) so that a relatively 
sensitive control mechanism is provided for primary regulation of 
this enzyme at the level of its synthesis. If haem is indeed in-
volved in the regulation of the rate of synthesis of ALA-S, its 
effect is thought to be mediated at the level of translation(24B, 
284,30~) 
It has been proposed that a 11 pool 11 of hepatic haem exists 
which regulates the activity of ALA-S( 59 ,l 9l ,2oo,3o4,322 ). However 
there have been a number of inconsistences associated with this 
hypothesised regulatory pool of haem. For example, presumably the 
regulatory pool is identical with the precursor pool for hepatic 
haemoprotein synthesis. However, exogenous haem, although it inter-
feres with the induction of ALA-S, may not be available for incorpor~ 
ation into haemoprotein( 254 ). Thus the question arises as to how 
endogenous and exogenous haem together can constitute a single 
regulatory hepatic haem pool. 
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The size of the regulatory pool would-be affected by the rate 
of endogenous haem synthesis .and exogenously administered haem. 
Bissell and Hammaker(20) have suggested that cytochrome P450 dis-
sociates into haem and apoprotein with the haem entering a "free" 
haem pool, prior to its degradation. If it is considered that . 
more than 50% of available haem in the liver is utilised in the 
synthesis of cytochrome P450(1,9), then dissociation of haem from 
cytochrome P450 would make a substantial contribution to the 11 free 11 
or regulatory haem pool. It was shown that endotoxin, like haem, 
appears not only to block the induction of ALA-S by AIA in rats, 
but also to accelerate the catabolism of cytochrome P450 haem(20). 
From the evidence presented(20) it appears that the haem moiety 
of cytochrome P450, in addition to being a constituent of cytochrome 
P450, is metabolically important. It was postulated(20) that the 
regulatory haem pool is fed by endogenous synthesis as well as by 
dissociation of haem from cytochrome P450, and that there is a 
dynamic equilibrium of haem between the regulatory pool and apo-
cytochrome P450, providing the fine control mechanism for haem 
synthesis i.e. a mechanism which is sensitive to changes in the meta-
bolism of cytochrome P450. 
In recent years another model has been proposed for the regu-
1 ati on of ALA-S, that is, that apocytochrome P450 (or a closely 
related protein) regulates ALA-S by positive control at the trans-
lational levels, and that haem binding to this apoprotein abolishes 
this positive effect( 216 )· Other evidence has been obtained which 
suggests that apocytochrome P450 may regulate haem synthesis. By 
reconstitution experiments, it was shown that in rats treated with 
phenobarbital and cobalt, i.e. a situation where protein synthesis 
is enhanced by the drug and haem synthesis is partially blocked 
by cobalt, apocytochrome P450 accumulated( 52 ). Furthermore, 
an induction of ALA-S was observed when this occurred( 52 ) and 
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observations suggest that under conditions of maximal induction of 
cytochrome P450, haem synthesis appears to lag behind apoprotein 
synthesis, consistent with the hypothesis that apoprotein synthesis 
is the primary and rate-limiting event in the control of cytochrome 
P450 format.ion. Rajamanickam et al( 232 ) have shown that by follow-
ing the incorporation of {3H} leucine and {2-14c}glycine into, 
respectively, the protein and haem moieties of cytochrome P450 
in phenobarbital-treated rats, an increased rate of apocytochrome 
P450 synthesis precedesthe induction of ALA-S activity, which in 
turn precedesan increase in the rate of haem synthesis. Only with 
a significant increase in the rate of haem synthesis was there any 
measurable increase in levels of cytochrome P450. Thus the primary 
effect of phenobarbital is to increase the rate of apocytochrome 
P450 synthesis at the level of translation as determined by studies 
with cyclohexamide( 232 ). 
The concept that apocytochrome P450 regulates the rate of 
haem synthesis is open to question. It might be argued that the 
availability of haem is ratelimiting for cytochrome P450 synthesis 
(12,13,108,191) 
Under conditions where there is increased apo-
cytochrome P450 synthesis, an increase in the levels of cytochrome 
P450 might result when the apoprotein draws haem from the regulatory 
pool. Consequently in an attempt to maintain homeostasis there 
might be increased degradation of the haemoprotein, thus diminishing 
the regulatory haem pool. At this time the ALA-S synthetic mecha-
nism may become derepressed, resulting in an induction of the 
activity of this enzyme. 
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Increased ALA-S activity alone cannot readily explain the dif-
ferent patterns of porphyrin accumulation and excretion as seen in 
the various hepatic porphyrias (Fig. 1). It has been shown that 
partial blocks at specific steps in haem biosynthesis can lead to 
decreased haem formation, with resultant derepression of ALA-S 
synthesis and haem precursor overproduction in a pattern which is 
consistent with the block( 3,GO,Gl,2l 8,229 ,284 ). From the data 
of De Matteis(GO) it becomes apparent that normal adaptive fluctuations 
in the rates of haem biosynthesis may become exaggerated when haem 
repression is altered in any way. In the hepatic porphyrias in 
man, reduced enzyme activity, possibly due to the presence of in-
hibitors, reduced enzyme synthesis or structural change of the 
enzyme (i.e. a genetically determined enzyme activity deficiency), 
is indicative of a defective step in haem biosynthesis( 219 ). Fur-
thermore, loss of intermediates due to changes in membrane per-
meability may occur,(lSS)or the irreversible oxidation of porphyrino-
gens to porphyrins could effectively impair haem biosynthesis( 219 ). 
Thus in cases of acute intermittent porphyria, which are character-
ised by an elevated excretion of urinary ALA and PBG, a partial block 
is indicated in the conversion of PBG to UROGEN III. The activity of 
UROGEN I synthetase, which catalyses this reaction, was examined and 
found to be reduced by more than 50% in the livers of patients with 
acute intermittent porphyria( 202,283). 
It is possible that in variegate porphyria (VP) (Fig. 1) the 
reported increase in activity of hepatic ALA-s(66 ,283 ) may be due to 
a defect in the mitochondrial enzyme ferrochelatase, to the extent 
that, owing to diminished haem synthesis, the mechanism for synthe-
sis of ALA-S becomes derepressed. In rats, 3,5-diethoxycarbonyl-1, 
4-dihydrocollidine (DDC) inhibits ferrochelatase and produces 
experimental porphyria, which resembles VP in that an increase 
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in ALA-Sand porphyrin excretion is observed(6D). On the premise 
that in a genetically determined hepatic porphyria, the enzymatic 
deficiency could be detected in extrahepatic tissue, measurements 
of skeletal muscle ferrochelatase have been made in patients with 
VP in remission( 222 ). However, no difference was recorded in 
activity of these patients and in age-matched controls( 222 ). It 
may be possible that the enzymatic defect in variegate porphyria 
is due to a decreased activity of PROTOGEN oxidase, the suggested 
site of glucose repression of haem biosynthesis( 230 ). 
Finally, it is important to note that the overall pathway 
for haem biosynthesis may be additionally regulated by the location 
of the enzymes within the cell{193 ). For example, the close 
proximity of ALA-S and ferrochelatase in the mitochondria might 
result in ALA-S being subjected to high local concentrations of 
haem, which has been shown to inhibit this enzyme( 259 ). In 
addition, the conversion of cytosol ALA-S to mitochondrial ALA-S 
and subsequent transfer into the mitochondria( 123 ,153 ) may be 
important regulatory events in the biosynthesis of haem. 
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.. CHAPTER. 5 
. EXPERIMENTAL. 'DESIGNS 'AND· 'TECHNIQUES 
Experimental Design will explicitly indicate the collection 
of patients studied, the source of experimental rats, the experi-
mental designs and the procurement of various tissues e.g. liver 
and red blood cells. Following this section, Experimental Techni-
ques will be detailed with appropriate discussion. 
I. EXPERIMENTAL DESIGNS 
A~ Human Patients Studied 
Liver tissue for this study was provided by 19 patients 
with PCT and 38 control patients. 
For the PCT patients, the. clinical diagnosis was made by 
physicians of the Porphyria Service at Groote Schuur Hospital, Cape 
Town. The disease was confirmed biochemically by the Porphyrin 
Diagnostic Laboratory, Groote Schuur Hospital, Cape Town in 2 ways:-
(1) Quantitative assay of 24 hour urine and stool porphyrins and 
porphyrin precursors using standard techniques( 132 ' 241 ' 289 ). 
(2) Qualitative examination by extraction and esterification of 
porphyri ns present . in excreta, fa 11 owed by thin layer chromatography 
and study of the porphyrin profile thus obtained using a Vitatron 
VLD 100 densitometer. I~ cases which were difficult to distinguish, 
the presence of porphyrin Pl (an isocoproporphyrin) in the stool, 
was taken as indicative of PCT(lB,l9). 
PCT is almost invariably associated with liver disease; 
usually with hepatomegaly being present, and in addition, liver 
function as judged by serum proteins, serum SGOT and bromsulph-
thalein excretion are abnormal in mor~ than 50% of cases(!2 ). 
Thus for diagnostic purposes, it was essential that liver histo-
logy also be examined. 
Control patients who supplied liver tissue were. admitted to 
Groote Schuur Hospital suffering from alcoholic lives~isease, 
' cirrhosis and other liver diseases. These patients re·quired liver 
biopsy for diagnostic purposes. All control patients ~xhibited 
no biochemical abnormalities of porphyrin metabolism. 
Procurement of Liver 
Patients were admitted to Groote Schuur Hospital after 
clinical diagnosis in the Outpatients Department. Many of the 
patients with PCT admitted to excessive alcohol intake, and one 
patient had recently taken oral contraceptives. Non-porphyric 
patients included those with a history of excessive alcohol intake. 
The patients were not told to alter their drinking habits prior 
to admission into the hospital wards. Percutaneous liver biopsy 
for diagnostic purposes was performed in the hospital wards by 
Dr. N.R. Pimstone, and in all cases within 48 hours of the patient 
being admitted. 
Procurement of Blood 
10 ml venous blood was drawn from 9 patients with PCT; from 
16 random patients; from 2 families where the father was the 
propositus of PCT; from 8 members of a family who showed no 
clinical or biochemical manifestations of PCT; and from the author 
of this thesis. 
B~ Rats Studied 
The rats used in all the experiments described were female 
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Wistar rats of a strain originating from 6 breeding pairs obtained 
from Professor G. Berlyne, Seroka Medical Centre, P.O. Box 151, 
Beersheba, Israel. 
For study of the various parameters rats weighing from 160g 
to 200g were used. 
In all experiments the rats were starved 24 hours prior to 
being sacrificed, but water was allowed ad libitum. In those 
experiments where urinary and faecal porphyrins were determined, 
the animals were kept in stainless steel metabolic cages during 
the 24 hour starvation period, and urine and faeces were collected. 
(i) · 'Control rats 
These were untreated animals, maintained on a diet 
of Epo l cubes (Vereeni gi ng Mi 11 s, Maitland, , Cape). 
(ii) HCB-treated rats 
Groups of rats were treated with 0,2% HCB, mixed 
with finely powdered Epo 1 cubes. The di et was a 11 owed 
ad libitum, then at various time intervals up to 60 
days, the rats were sacrificed after the 24 hour starva-
tion period . 
.(iii) HCB and Iron treatment 
In addition to HCB treatment, some groups of rats received 
25 mg elemental iron/kg twice weekly. The iron as Jecto-
·fer, an iron-sorbitol-citrate complex was injected intra-
muscularly into the upper hind leg of the animals 
(iv) Other Treatment Schedules 
' Rats were rendered haemosiderotic by injection of iron as 
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Jectofer into the upper hind leg at a dose of 25 mg elemental 
iron/kg twice weekly. 
Allyli~npropylacetamide (AIA) was injected intraperi-
toneally at a dose of 300 mg AIA in physiological saline/ 
kg, after the rats had been starved for 24 hours. Sixteen 
hours later the rats were killed. 
Phenobarbital was administered intraperitoneally as 
Gardenal (sodium salt) at a dose of 80 mg/kg daily for 5 
days. Rats were starved during the last 24 hours of 
treatment before killing. 
C; ·Preparation:of ·Tissue 
L ·Human·Liver 
(a) Initial handling 
The liver specimen was treated in 5 different ways immediately 
following biopsy: 
(i) A portion of 5 - 10 mg was placed in 10% formalin 
for light microscopy following staining. 
(ii) A portion of 5 - 10 mg for fluorescence microscopy 
was placed in a dry tube covered with aluminium 
\ 
.foil, i.e. the sample was kept in total darkness, 
before further processing. 
(iii) A portion of 5 - 10 mg was taken for electron 
microscopy. This was placed on a sheet of Glassine 
paper together with a drop of 5% phosphate-buffered 
glutaraldehyde. This sample was very finely chopped 
with a blade, then transferred into a vial containing 
fresh 5% phosphate-buffered glutaraldehyde. 
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All the work pertaining to light, fluorescence and electron microscopy 
was performed by a histopathologist, Dr. B.L. Webber, of the Department 
of Pathology, University of Cape Town Medical School. 
(iv) Approximately 10 mg liver was placed in a dry test 
tube covered with aluminium foil, for the determina-
tion of the porphyrin profile by the Porphyria Diagnostic 
Laboratory, Groote Schuur Hospital. 
(v) The remainder of the biopsy material, weighing from 
30 to 70 mg was further prepared for determinations 
of ALA-S activity, cytochrome P450 levels; and 
aminopyrine-N-demethylation and 3,4-benzpyrene hydroxy-
lation kinetics. The material was placed in a vial 
containing 10 ml ice cold KCl:tris buffer (4 parts l ,15% 
KCl, l part 0,25 M tris:HCl, pH 7,5) and transported 
to the laboratory under ice, with weighings and homo-
genisations being performed within 2 hours of obtaining 
the biopsy material. 
(b)· ·Preparation· of· human· liver· homogenates 
(i) ·For ALA-S·assay 
After drying between 2 sheets of tissue paper, approxi-
mately 4 to 7 mg of the biopsy material was weighed out 
and homogenised 1:9 w/v with ice cold 0,9% NaCl solution 
which was 0,5 mM in respect of EDTA and O,OlM in respect 
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of tris:HCl~ pH 7,4. The homogenisation was carried out 
under ice using a Potter type homogeniser of l ml capacity 
fitted with a Teflon pestle (No. 0678, Thomas, Philadelphia, 
U.S.A.) Homogenates were stored under ice for a maximum 
period of 2 hours before assay for ALA-S. 
(ii) · ·For· cytochrome· P450 · determi nations, ami nopyri ne-N-demethy-
· 1 ati on ··and. 3-~4.:.benzpyrene' hydroxyl a ti on. 
The remainder of the biopsy material was dried between 
tissue paper and weighed. This was homogenised 1:10 
w/v with fresh KCl:tris (4 parts 1,15% KCl, l part 0,25M 
tris:HCl, pH 7,5) under ice, again using an homogeniser of 
l ml capacity. The homogen~te was stored under ice for a 
period of not longer than 2 hours before the start of any 
of the determinations. 
2.· Human Blood 
Venous blood was collected in heparinised tubes and kept under 
ice for the minimum period of time i.e. less than 2 hours, before 
further manipulations were commenced. 
(a) Preparation of haemolysates from ·human blood for assay of 
red blood cell UROGEN-I decarboxylase 
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Each blood sample was poured into a 50 ml polyethylene 
centrifuge tube and approximately 30 ml of ice cold normal saline 
was added. This was gently mixed and centrifuged at 500xg for 
10 min. using a Sorvall RC 2 centrifuge at 4°c. The supernatant 
and buffy layer were gently as pi rated off, then the remaining 
red cells were washed twice more with 30 ml cold normal saline. 
After the last wash, the packed red cells were suspended in an 
·equal volume of 0,lM tris:HCl,pH 6,8. The cells were sonicated 
for 20 sec. using an Ultrasonics Rapidis 300 sonicator fitted 
with a 3 mm· tip, at power setting 3. During the sonication 
the tube was kept in an ice bath. Cells were twice frozen and 
thawed, using liquid nitrogen for freezing and a water bath at 
37°c for thawing. After the last thaw, the haemolysed cells 
were centrifuged at 32000xg for 45 min. at 4°c in a Sorvall RC-2 
centrifuge. The supernatant was decanted and used as a source 
for UROGEN-I decarboxylase. 
3. Rat Liver 
When whole liver homogenates were to be prepared, or when porphyrin 
contents of the liver were to be examined, rats were killed by decapi-
tation, the livers excised and dried superficially with tissue paper. 
In those experiments where rat liver microsomes were prepared, rats 
were killed by decap'itation, then the liver was exposed. The liver 
was thoroughly perfused in situ with ice cold 0,9% saline, excised, 
and dried superficially with tissue paper. 
(a) Preparation of rat liver homogenates: 
(i) For ALA-S assay 
I ...... . 
(i) For ALA-S Assay 
One g liver was weighed out and placed under ice cold 
homogenising medium (0,9% sodium chloride solution 
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which was 0,5mM in EDTA and 0,01 Min tris:HCl, pH 7,4). 
The liver was cut with scissors into small pieces and 
after swirling the medium was decanted. Fresh homogeni-
sing medium was added to result in a total volume of 10 
ml and the liver was homogenised under ice in a 50 ml 
capacity glass homogeniser fitted with a motor-driven 
Teflon pestle. The homogenate was stored under ice for 
a maximum of 2 hours before the assay. 
(ii) For cytochrome P450 determinations; aminopyrine-N deme-
thylation and 3,4-benzpyrene hydroxylation kinetic studies 
One g liver was treated in exactly the same way as des-
cribed in the previous section, but the homogenising 
medium in this case was KCl:tris buffer (4 parts l,15% 
KCl, 1 part 0,25 tris:HCl, pH 7,5). Again the homogenate 
was stored under ice for not longer than 2 hours before 
commencement of any of the determinations. 
(iii) For UROGEN-I decarboxylase assay 
One g liver was again treated as described for the prepara-
tion of homogenate for ALA-S assay, but the homogenising 
medium was 0,1 M tris:HCl buffer, pH 6,8. The homogenate 
was centrifuged at 32000xg at 4°C for 45 min. in a Sorvall 
RC-2 refrigerated centrifuge. The supernatant was decanted 
and used as a source of UROGEN-I decarboxylase. This post 
mitochondrial supernatant was kept under crushed ice for a 
maximum of 2 hours before the start of the assay. 
(iv) Preparation of liver for determination of porphyrin profile 
Approximately l g liver was weighed, placed into a test tube 
covered with aluminium foil to protect porphyrins from being 
degraded by light. The tissue was kept in a deep freeze at 
-20°c until the time of assay for the porphyrins, usually 
about 2 weeks later~ 
(b) Preparation of rat liver microsomes 
Microsomes were always prepared from livers pooled from 3 
rats. 3g of perfused liver from each of 3 rats were weighed, 
pooled and homogenised 1:3 w/v with KCl :tris buffer (4 parts 
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1,15% KCl, l part 0,25M tris:HCl, pH 7,5), under ice using an 
homogeniser fitted with a motor driven Teflon pestle. The homo-
genate was centrifuged at 9000 x g for 20 minutes at 4°C in a 
Sorvall RC-2 refrigerated centrifuge. Microsomes were sedimented 
by centrifugation of the supernatant in a Beckman Model L3-50 
Ultracentrifuge at l05000x~ using a 40 Ti fixed angle rotor. 'After 
discarding the supernatant, the microsomal pellets were resuspended 
with -2 ml aliquots of ice cold 0,25 M potassium phosphate buffers 
at pH 6;0; 6,5; 7;0; 7,5;8,0. .A Potter Elvejhem homogeniser of 
5 ml capacity was found to be convenient for resuspending the 
microsomes. The microsomal suspensions were kept under ice and 
used within 8 hours of preparation for cytochrome P450 determina-
tions. Following this the suspensions could be stored, deep-
frozen for subsequent protein determinations. 
II. EXPERIMENTAL TECHNIQUES 
Introduction 
Methods used for the investigation of the following para-
meters will be discussed: 
1) Hepatic ALA-S activity, with a subsection on the determina-
tion of bacterial succinyl coenzyme A synthetase activity. 
2) Levels of hepatic cytochrome P450. 
3) Kinetics i.e. ~and Vmax of aminopyrine-N-demethylation 
by the liver in vitro. 
4) Kinetics i.e. ~and Vmax of 3,4-benzpyrene hydroxylation 
by the liver in vitro. 
5) Red blood cell and hepatic UROGEN-I decarboxylase activity. 
6) Porphyrin levels in liver, urine and faeces. 
Other methods used, viz. haemoglobin determination, protein 
determination and total hepatic iron determination will also be 
described. 
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Results from light, fluorescence and electron microscopy formed 
an integral part of this project. This work was performed by a 
histopathologist, Dr. B.L. Webber of the Department of Pathology, 
University of Cape Town Medical School, and methods used in these 
studie~ will be described briefly. 
Each of the experimental techniques used will be presented in 
the following format: 
(a) .. Principles of the particular assay will be discussed 
(b) A detailed account of materials and methods will be given. 
(c) The assay procedure will be succinctly described. 
( d) Comments_ on any particular assay will be made when necessary. 
(e) Ancillary procedures to any particular assay will be described. 
Of the methods to be described, the radiochemical micromethod 
used for assay of ALA-·S activity is the most complex. The assay is 
successful only if meticulously performed. For this reason, the 
section on ma teri a 1 s and techniques will be presented at length, with 
scrupulous attention being given in particular to the finer detail. 
The methods for calculation of results from the experimental data 
as well as statistical methods are given in Appendix A. 
A list of all reagents and specialised equipment together with the 
names of suppliers will be found in Appendix B. 
All light absorbance readings and spectral recordings of 
solutions were made on a Pye Unicam SP 1700 Ultraviolet Spectro-
photometer fitted with a Uni cam AR 25 Recorder. In addition the 
readings were always made at room temperature. 
5.1. Hepatic ALA-S Activity 
(a) Principles of Assay 
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The radiochemical micromethod used for the assay of this enzyme 
was essentially the method of Strand et al( 285 ) with modifications 
as described by Pimstone et a1( 222 ). 
~LA-S catalyses the condensation of glycine and succinyl-CoA 
in the presence of pyridoxal-5-phosphate to form ALA( 267 ). 
The assay method, in principle, is the measurement of incorpora-
tion of 
14
c-succinate into ALA in the presence of the enzyme source 
viz. liver tissue homogenate, CoA, and succinyl CoA synthetase with 
. subsequent isolation of 14C-ALA by employment of a triple column 
technique. 
Using liver homogenates as enzyme source for the ALA-S assay 
to prevent the 
14
c-succinate being metabolised to other compounds 
via the tricarboxylic acid cycle, inhibitors are used( 134). Anti-
mycin A together with malonate are present to inhibit succinic dehy-
drogenase, the malonate being a specific competitive inhibitor with 
the antimycin A present as an inhibitor of electron transport, block-
ing electron flow via ~he cytochromes b and c. Malate is present to 
trap any 
14
c-malate produced which f s subsequently removed by a cation 
exchange column. Arsenite will inhibit the a-oxoglutarate oxidase 
system, since Granick and Urata(lll) showed that mitochondria are able 
to synthesise ALA with a-oxoglutarate as ·a source of succinyl CoA. 
It is necessary in this assay to prevent succinyl-CoA formation from 
a-oxoglutarate since this will be unlabelled and will compete with 
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14
c - succinyl - CoA: Inhibition of ALA dehyratase is effected with 
EDTA( 195 ). 
A succinyl CoA generating system i.e. succinyl CoA synthetase, 
succinyl CoA and ATP is included in the assay system, together with 
magnesium to activate succinyl CoA synthetase. It has been shown 
that methods which rely on endogenous succinyl CoA synthetase( 76 ,94 ) 
will underestimate total homogenate ALA-S activity( 122 ,259 ). 
The effects of the reagents used in the assay have undergone 
extensive investigation( 76 ' 134 , 195 ' 285 ) 
(i) Triele Column Technigue 
Ion exchange column chromatography in 3 sequential 
steps is us~d to separate the 14C-ALA from succin-
ate and other metabolic products after incubation and 
termination of the reaction. Initially the pH of 
the incubation mixture is adjusted to 7,0 which is 
passed over Dowex-1-Acetate at pH?, then the eluate 
is passed over Dowex-50 H+ at pH2. The Dowex-
50 H+ is washed with O,lN HCl and subsequently 
eluted with IM sodium acetate. The ALA is converted 
to 27methy1-3-acetyl-4-(3-propionic acid) pyrrole 
by condensation with acetyl acetone according to 
the Knorr reaction shown in Fig, 7. 
The pyrrole is applied to a Dowex-1-acetate 
column at pH 4,6 and eluted with methanol/glacial 
acetic acid 2:1. 
(ii) Resin Fl ow 
Table 2 lists the values for pK1 and pK2 at 25°c 
in aqueous solution of the acids present in the 

































Figure 7 The condensation of ALA with acetylacetone. 
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TABLE 2 
IONISATION CONSTANTS FOR THE ACIDS PRESENT IN THE ALA-S 
INCUBATION SYSTEM(l 3) 
Acid 
Succi ni c Acid 4,21 5,64 
ALA 4,05 8,90 
·Mali c Acid 3,46 5,05 
Malanie Acid 2,86 5,70 
Oxaloacetic Acid 2,56 4,37 
Fum¥ic Acid 3,02 4,38 
,.Dowex-1 is a strongly basic anion exchange resin composed 
of quaternary ammonium exchange groups attached to a styrene 
divinylbenzene polymer lattice. For use in the first ion 
exchange column in the isolation of ALA it is converted to the 
acetate form and used at pH 7. At this pH the succinate will 
be in anionic form and will replace acetate as will the other 
carboxylic acids. However, ALA will not be exchanged by the 
column since it has a net positive charge at pH 7. 
Dowex -50, which is a strongly acidic cation exchange 
resin composed of nuclear sulphonic acid exchange groups 
attached to a styrene divinylbenzene polymer lattice, is 
used in the second chromatography step in the acid form at 
pH 2. 
At this pH, ALA will be retained by the resin, 
probably with greater affinity thfn remaining succinate 
and other dicarboxylic acids, since they have relatively 
lower constants for dissociation .. 
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Washing the resin with O,lN HCl will displace remaining 
succinate and dicarboxylic acid cationic groups. Sodium 
acetate lM (pH 8,4) wil I displace the ALA retained on the 
resin; the eluate is collected and reacted with acetyl acetone to 
form a pyrrole. The sodium acetate acts by 
(a) decreasing the cationic NH
3
+ charge 
(b) cationic competion. 
The pyrrole formed by condensation with acetylacetone has 
a propionic acid residue, which permits a further purification· 
by an anionic exchange column. This column contains Dowex-1 
in the acetate form, at pH 4,65. At this pH the pyrrole exists 
in the anionic form, and will strongly bind to the resin. 
Any residual dicarboxylic acids and succinate will also 
be bound to the resin, but with the ionisation constants from 
2,5 to 5 will not be predominantly in the salt form. These are 
eluted with lM acetic acid, followed by elution with methanol, 
which will remove any "aminoacetone pyrrole-like material" that 
may have been formed. The aminoacetonemay have been formed 
in the incubation mixture originally by condensation of glycine 
with acetyl-CoA. The final elution step with glacial acetic 
acid and methanol will displace the ALA pyrrole, methanol 
being included since it is a good solvent for the pyrro-le. 
(iii) Specificity of the Assay 
The radiochemical assay method for determination of ALA-S 
activity is extremely sensitive, and measures specifically 
newly formed ALA. ALA-S activities are normally measured by 
conversion of the produced ALA to a pyrrole by condensation 
with acetylacetone, the pyrrole being measured colorimetrically 
with Ehrlich's reagent. Aminoacetone as well as ALA is produced 
by the liver and other cells(ss,s5,ll 4), and both will give 
rise to pyrroles. Thus it is necessary to separate ALA 
and aminoacetone in ALA-S activity measurements, and 
methods used have been described where resin columns are 
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used either before( 310) or after( 196 ) conversion to pyrroles. 
The radiochemical ALA-S assay, however, excludes aminoacetone 
synthesis. 
(b) Materials and Methods 
(i) Incubation Conditions 
(1) An inhibitor/cofactor solution was made up freshly 
for the assay as described below and kept under ice. 
Except where otherwise ind·icated, the reagents were made 
as stock solutions, and stored at 4°c. The stock solu-
-
tions were discarded after 3 months. All reagents were 
made up in 0,125M tris:HCl buffer, pH 7,4. 
2 parts each of:- (a) EDTA 0,025M 
(b) Glycine 2,5M 
(c) Sodium arsenite 0,25M 
(d) Antimycin A 6,25rng/100ml. (Freshly 
made). Tt1e antirnycin A, which is not 
readily soluble in an aqueous medium 
was dissolved in 5 ml ethanol with the 
resulting solution being made up to 
100 ml with 0,125M tris: HCl buffer, pH 
7,4,which contained 0,1% bovine serum 
albumin. 
(e) Sodium d-1 malate 0,125M 
(f) Adenosine triphosphate 0,625M (Freshly 
made). 
I 
(g) Dithiothreitol 0,025M which was 0,010625M 
in respect of coenzyme A. (Freshly made). 
l part each of:- (h) Magnesium chloride l ,OM 
(i) Pyridoxal-5-phosphate 0,05M {Freshly 
made). 
4 parts of:- (j) Malonic acid 1 ,25M 
/ 
The pH of this solution was adjusted to 7,4 with 1 N NaOH. 
(2) To a ~ial containing 250 µCi {l ,4 - 14c} succinic acid, 
0,5 ml distilled H2o was added,-the resulting solution 
neutralised with NaOH O,lM, then made up to 1 ml with H
2
o. 
This solution was stored at 4°C. · 
{3) A fresh solution containing approximately 100 U of 
activity per ml of succinyl - CoA synthetase was made up 
with 0,125 M tris:HCl pH 7,4, and kept under ice. 
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For assay of hepatic ALA-S, the incubation mixture 
consisted of 0,020 ml cofactor/inhibitor solution, 0,010 ml 
neutralised {1,4 - 14c} succinic acid, and 0,010 ml succinyl -
.CoA synthetase. At the start of the reaction 0,010 ml 
liver homogenate, corresponding to 1 mg liver tissue (wet 
weight), was added.· The mixture was incubated at 37°C for 
30 min. with shaking in a .Dubnoff Metabolic Shaking Incubator 
at 100 r.p.m. The reaction was stopped by adding 0,020 ml 
25% trichloracetic acid. 0,050 ml of carrier solution (4,19 
mg ALA. HCl and 0,675 g sodium succinate per 10 ml H20) was 
added, then reaction tubes were stored frozen at ~2o0c until 
isolation of the radioactive ALA by the triple column method 
took place. 
{ii) Chromatography - Preparation of Resin 
Dowex - l Cl-was converted to the acetate form in the 
following way: Approximately 300 g of the resin was added 
to 2 litres lN NaOH and stirred gently with a magnetic 
stirrer and bar for 1 hr. The resin was filtered using 
a Buchner filter flask, and washed with a total of 3 litres 
distilled water. After suspension in 2 litres3M sodium 
acetate and stirring for 1 hr, the resin was again filtered 
and washed with 2 litres distilled water. This last step was 
repeated twice more. Two-thirds of the resin was then 
further prepared for use in the first column, by initial sus-
pension in l litre lM acetate buffer pH 7, followed by fil-
tration and washing with the same buffer. Resin was then 
suspended in l litre O,lM acetate buffer pH 7,0, again 
filtered and washed and finally suspended in approximately 
500 ml 0,025M acetate, pH 7,0. Slurry was poured into the 
polyethylene columns to give a final column height of 4 cm. 
Columns were washed with 0,025M sodium acetate, pH, 7,0 
until the pH of the wash fluid was 7,0. This final step 
required approximately 100 ml buffer to achieve. 
The remaining third of Dowex-1 was prepared for use 
in the third (anion) exchange column exactly as above, 
except that the sodium acetate buffers were at pH 4,6, 
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and the final slurry suspension was in 0,05M sodium acetate 
pH 4,6. The slurry was poured to result in a column 
height of l ,5 cm and wash~d with 0,05M sodium acetate'at 
pH 4,6 until the pH of the wash was 4,6 - this usually re-
quired 30 ml of the buffer. 
Dowex - 50 H+ was prepared for use by suspension of 
approximately 300 g resin in 2 litres lN HCl, and stirring 
gently for 1 hr. This was followed by filtration and wash-
ing with distilled water. Resin was suspended in, and 
subsequently washed with 0,5N HCl, followed by suspension 
and washing with O,lN HCl ( 2 litres). Finally, the resin 
was suspended in 500 ml 0,01 N HCl, the slurry then being 
poured into columns to give a resin bed height of 4 cm. 
The resin in the columns was.- equilibrated to pH 2 with O,OlN 
HCl. This step required approximately 100 ml. 
The resin in the columns was at all times kept under 
the various equilibration solutions by blocking off the 
flow with plastic caps, the tops of the columns being 
covered. It was found possible to store the resin columns 
;n this way for up to 6 months, although it was always 
necessary to equilibrate the resin to the required pH with 
about 20 ml of equilibrating solution before use. 
(iii) ~hromatography - Isolation of 14c-ALA 
A three-step sequential ion-exchange procedure was used. 
(1) The pH of the incubation mixture was adjusted to pH 7 
with O,lN NaOH after addition of 4 ml H20, then passed over 
a Dowex-1-acetate column (l x 4 cm) equilibrated to pH 7,0 
with 0,025 M sodium acetate. The column was washed through 
with 20 ml H20, and the total eluate from the column was col-
lected. 
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(2) The total eluate from the fir~t column was charged to 
a 1-x 4cm ·Dowex:... 50 H+, column equilibrated to pH 2 
with 0,01 N HCl. The column was washed with 20 ml 0,1 
N HCl followed by 3 ml lM Na acetate. The ALA was eluted 
with a further 10 ml lM Na acetate and collected in a 
large boiling tube. Conversion to 2~methyl-3-acetyl-4-
(3-propionic acid) pyrrole was achieved by .heating this 
eluate together with 0,2 ml acetylacetone in a boiling 
water bath for 20 min., after placing a very loose fitting 
stopper on the boiling tube. 
(3) After being allowed to cool, the pyrrole was 
applied to a Dowex-1-acetate (1 x l, 5 cm) column 
equilibrated to pH 4,6 with 0,05M Na acetate. The 
~olumn was washed with 15 ml H2o, 5 ml lN acetic acid, 
then with l ml methanol. The ALA pyrrole was eluted 
_with 10 ml methanol glacial acetic acid (2:1 v/v). The 
volume of this final eluate was recorded, then 3 ml was 
added to 12 ml Instagel and counted in a Beckman L~S. 
scintillation counter. Samples were again counted after 
the addition of 14c-n-hexadecane for determination of 
counting efficiency. 
(iv) seectrophotornetri c. Determi nation of Recovery of ALA 
The recovery of ALA was determined · · spectrophoto-
metri cal ly using Ehrlich mercury reagent(lB?). This 
reagent was always freshly made up before use and con-
sisted of p-dimethylaminobenzaldehyde lg; 10 ml of a 
solution of HgC1 2 in glacial acetic acid (16g/L); 9 ml 
perchloric acid (70%), the solution being made up to 
50 ml with glacial acetic acid. 
2 ml of the eluted pyrrole from the 'third column 
was added to 2 ml of Ehrlich mercury reagent, and absorb-
ance determined at 556 nm after 20 min. 
A standard was made by reacting 0,050 ml of a solution 
of ALA, HCl (4, 19.~/lOml H20) in l ml l M Na acetate with 0,2 
ml. acetylacetone at 100°c for 20 min; then after cooling 
methanol glacial acetic acid (2:1} was added to result in a 
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final volume of 10 ml. A 2 ~l aliquot of the standard 
pyrrole was reacted ~Jith 2 ml Ehrl"ich's mercury reagent 
as above, and the absorbance determined at 556 nm. For 
determination of efficiency of recovery, the absorbance 
reading for the pyrrole was converted to an absorbance 
reading which would be obtained if the volume of eluate 
from the third column was 10 ml. This value was then 
compared directly to the value obtained for the standard 
ALA-pyrrole. 
\C) Assay Procedure 
The incubations were carried out at 37°c for 30 min. aero-
bically with shaking in a Dubnoff Metabolic Shaking incubator 
at 100 r.p.m. The incubation mixture contained in a total of 
0,05ml: EDTA (disodium salt) 0-05 µmol; glycine 5 µmol; 
sodium arsenite 0,5 µmol; magnesium chloride 1 µmol; anti-
mycin A 0,125 µg; sodium d-1 malate 0,25 µmol; malonic acid 
5 µmol; pyridoxal-5-phosphate 0,05 µmol; ATP 1,25 µmol; 
coenzyme A 0,021225 µmol; dithiothreitol 0,05 µmol; succinic 
acid including {l,4 - 14c} succinic acid 0,01225 µmol; puri-
fied bacterial succinyl coenzyme A synthetase (E.C. 6.2. l .5.) 
0,89 units; tris:HCl 3,75 µmol, The pH of the reaction 
mixture was adjusted to 7,4 and reaction started with 0,010 ml 
liver homogenate (100 mg/ml). The reaction was terminated with 
0,020 ml 25% trichloracetic acid, and sodium succinate 12,5 µmol 
and ALA.HCl 0,125 µmol were added as carriers. 
The pH of the incubation mixture was adjusted to 7,0 with 
NaOH and passed over Dowex l acetate (1 x 4 cm) equilibrated to 
pH 7,0 with 0,025 M Na acetate. The column was washed through 
with 20 ml water and the total eluate was applied to Dowex 50 H+ 
55 
{l x 4 cm) equilibrated to pH 2 with 0,01 N HCl. The Dowex 
50 H+ column was washed with ~O ml O,lN HCl, then with 3 ml 
lM Na acetate. The ALA containing fraction was eluted with-
7 ml lM Na acetate, then the ALA was converted to 2-methyl-
3-acetyl-4-{3-propionic acid) pyrrole by boiling with 0,2 ml 
acetylacetone. This pyrrole was applied to Dowex l acetate 
{l x 1,5 cm) equilibrated to pH 4,6 with 0,05M Na acetate buffer, 
followed by washing with 15 ml water, 5 ml lN acetic acid and 
l ml methanol. The pyrrole was eluted with rn ml methanol/ 
glacial acetic acid {2:1). 
3 ml of the eluate was added to 12 ml Instagel and counted 
in~a Beckman liquid scintillation counter. Samples were re-
counted after addition of 14c-n-hexadecane as internal standard 
for determination of counting efficiency. Recovery of ALA was 
determined spectrophotometrically with Ehrlich mercury reagent. 
{d) Comment on ALA-S Activity Determinations 
The assay was always performed in triplicate where possible. 
In each run, blanks were always included and consisted of the 
entire reaction mixture with the exception of liver homogenate, 
this being replaced by 0,125 M Tris:HCl buffer, pH 7,4. 
When a· batch of columns was prepared, the efficiency of 3 
sets of triple columns selected at random was determined prior 
to chromatographic isolation of ALA from incubated samples. The 
procedure followed was that detailed in (b} {iii) and {iv) above 
but the entire incubation mixture was replaced by 0,050ml carrier 
solution (4,19 mg ALA:HCl and 0,675 g sodium succinate per 10 ml 
H20). The Dowex 1 and Dowex - 50 was reprocessed as detailed in 
(b) (ii) above if the efficiency of ALA recovery as determined 
spectrophotometrical ly was less than 50%. Usually the recovery 
of ALA from the triple columns ranged· from 50% to 80%. The 
columns were never allowed to run dry during the char;ging or 
washing procedures. 
(e) Bacterial Succiliyl-CoA Synthetase Activity 
(i) Princieles of Assax 
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The purified bacterial succinyl coenzyme A synthetase 
was assayed essentially according to the method of Kaufman< 150J. 
The reaction involved is as follows:-
Succinate + ATP + Coenzyme A-SH 
succinyl CoA 
synthetase 
, Succi nyl -Co enzyme A 
+ ADP + P 
In the presence of hydroxylamine, the succinyl coenzyme-A 
reacts to form succinohydroxamic acid, with coenzyme A being 
constantly regenerated. The ferric chloride reagent of Lipmann 
and Tuttle{l?4) is used to determine the succinohydroxamic acid 
at 540 nm. One unit of activity of the enzyme is defined as 
the amount of enzyme which catalyses the formation of l µmol ·. 
of succinohydroxamic acid in 30 min at 37°C. 
(ii) Materials and Methods 
A "substrate mixture 11 was made up consisting of 2,5 ml 
l,OM tris, 5 ml O,lM MgC1 2 and 5 ml l ,OM disodium succinate 
The pH was adjusted to 7,4 with HCl and the volume was made up 
to 17,5 ml with water. A"cofactor mixture" was made up with 
2 ml 0,2M ATP, l ml coenzyme A ( lOmg/ml) and neutralized before 
adding water to result in a total volume of 6,5 ml. Hydroxyl-
amine was prepared by mixing equal volumes of 4M KOH and 4M 
NH20H.HC1, the pH subsequently being adjusted to 7,4 by the 
addition of either reagent dropwise. It was important that 
this solution be freshly made before use. For the assay 
0,35 ml "substrate mixture", 0,1 ml "cofactor mixture" and 
0,1 ml hydroxylamine were pipetted into test tubes. Purified 
bacterial succinyl CoA synthetase (lOmg/ml H20J and H2
0 were 
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added to result in a final volume of 1 ml at the start of 
the reaction. Incubation was at 37°c for 30 min. The 
reaction was terminated by addition of 1 ml of a solution 
of lOg ferric chloride hexahydrate and 3,3g trichloracetic 
acid in lOOml 0,66 N HCl. After addition of 2 ml H20, 
the solutions were centrifuged at 2000 r.p.m. for 20 min. 
on a Rota-Uni bench centrifuge. The absorbance of the 
supernatant was determined at 540 nm using as reference a 
sample tube to which no enzyme preparation had initially 
been added. Standards were prepared which contained the 
substrate and cofactor mixtures and 1 µmol succinohydroxamic 
acid~ . (Succinohydroxamic acid was prepared by making a 
JOmM solution of succinic anhydride in neutralised hydroxyl-
amine). The total volume of the standard solutions was 
made up to lml w1th water, then after the addition of lml 
ferric chloride reagent and 2 ml water, the absorbance was 
determined at 540nrn. Absorbance readings were compared 
directly to those for the standard for calculation of 
activity of the enzyme preparation. 
5.2. Hepatic Cytochrome P450 Determinations 
I. Cytochrome P450 Levels in Whole Liver Homogenate with Carbon 
Monoxide as Ligand. 
(a) Principles of Assay 
Cytochrome P450 is a microsomal enzyme system and under normal 
circumstances is measured in microsomal preparations. However, due 
to the limited amount of tissue available from human liver biopsies, 
a micromethod was adapted from Schoene et a1( 258 ) as described pre-
viously(222)for whole liver homogenates. 
Omura and Sato(
212
) indicated that cytochrome P450 was a reducible 
pigment and only the reduced form could bind CO. A difference spectrum 
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could be obtained between cytochrome P450:Fe2+: CO and cyto-
chrome P450:Fe2• with a peak at 450 nm after reduction of all 
cytochromes and possibly flavins in both spectrophotometer 
cuvettes with sodium dithionite and subsequently bubbling the 
sample cuvette with CO. However~ in homogenates, haemoglobin 
will interfere in the assay since the difference spectrum between 
haemoglobin: Fe2+: CO (418nm) and haemoglobin1·: Fe2+ (430 nm) win 
overlap the cytochrome P450 peak. Further, the 30 fold excess cf 
haemoglobin over cytochrome P450( 258 ) would cause so much overlap 
in the difference spectrum that quantitative measurements of the 
cytochrome P450 by this procedure wou.ld be useless. 
By modification of this method to measure difference spectra 
between cytochrome P450: Fe2+: CO and cytochrome P4-50:Fe3+, which 
can be achieved by passing CO through both spectrophotometer 
cuvettes, with subsequent reduction of only the sample cuvette, haemo-
globin will not interfere in the assay for cytochrome P450 in liver 
homogenates. In this case the haemoglobin which is almost all pre-
sent in the reduced form (234 ) wi 11 combine wHh CO to form CO-
haemoglobin, the absorbances due to this balancing out in the dif-
ference spectrum. 
(b) Materials and Methods 
A sample of human or rat liver homogenate (100 mg/ml) was 
diluted with KCl: Tris buffer (4 parts l ,15% KCl and 1 part 0,25M 
Tris:HCl pH 7,5) to result in a solution containing from 2,5 to 10 
mg wet weight liver per ml, in a total of 2 ml. This solution 
was bubbled with CO at room temperature for 60 seconds, then divided .. 
between 2 semi-microcuvettes. These were placed in the "second 
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sample position" of the spectrophotometer, i.e. closest to the 
photomultiplier tube to minimise light scattering errors due to \ 
turbidity of the samples. In those cases where the hepatic cyto-
chrome P450 ·1evels were very low, e.g. in non-porphyric patients, 
recorder amplification was such that a full scale deflection cor-
responded to a change in extinction of 0,04 O.D. units. 
A baseline was· recorded from 410 nm to 500 nm then the sus-
pension in the sample cuvette was reduced by the addition of about 
l mg sodium dithion·ite. After a time interval of 2 to 3 min. the 
difference spectrum was recorded from 410 nm to 500 nm. 
(c). Comment on the Assay Method for Cytochrome P450 in whole 
Liver Homogenate 
Bubbling of the sample with CO was gentle, at approximately 
10 bubbles/sec. The fo-llowing criteria were applied for accepta-
bility of results:- In the baseline the change in absorbance 
readings between 490 and 450 nm should be less than 0,006, from 
490 to 430 nm less than 0,0150 and from 490 to 470 nm, less than 
0,004. Occasionally after addition of dithionite precipitation 
of sulphur in the cuvette caused rapid changes of absorbance with 
time. Results from experiments where this occurred were considered 
meaningless. The absorbance at 490 nm was monitored after addition 
of dithionite until the change in absorbance was less than 0,002 
per min. before scanning the spectrum. This time interval was usually 
between 2 and 3 min. The peak of absorbance at 450 nm requires 
this amount of time to develop after the addition of the reducing 
agent, which is in contrast to the almost immediate maximum found 
with the addition of CO in the method of Omura and Sato< 212 ). 
II. Cytochrome P450 Leve ts in Rat· Liver: Microsomes ·with: Carbon 
Monoxide as Ligand 
(a) Principles of Assay 
The method used for the determination of cytochrome P450 
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levels in microsomes was similar to that used by Omura and Sato< 212 ). 
The difference spectrum between cytochrome P450: Fe2+ : CO and 
cytochrome P450: Fe2+ was recorded. 
{b) Materials and Methods 
Q,6 ml of a microsomal suspension in 0,25M potassium phos-
phate buffer, pH 7,5 was diluted with 5,4 ml of the same buffer. 
The sample was equally divided between a sample and reference 
cuvette, then a baseline of equal light intensity was recorded 
from 410 nm to 500 nm. The contents of both the reference and 
sample cuvettes were reduced with approximately 1 mg sodium di-
thionite, then only the sample cuvette was gassed gently with 
CO for l min. The difference spectrum between the two cuvettes 
was recorded from 410 nm to 500 nm. 
(c) Comments on Assay Method for Determination of:Microsorilal 
Cytochrome P450 with Carbon Monoxide. 
The baselines always showed a difference in absorbance readings 
between 450 nm and 490 nm of less than 0,005. Cuvettes contained 
from 0,8 mg to 1,5 mg protein per ml. 
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III. CytochromeP450Determinatfons:fo:Rat;Liver:Mitrosomes·with 
Ethyl Isocyanide as Ligand 
(a) Principles of Assay 
In 1966, Imai and Sato<133) suggested the existence of two 
forms of cytochrome P450 in rabbit liver microsomes. Using 
ethyl isocyanide rather than carbon monoxide as the ligand for 
reduced haemoprotein (since ethyl isocyanide combines reversibly 
with haemoglobin and myoglobin to give characteristic spectra(317>, 
they observed Soret peaks at 430 and 455 nm. It was further found 
that the relative heights of the two peaks in respect of absorb-
ance at 500 nm was pH dependent. 
The use of ethyl isocyanide as a ligand for reduced P450 
haemoprotein is not quantitative but qualitative, in that a change 
in the ratio of 455 to 430 nm peak heights at a particular pH 
suggests the existence of a different haemoprotein from that which 
in its reduced form combines with CO to result in a peak at 450 nm 
in the difference spectrum< 274 l. 
(b) Materials and Methods 
0,6 ml of each microsomal suspension in 0,25 M potassium phos-
phate buffer at pH 6,0; 6,5; 7,0; 7,5 and 8,0 was di luted with 
5,4 ml of the corresponding buffer. Samples were divided between 
sample and reference cuvettes (3 ml capacity), and a baseline of 
equal light absorbance was recorded between 400 and 510 nm. A 
few grains of sodium dithionite {about l mg) were added to both 
cuvettes, then 0,6 ~l ethyl isocyanide was added to the sample cuvette. 
Absorbance was again recorded between 400 and 510 nm. 
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{c) Comment on P450 Assay with Ethyl Isocyanide 
Baselines of equal light intensity always showed a difference 
in absorbance readings at 430 nm and 455 nm of less than 0~004. The 
amount of protein per cuvette ranged from 2,2 mg to 3,3 mg, at the 
different pH's. 
(d) Ancillary Procedure - SynthesiS:of:Ethyl·Isocyanideaccording 
to Jackson and McKusick( 137). 
Ethyl isocyanide is not commonly synthesised hence the pro-
cedure is presented in detail. 
The reactions involved are as follows: 
.c2H5I + Ag CN + c2H5 NC.Ag! 
c2H5NC.AgI + 2 KCN + c2H5NC +· K Ag (CN) 2 + KI. 
(The recommended procedure was scaled down to one/tenth). 
Silver cyanide 45s49 (0,34 mol) was added with stirring to 53g 
(0,34 mol) ethyl iodide in a 500 ml round-bottomed flask with 
2 necks and containing a magnetic stirrer bar. One neck was 
then fitted with a reflux condenser, the other neck was closed. 
The flask was lowered into a beaker containing boiling water on 
a magn~tic stirre~ fitted with a heating plate. The reagents 
were vigorously stirred with the magnetic stirrer whilst in the 
boiling water bath, until a viscous homogeneous brown liquid re-
sulted (about 2 hours). The boiling water bath was removed and 
30 ml water was added through the condenser. Potassium cyanide 
6lg (0,937 mol) and 26 ml H20 was added through the second neck of 
the flask, and the reaction mixture was stirred without further 
heating for 10 minutes. Stirring was stopped, and the reflux 
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condenser was replaced with a distilla~ion condenser. A ther-
mometer was placed through the second neck of the flask into the 
aqueous layer. A receiving flask was put into an ice bath, and 
the reaction mixture was heated withan electric mantle. When 
the temperature of the residual mixture in the reaction flask was 
ll5°C, the distillation was discontinued. Sodium chloride 0,7g 
was dissolved in the aqueous layer contained in the receiving 
flask, then the ice~cold mixture was transferred to a separating 
funnel. The aqueous layer (lower phase) was separated and dis-
carded. The crude ethyl isocyanide was washed with two 5 ml por-
tions of ice cold saturated sodium chloride solution, then dried 
overnight with 1 g anhydrous magnesium sulphate. After decanting, 
the material was distilled, and the product which boiled off 
between 77 and 79°C was collected in an ice bath. 
Caution was exercised throughout the synthesis, since ethyl 
isocyanide has been known to explode. Ethyl isocyanide has a 
vile odour and the entire procedure was carried out in an efficient 
fume hood, equipped with a thick glass front. Furthermore, aqueous 
cyanide is extremely toxic, and was disposed of by flushing down a 
drain together with copious quantities of water. 
The pure ethyl isocyanide was stored in a sealed container 
at 4°c. 
5.3. Hepatic Aminoeyrine-N-Demethylation 
(a) Principles of Assay 
The hepatic microsomal mono-oxygenase system metabolises 
a wide variety of structurally dissimilar xenobiotics such as 
therapeutic agents, food additives, insecticides and chemical car-
cinogens(49). The usual in vitro assay of activity of a drug-
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metabolising enzyme is achieved by incubation of the hepatic post-
mitochondrial supernatant or microsomal fraction with a substrate 
and cofactors which include NADPH or an NADPH generating system, 
then measuring either substrate disappearance or metabolite forma-
tion. A widely used marker enzyme assay is oxidative demethylation 
(l02) of drugs, whereby the formaldehyde formed is quantitated spectro-
photometrical"ly after conversion to a chromogen in the Hantzsch re-
action<46,206). However, due to a limited sensitivity (l0-7 to 
10-8 moles of formaldehyde) using this method, a radiochemical 
method was developed by Poland and Nebert< 224 ) which enabled oxi-
dative N-demethylation to be measured in vitro in small samples of 
human liver biopsy material. 
Aminopyrine is metabolised to 4-aminoantipyrine and formalde-
hyde in two successive oxidative N-demethylations (163 ) as shown 
in fig .. 8, the reaction being catalysed by the hepatic microsomal 
oxygenase system. 
. 14 } For the radiochemical assay, the substrate used was 4- { CH3 2-
amino-2,3 dimethyl - l - phenyl - 3 - pyrazolin - 5 - one. Unreacted 
lipophilic substrate can be separated from the hydrophilic 14c-formal-
dehyde after reaction. In the course of reaction the 14c - formalde-
hyde reacts with sei:nicarbazide present in the assay mixture to form 
a semicarbazone: 
H14CHO + NH2NHCONH2 + 
Formaldehyde Semicarbazide 
H2
14cN : NHCONH2 
Formaldehyde Semicarbazone. 
The hydrophilic carbazone is easily separable from the hydro-






















Figure 8 Oxidative N-demethylation of aminopyrine by the 
hepatic mixed function oxidase system. 
65 
(b) · Materials:and:MethOds 
(1) A "cofactor" solution was freshly prepared as follows before 
the assay and kept under ice. All reagents were made up in 40 mM 
potassium phosphate buffer, pH 7,4. 
1 part each of: a. Semicarbazide Hydrochloride 0,5 M 
(stock solution) 
b. Nicotinamide 0,5M (stock solution) 
c. Magnesium Chloride 0,25 M (stock solution) 
d. NADP 0,05M 
10 parts of: e. Glucose-6-phosphate 0,15M 
The pH of this solution was adjusted to 7,4 with NaOH. 
(2) a. The substrate solution consisted of aminopyrine 0,05 M 
in 40 mM potassium phosphate buffer, pH 7,4, kept under 
ice. 
b.· {dimethylamino 14-c} Aminopyrine stock solution.was 
prepared by the addition of 5 ml 40 mM potassium phos-
phate buffer to a vial containing 250 µCi radioactivity, 
with specific activity of 9,6 mCi/mmol. 
Degradation of the stock solution of {dimethyl amino 
14-c} aminopyrfoe occurred. on storage -,at 4°c. To 
overcome this problem, just prior to assay, the stock 
solution was extracted with LO ml chloroform, then the 
chloroform was evaporated using a water bath at so0 c. 
The radioactive aminopyrine was red·issolved in 40 mM 
potassium phosphate buffer, pH 7,4. 
(3) Glucose-6-phosphate dehydrogenase solution was made up in 40 mM 
potassium phosphate buffer, such that 0,005 ml contained 0,5 Kornberg 
units of activity. 
For assay of aminopyrine demethylation, the incubation mixture 
consisted of 0,14 ml 11 cofactor 11 solution, varying amounts of substrate 
solution, ranging from 0,005 ml to 0,05 ml; and 0,020 ml· {dimethylamino 
14-c } aminopyrine. The volume of the incubation mixture was adjusted 
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to 0,445 ml with 40 mM potassium phosphate buffer, pH 7,4. 
At the start of the reaction, 0,005 ml glucose-6-phosphate 
dehydrogenase and 0,050 ml liver homogenate, (corresponding to 5 mg 
wet weight liver) were added to the incubation tube. 
was for 20 min. at 37°C, in a shaking water bath. 
Incubation 
The reaction was terminated by the addition of the incubation 
mixture to 8 ml cold chloroform contained in a 50 ml round bottomed 
glass test tube fitted with a ground glass stopper. One ml of 
O,l N NaOH was added for alkalinity and to facilitate sample handling. 
The tube was stoppered, and mixed using a Vortex mixer. The substrate 
was.by this step extracted into the chloroform phase, with the formal-
dehyde semicarbazone remaining in the aqueous phase. After centri-
fugation at 500 g for 20 minutes, 1,0 ml of the aqueous phase was 
reextracted with 8 ml chloroform, and the centrifugation was repeated. 
The radioactivity of the formaldehyde semicarbazone was determined by 
counting 0,5 ml of aqueous phase with 10 ml Instagel in a Beckman 
LS scintillation counter. 
In addition, the radioactivity of the· {dimethyl amino 14-c} 
aminopyrine used for each set of assays was determined by counting 
0,010 ml of a 1:100 dilution of the radioactive aminopyrine with 
10 ml Instagel in the liquid scintillation counter. 
Blanks were always assayed, and consisted of the entire reaction 
mixture to which liver homogenate had been added after incubation and 
addition to chloroform. 
For determination of 14c - formaldehyde recovery, 14C-formalde-
hyde was added to the reaction mixture containing rat liver homogenate 




c- formaldehyde semicarbazide in the aqueous phase after 
extraction was determined. 
All samples were recounted after the addition of 0,010 ml 
14
c-n-hexadecane to determine i counting effi ci enci es. 
(c) · Assay Proced~~ 
In a total incubation volume of 0,5 ml contained in a small 
glass test tube 0,05 ml liver homogenate .flOO mg wet weight liver/ 
ml) was incubated with NADP, 0,5 µmol; glucose-6-phosphate 
15 µmol; glucose-6-phosphate dehydrogenase, 0,5 Kornberg units; 
magnesium chloride 2,5 vmol; potassium phosphate, 20 µmol; 
semicarbazide hydroc;hloride 5 µmo·1; nicotinamide, 5 µrnol; and 
varying amounts of aminopyrine (0,25 µmol to 2,5 µmol) containing 
2 to 8 x 10
5 
dpm radioactive aminopyrine. Incubation was for 20 
0 min at 37 C, at pH 7,4. 
The reaction was terminated by addition of the incubation 
mixture to 8 ml cold chloroform, then l ml O,l N NaOH was added. 
The unreacted lipophilic substrate was extracted into the chloro-
form. The aqueous phase was re-extracted with a further 8 ml 
cold chloroform, then 0,5 ml of the aqueous phase was counted with 
10 ml Instagel in a Beckman scintillation counter. Samples were 
again counted after addition of 14c-n-hexadecane as internal 
standard. 
5.4. Hepatic 3,4-Benzpyrene Hydroxylation 
{a) Principles of Assay 
Another widely used marker enzyme assay for the hepatic 
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microsomal mono-oxygenase system is the hydroxylation of 3,4-
benzpyrene. The assay method foll owed was the spectrofl uoro-
metri c method of Kuntzman et al(lS?) as modified by Alvares et 
a1<
5
) as described previously( 22 ). Small amounts of tissue may 
be used in the assay system, since the product of the hydroxyla-
tion reaction, viz. hydroxy-3,4-benzpyrene is highly fluorescent, 
thus small amounts of product can be determined. 
Under the conditions of the assay, 3,4-benzpyrene is con-
verted to a variety of phenolic and other hydroxylated products 
(131,264) 
However the activation and fluorescence spectra of 
the.hydroxylated metabolites are largely identical to that of 3-
hydroxy-3,4- benzpyrene, one of the major products, and thus used 
as a standard to calculate the amount of hydroxy-3,4-benzpyrene 
. formed. The reaction involved is shown in fig. 9. The 3,4-
benzpyrene and its metabolites are extracted into an organic 
phase, then the hydroxylated products are extracted into sodium 
hydroxide solution in which they are more soluble. The 3-hydroxy-
3, 4-benzpyrene can then be determined spectrof I uorophotometri ca lly. 
By addition of albumin to the incubation system, linear re-
action rates could be obtained with microsomes from small amounts 
of liver (less than 10 mg) (S). Two possibilities for the mecha-
nism of action for albumin were proposed: a. that albumin or a high 
concentration of microsomes could solubilise the 3,4-benzpyrene, or 
b. an inhibitor e.g. a heavy metal, in the cofactor mixture, inhibits 
the enzyme system at low enzyme concentrations. Added albumin 
could bind the inhibitor and prevent its access to enzymatic sites 
in the microsomes. Thus to ensure that the reaction was linear for 
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Hydroxylation of 3,4-benzpyrene by the hepatic mixed 
function oxidase system. 
biopsy samples, albumin was always included. 
(l) A"cofactor"solution was freshly prepared as detailed below 
and kept under ice. All reagents were made up in O,lM potassium 
phosphate buffer, pH 7,4. 
1 part each of: a. NADP 0,005 M 
b. . NAO 0,006 M 
c. ATP 0,01 M 
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d. Potassium chloride 2 M {stock solution) 
e. Magnesium chloride 0,1 M (stock solution) 
2 parts each of: f. Nicotinamide 0,06 M (stock solution) 
g. Glucose - 6 - phosphate 0,03 M 
The pH of this solution was readjusted to 7,4 with NaOH. 
{2) A substrate solution was freshly prepared, and consisted of 
50 µg 3,4-benzpyrene dissolved in l ml acetone. 
(3) Glucose - 6 - phosphate dehydrogenase solution was made up in 
0,1 M potassium phosphate buffer, pH 7,4, such that 0,005 ml con-
tained 5 Kornberg units of activity. 
(4) Albumin was dissolved in O,l M potassium phosphate buffer to 
a concentration of 300 mg/l. 
For assay of 3,4··benzpyrene hydroxylation, the incubation medium 
consisted of 0,9 ml cofactor solution, 2 ml O,lM potassium phosphate 
buffer containing 0,6 mg albumin and 0,020 ml liver homogenate (cor-
responding to 2 mg liver wet weight). This incubation system was 
preincubated at 37°C for 5 min. The reaction was initiated by the 
addition of 0,005 ml glucose - 6 - phosphate dehydrogenase solution 
and varying quantities from 0,020 ml to 0,100 ml of the 3,4-benz-
pyrene substrate. A further quantity of acetone was added so 
that the total incubation volume was 3,025 ml. 
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Incubation was for 20 min at 37°c in a shaki.ng water bath, 
in very dim light. 3 ml cold acetone was added to terminate 
the reaction, followed by the addition of 9 ml n-hexane. 3,4-
benzpyrene and its hydroxylated metabolites were extracted into 
the organic phase by mixing on a Vortex mixer. An 8 ml aliquot 
of the organic ·1ayer was shaken with 5 ml 1,0 N NaOH for l min, and 
the fluorescence of the extracted hydroxylated metabolites of 3,4-
benzpyrene in alkaline solution was determined exactly 10 min. later 
using an Aminco-Bowman Spectrophotofluorometer at an activating 
wav~1ength of 382 nm and emission wavelength 510 nm, after standardi-
sation of the instrument with quinine sulphate. The solvent ex-
tractions were performed in very dim light. 
In order to standardise the Aminco-Bowman Spectrophotofluoro-
meter, adjustments were made so that the reading was 33% when 
the meter multiplier was set on 0,1 for quinine sulphate solution 
(300 ng/ml) in 0,1 N sulphuric acid, at an excitation wavelength of 
340 nm and an emission wavelength of 455 nm. When a 100 ng/ml solu-
tion of 3-hydroxy-3,4-benzpyrene in 1 N NaOH was measured spectro-
photofl uorometrical ly at an excit~tion wavelength of 382 nm and an 
emission wavelength of 510 nm, without further adjustment of the 
machine after standardisation with quinine sulphate, the reading ob-
tained was 51. 5%. Thus each division on the.scale corresponded to 
l,942 ng 3-hydroxy-3,4-benzpyrene. Because of the limited supply 
of 3-hydroxy-3,4-benzpyrene, quinine sulphate was routinely used for 
standardisatfon. 
Blanks were always included for each set of assays and consisted 
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of the entire reaction mixture to which 3,4-benzpyrene ,substrate 
was added only after the addition of 3 ml cold acetone. 
In order to determine the recovery of hydroxylated metabolites 
from the incubation system by the solvent extraction procedure 
described above, 50 ng 3-hydroxy-3,4-benzpyrene contained in 0,050ml 
acetone was added to a complete reaction mixture including liver 
and 3,4-benzpyrene and extracted immediately. 
(c) Assay Procedure 
The reaction mixture for the assay in a total volume of 3,025 
ml contained 0,02 ml liver homogenate (100 mg/ml); glucose-6-phos-
phate, 6 µmol; NAOP, 0,5 µmol; NAO, 0,6 µmol; ATP l µmol; nico-
tinamide, 12 µmol; potassium chloride, 200 µmol; magnesium 
chloride, 10 µmol; glucose-6-phosphate dehydrogenase, 5 Kornberg 
units; potassium phosphate, 300 µmol;bovine serum albumin 0,6 mg; 
and from 4 to 20 nmol 3,4-benzpyrene (added in O,l ml acetone). 
Reactions were initiated with glucose-6-phosphate dehydrogenase 
and 3,4-benzpyrene after pre-incubation for 5 min. at 37°c. The 
mixture was incubated for 20 min. at 37°c in a shaking water bath 
in the dark. The reaction was terminated by the addition of 3 ml 
cold acetone, then the 3,4-benzpyrene and its hydroxylated products 
were extracted with 9 ml n-hexane. 8 ml of the organic phase was 
extracted with 5 ml 1,0 N NaOH for l min.,then the fluorescence of 
the extracted 3-hydroxy-3,4-benzpyrene in the alkaline aqueous 
phase was determined in an Aminco-Bowman spectrophotof luorometer 
(activation 382 nm; fluorescence 510 nm) exactly 10 min. later. 
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{d) Comment 
The entire assay procedure for 3,4-benzpyrene hydroxylation 
was performed in very dim light because the decomposition of the 
hydroxylated metabolites of 3,4-benzpyrene is accelerated by light. 
Fluorometric measurements were speedily executed after addition of 
1,0 N NaOH, since the fluorescence of the metabolites in alkaline 
solution decreases with ti me. 
5.5., Red Blood Cell and Hepatic UROGEN-I Decarboxylase 
(a) Principles of Assay 
UROGEN III is converted to the tetracarboxylic COPROGEN-III 
in an intermediate step in the biosynthesis of haem( 165 )~ Enzyme 
preparati ans from bacteria (1 25 ), ·avian red ce 11 s ( 301 ) ,mamma 1 i an 
reticulocytes( 198), erythropoietic murine spleen( 242 ) and porcine 
liver(
162
) have all been shown to catalyse the sequential decar-
boxylation of the four acetic acid side chains. A single enzyme 
is thought to be responsible for the removal of all four carboxyl 
groups, although the first decarboxylation proceeds more readily 
than the subsequent three( 39 ). 
UROGEN-I was chosen as the substrate for the decarboxylase 
assay, since it was shown that UROGEN decarboxylase from mouse spleen 
(
242
) and a pig liver extract as enzyme source( 162 ) decarboxylated 
both I and III isomers at the same rate. The radiochemical assay 
used was essentially that of Kushner et a1(lSB,lfi2) with further 
modifications described hereunder. In essence, 14c-PBG is converted 
to UROGEN-I at pH 7,65 using a bacterial preparation of UROGEN-I-
synthetase. No UROGEN cosynthetase is present, thus only the isomer 
I will be formed. The 14C-UROGEN-I formed is used directly at pH 6,8 
as substrate for the decarboxylase present in an haemolysate or liver 
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post-mitochondrial supernatant. At this pH no further UROGEN I 
is generated. By a stepwise decarboxylation the 14c-UROGEN-I 
is converted to COPROGEN-I as shown in Fig. 10. 
The substrate and 'products of the reaction, which include 
all the intermediate porphyrinogens, viz. 7,6,5 and 4 carboxyl 
porphyrinogens are firstly converted to the porphyrins and subse-
quently to methyl esters, which are eas1 Jy separable by thin layer 
chromatography. The 14c-labe11ed porphyrfo metllyl esters can then 
be isolated from the thin layer chromatography plates, and counted 
in a liquid scintillation counter. 
(b) Materials and Methods 
(i) Incubation Conditions 
The usual incubation system contained 0,15 ml 
0,00885 M 
14
c-PBG of specific activity 0,12 mCij.mmol; 
0,1 ml 0,066M L-cysteine; and 0,1 ml of a 7 mg/ml solu-
tion of bacterial UROGEN-I synthetase. The solutions 
were made up in 0,1M tris:HCl, pH 7,65, and the volume 
of the incubation mixture was adjusted to 0,~ ml with 
the same buffer. 
In some of the experiments, a modi fi ca ti on w·as 
made in that 
14
c-UROGEN-·I was generated from 14c-ALA 
in the presence of a mixture of bacterial ALA-dehydra-
tase and UROGEN-I synthetase. In this case, the 
assay mixture consisted of usually 0,05 ml 0,02994M 
14
c-ALA of specific activity· 0,42 mCi/mmol; and 0,1 ml 
0,066 M L-cysteine and 0,1 ml of a 7 mg/m"J solution of 
ALA dehydratase and UROGEN-I synthetase. Again,the 
solutioris were made up in 0,1 M tris:HCJ buffer, and the volume 
of the incubation system was adjusted to 0,5 ml with the 
same buffer. 
Reactions were initiated by the addition of the en-
zyme solutions. After an initial incubation in the dark 
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Figure 10 The stepwise decarboxylation of UROGEN-I through 7-, 6-
and 5-carboxyl porphyrinogens to COPROGEN-I, catalysed 
by UROGEN decarboxylase. 
0,2 ml liver post mitochondrial supernatant. The 
final incubation volume was adjusted to 1 ml with 
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0,1 M tris:HCl, pH 6,8 then the sample was incubated 
for a second period of 30 min. at 37°c, with shaking, 
in the dark. The reaction was terminated by the addi-
tion of 1 ml 3 N HCl. 
(ii) Extraction and Esterification of Porphyrins 
The sample was centrifuged on a Roto-Uni bench 
centrifuge, and after transfer of the supernatant to 
a second centrifuge tube, the pH was adjusted to 3,1 
, J 
with saturated sodium acetate. Approximately lg talc 
was ~dded to adsorb and oxidise the porphyrinogens. The 
sample was allowed to stand in the dark for l hr with 
occasional stirring using a Vortex mixer. After centri-
fugation on a bench centrifuge and discarding the super-
natant, the talc was dried by washing with 2 ml methanol. 
The porphyrins were converted to their methyl esters on 
the talc with 3 ml 5% H2so4 in methanol, the sample 
being left overnight in the dark. 
(iii) Extraction of Porphyri n Methyl Esters 
The talc was repeatedly washed with 2 ml aliquots 
of 5% sulphuric acid in methanol until no further 
fluorescence was detectable in the wash under ultra-
violet light. The porphyrin esters in the pooled 
washes were extracted into CHC1 3 by addition of CHC1 3 
equal to half the volume of methanol/sulphuric acid, 
and 7% NaCl,resulting in a final volume 3 times that 
of the methanol/sulphuric acid. After washing of the 
CHC1 3 layer with an equal volume of 10% NH40H, followed 
by washing with an equal volume of 7% NaCl, it was fil-
tered through CHCl 3-wetted filter paper (~Jhatman no. 1) 
into a beaker. 
(iv) Chromatography of Porphyrin Esters 
The ch 1 oroform was evaporated by di rec ting a stream 
of air from a hairdrier into the beaker containing the 
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porphyrin ester solution. The esters were redis-
solved in 0,5 ml fresh chloroform and either an ali-
quot of 0,2 ml was applied to a silica gel TLC aluminium 
backed plate as a spot, or the entire sample was applied 
as a band, in both cases using a 100 µl Hamilton syringe 
to apply the porphyrin ester solution. Applications to 
TLC plates werf~ made with a stream of air from a hair-
drier blowing onto the plate. To each plate URO-
COPRO- and PROTO- esters were applied as chromatographic 
markers. Plates were eluted with a solvent system 
consisting of carbon tetrachloride, dichloromethane, 
ethyl acetate and ethyl propionate in the ratio 2:2:1:1 
{263) . 
Development of the plate in the solvent system was 
allowed to proceed until the solvent front had migrated 
12 to 16 cm from the origin. 
(v} Scintillation Counting 
After drying,the TLC plate was exposed to ultra-
violet light and the positions of 8-COOH, 7-COOH, 
6-COOH, 5-COOH and 4-COOH porphyrin esters were marked. 
Each of the fluorescent spots or bands was scraped off, 
the scr$ipings being placed in a counting vial. 10 ml 
Instagel was added to the scrapings and samples were 
counted in a Beckman scintillation counter. 
(vi) Control Assay 
A blank assay for UROGEN-I-decarboxylase was always 
perfonned in duplicate witheach set of assays. Assay 
was done exactly as described previously, but no enzyme 
source for the decarboxylase was added prior to the 
second incubation, the volume being made up to l ml with 
0,1 M tris:HCl, pH 6,8. The apparent UROGEN-I-decarboxy-
lase activity observed in these samples (due to the pos-
sible presence of UROGEN-I-decarboxylase as a contaminant 
in the enzyme preparations) was then applied as a correction 
factor in the calculation of UROGEN-I-decarboxylase activity 
in red blood cells or liver. 
(c)·· Assay:p~otedore 
In a total volume of 0,5 ml, the reaction mixture contained 
PBG including 
14
C-PBG, 1,33 wiol; L-cysteine, 6,61 µnol; 
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UROGEN-I synthetase (sufficient to produce 25 - 30 nmol UROGEN-I); 
tris:HCl 50 wiol; pH 7,65. For preparation of the 14c-UROGEN-I 
substrate from 
14
C-ALA, the reaction mixture contained ALA including 
14 -
4- C-ALA, 1,497 lJmol; L-cysteine, 6,61 JJJTiol; a mixture of ALA-
dehydratase and UROGEN-I synthetase (sufficient to produce 25 - 30 
nmol UROGEN-I); tris:HCl 50 lJJTiol, pH 7,65. Reactions were always 
initiated with the enzyme preparation. 
After incubation for 30 min. at 37°c in the dark with shaking, 
KH2Po4, 40 lJJTlol; haemolysate containing from 30 to 60mg haemoglobin 
or a post-mitochondrial liver supernatant containing l ,5 to 2,5 mg 
protein; and 0,1 M tris:HCl pH 6,8 were added to result in a total 
volume of 1 ml. Following a further incubation of 30 min. at 
37°C in the dark with shaking, reactions were terminated by addition 
of 1 ml 3 N HCl. After centrifugation, the pH of the supernatant 
was adjusted to 3,1 with saturated sodium acetate, and the porphyrins 





The porphyrin methyl esters were transferred into chloroform, and 
identified chromatographically on aluminium backed silica gel TLC 
plates, developed with carbon tetrachloride, dichloromethane, ethyl 
acetate and ethyl propionate in the ratio 2:2:1:1(263). The silica 
gel at the fluorescent spots was scraped off into Instagel and the 
radioactivity determined .. 
(d) Comment 
In each series of assays for UROGEN-I decarboxylase, the 
amount of enzymatically produced UROGEN-I substrate was determined 
as detailed in (e)(i) below. In one series of experiments, the 
effects on UROGEN-I decarboxylase of ferrous ammonium sulphate, 
ferritin and l, 10-phenanthroline added to the assay medium were 
assessed. Solutions were made up in O,lM tris:HCl, pH 7,65 and 
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. either 0,05 ml 0,020M ferrous ammonium sulphate or 0,005 ml of a l:l 
dilution of commerdal ferritin in .15 M NaCl or 0, 15 ml 0,020M 
l,10-phenanthroline, were added at the start of incubations. The 
volume· of O,lM tris:HCl, pH 7,65 was adjusted to result in an initial 
incubation volume of 0,5ml. The assay was perfonned as described 
in (b) and (c) above using rat liver as the source of UROGEN-I 
decarboxylase. Further, the quantity of UROGEN-I generated in the 
presence of each of these additives was determined as described in (e)(i) 
below. 
In another experiment, the effect of increasing concentrations of 
ferrous iron in the incubation medium on UROGEN-I decarboxylase was 
investigated. From 0,002 ml to 0,05 ml 0,005 M ferrous ammonium sul-
phate in 0, lM tris:HCl, pH 7,65 for the lower concentrations and from 
0,02M to 0, 10 ml 0,0200 ferrous ammonium sulphate in the same buffer 
for the higher concentrations, was added at the start of incubation. 
Suitable adjustments in the volume of O,lM tris:HCl buffer, pH 7,65 
again were made, to result in an initial incubation volume of 0,5 ml. 
The assays were performed as described previously with rat liver as 
the source of UROGEN-I decarboxylase. Again, the quantity of UROGEN-I 
substrate generated at each concentration of Fe2+ was determined. 
In some of the later experimental work, an alternative method was 
utilised for the oxidation of the porphyrinogens produced in the 
the UROGEN-I-decarboxylase assay, and a modified method was 
used for the esterification and extraction of porphyrins. 
These modifications will be described in Section 6.12. 
( e) ·Anti l_l ary ·Procedures ·to· UROGEN_._ I _._Decarboxyl ase · Atti vi ty 
· · Determilia tions 
{i) Determination of· UROGEN-I Substrate Formed 
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The determination was performed in duplicate concur-
rently with each group of assays for UROGEN-I-decarboxy-
lase. The incubation mixture was identical to that 
described in section 5.5.(b) for UROGEN-I-decarboxylase 
assay, as were the incubation conditions. However, no 
enzyme source for UROGEN decarboxylase was added prior 
to the second 30 minute incubation, this beingreplaced 
by the appropriate volume of 0, l M tris:HCl, pH 6,8. 
At the end of the second 30 min. incubation period, the 
UROGEN-I which had been formed was converted to URO-I 
by the dropwise addition of 0,2 M iodine in 0,3 M potas-
sium iodide to the assay tube until a straw yellow colour 
was obtained. This was immediately fol lowed by the 
addition of a crystal of sodium thiosulphate to reduce 
any excess iodine. 
The absorbance of the solution was determined im-
med"iately at 560 nm <29 ). The reference cuvette contained 
all reagents used in the assay including UROGEN-I synthetase 
or a mixture of ALA-dehydratase and UROGEN-I synthetase, 
added just prior to spectrophotometry. 
To determine the degree of autooxidation of UROGEN-I 
under the conditions of assay, porphyrin content was deter-
mined both before and after treatment with iodine. 
(ii) The Extinction Coefficient for URo~r at 560 nm in the 
· ·rntubation Mixture for UROGEN~r~necarboxylase. 
The millimolar extinction coefficient for URO at 560 nm 
has been determinedas 7,59 cm-1mM-l in 0,1 M tris, pH 8,2, 
using a Cary spectrophotometer< 29 >. It was felt necessary 
to check this figure, since UROGEN-I determinations (equiva-
lent to URO-I determinations assuming complete oxidation of 
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the porphyrinogen) described in the previous section 
were made at pH 6,8 using a Pye Unicam SP 1700 Ultra-
violet Spectrophotometer, in the presence of UROGEN-I 
synthetase. 
Approximately 10 mg chromatographically pure URO-I 
was weighed and dissolved in O,lM tris:HCl, pH 7,65 to 
result in a solution which was 200 µM in respect of 
URO~I. Varying quantities of this up to 0,14 ml were 
added to solutions containing 0,15 ml 8,85 mM solution 
of 
14
c-1abelled PBG, 0,1 ml 0,066 M .~~cysteine and O,lM 
tris:HCl, pH 7,65. to result in a volume of 0,4 ml. In 
each case, 0,1 ml 0,4M KH2Po4 and 0,4 ml O,lM tris:HCI, 
pH 6,8 were added. 
0,2M iodine in 0,3M KI was added dropwise to each 
sample until a straw yellow colour was obtained, followed 
immediately by the addition of a crystal of sodium thio-
sulphate. Optical densities of the solutions at 560nm 
(i.e. the maximum absorbance in the region 550 nm to 565 nm) 
were determined after the addition of O,l ml of a 7 mg/ml 
solution of UROGEN-I synthetase to each solution. A 
solution containing the above reagents, with the exception 
of URO-I, which was replaced by O,lM tris:HCl, pH 7,65, 
was· used-in the-reference cuvette. 
(iii) Establishment of Substrate and Enzyme Concentrations for 
G~neration of Sufficient UROGEN-[ for the Assay of 
UB.0.G.Ul- T - Dt.=>ca.r.b.ax.'ll..as.e... 
In most of the studies where the activity of UROGEN-I-
decarboxylase in human red blood cells and in the livers of 
rats was determined, UROGEN-I synthetase and 14c-PBG were 
used in the generation of 14C-UROGEN-I. It was necessary 
at an early stage to determine·the concentrations of enzyme 
and substrate, which, under the conditions of incubation, 
would result in the formation of the 25 - 30 nmol UROGEN-I 
required as substrate for the UROGEN-I decarboxylase. Thus 
in an initial experiment, incubations were performed as des-
cribed in (i) above, but where an arbitrary and convenient 
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amount of enzyme, O,lml of a 7 mg/ml solution was incu-
bated in the presence of varyi_ng volumes of a 2 mg/ml 14c-
PBG solution. 
In some of the later studies, a mixture of ALA de-
hydratase and UROGEN-I synthetase was used to generate 
14 . . 14. . 
C-UROGEN-I from C-ALA. In the initial experiment to 
determine the enzyme and substrate concentrations required 
for the generation of 25 - 30 nmol UROGEN-I, incubations 
were performed exactly as described above, but 0,1 ml of 
a 7 mg/ml solution of the ALA dehydratase/UROGEN-I synthe-
tase mixture was incubated in the presence of various quan-
tities of a 5 mg/ml [0,02994M) 14c~ALA solution.· 
5.6; Porphyrin Deternrinations in Liver, Urine and Faeces of Rats 
I. Liver 
(a) Principles of Assay 
After excision of the livers from rats,weighed amounts of 
liver are homogenised with 5% H2so4 in methanol. In this way the 
porphyrins present are directly esterified, the esters subsequently 
being extracted into cl11oroform. Aliquots of the chloroform extract 
are chromatographed on thin layer plates, then the plates are scanned 
using a Vitatron VLD 100 densitometer, fitted with an integrating 
recorder. By comparison of areas under each peak with the areas under 
the peaks of known quantities of porphyrin ester standards, the 
quantity of each porphyrin in the liver can be calculated. 
(b) Materials and Methods 
From 40 to 80 mg liver (in the case of HCB-treated animals} 
and from 200 to 250 mg liver (in the case of control animals) were 
accurately weighed. The liver samples were homogenised with 5 ml 
5% H2so4 in methanol. After al towing the porphyrins to esterify 
overnight in the dark, the methyl esters were extracted into 
CHC1 3 by addition of 5 ml CHC1 3 and 5 ml 7% NaCl. The CHC1 3 
layer was then washed successively with 10% NH40H and 7% NaCl, 
followed by filtration through CHC1 3-wetted Whatman no. 1 filter 
paper. After evaporation of the CHC1 3 as described in Section 
5.5{b), the esters from the porphyric livers were redissolved in 
1 ml CHC1 3. A 5 µl aliquot of the ester solution was applied as 
a spot with a Hamilton syringe to an aluminium-backed thin layer 
chromatography plate. The porphyrin esters from the control 
livers were redissolved in 0,5 ml CHC1 3, with 50 µl being applied 
as a spot to the thin layer chromatography plate. 
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To each plate, URO- COPRO- and PROTO- esters in CHC1
3 
with 
respective concentrations of .006361 mg/ml, 00832 mg/ml and .005553 
mg/ml were applied to the same spot. (The concentrations of the 
standard solutions was checked periodically by measuring the ab-
sorbance at 380nm, the absorbance maximum between 395 and 410 nm 
and at 430 nm). The plates were eluted with a solvent system 
consisting of 2:2:1:1 carbon tetrachloride, dichloromethane, ethyl 
acetate and ethyl propionate. After development and drying, each 
spot was scanned in a Vitatron VLD 100 densitometer, fitted with a 
399 nm activating filter and 620 nm emission filter. The area 
under each peak was recorded with an integrating recorder. 
II. Urine 
(a) Principles of As~ 
The quantitative assessment of urine by thin layer chroma-
tography is not satisfactory, but this method can be used· for 
qualitative work. The method of choice for quantitating URO and 
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COPRO is the solvent extraction method of Rimington and Sveins-
son(241 >. Using this classical technique, COPRO is extracted 
from urine with glacial acetic acid and ether, and URO is ex-
tracted with cyclohexanone at pH l ,5. However, it should be 
realised that the 7-, 6-, and 5 carboxylated porphyrin"s will con-
taminate both fractions. 
{b) Materials and Methods 
(i) Qualitative Assessment 
The pH of 5 ml of pooled rat urine was adjusted 
to 3,1 with saturated sodium acetate. Approximately 
lg talc was added to adsorb the porphyrins, then the 
sample tube was allowed to stand in the dark for l hr 
·with occasional stirring using a Vortex mixer. The 
tube was centrifuged on a Roto-Uni bench centrifuge, 
and the supernatant was discarded. The talc was dried 
by washing with 2 ml methanol, then the porphyrins were 
esterified overnight in the dark by the addition of 5 
ml 5% H2so4 in methanol until no further fluorescence 
under a Woods lamp was detectable in the wash. The 
esters were extracted into chloroform as described in 
Section 5.5.(b)(iii), washed, filtered and evaporated. 
After reconstitution with 1 ml chloroform, an aliquot 
of the porphyrin ester solution was applied as a spot 
to a thin layer chromatography plate - sufficient 
being applied to be easily visible as a fluorescent 
red spot under ultra-violet light. Standard URO-, 
COPRO-, and PROTO- esters were applied to each plate 
as markers. The plates were eluted and scanned as in section 
5.6.I(b), without recording of the areas under the peaks. 
_ (ii) Quantitative Assessment 
Urinary 11 UR0 11 and 11 COPR0 11 fractions were quantitated 
according to Rimington and Sveinsson( 241 ). A 5 ml ali-
quot of pooled urine from control rats or an 0,5-1,0 'ml 
aliquot of pooled urine from HCB-treated rats was taken 
for analysis. The urine was acidified with 0,1 volumes 
83 
of glacial acetic acid and extracted with 20 ml aliquots 
of ether until no further fluorescence was extractable. 
The ether extracts were pooled, and washed with 20 ml 
0,5% sodium acetate, 20 ml 0,005% iodine and 10 ml dis-
tilled water. All aqueous phases from the ether extraction 
were pooled for uURO" determination. 
The ether solution was extracted with repeated 2 ml 
volumes 1 ,5 N HCl until no further fluorescence could 
be extracted. The HCl extracts were combined for 11 COPR0 11 
determination and volume recorded. 
The pH of the residual urine and combined aqueous washes 
was adjusted to l ,5 with 10% HCl. The solution was extrac-
ted twice with 40 ml volumes of cyclohexanone, then 80 ml 
petroleum ether was added to the pooled cyclohexanone. 
"UR0 11 was extracted with repeated 2 ml volumes of 2% HCl 
until no further fluorescence was extractable, and the 
HCl extracts combined for URO determination. The volume 
of the HCl pooled extracts was recorded. 
The absorbances for "COPRO" and "URO" against 1 ,5N 
HCl and 2% HCl respectively at 380 nm, the absorbance 
maximum between 400 and 410 nm, and at 430 nm were deter-
mined. 
I I I. Faece~ 
(a) Pri nci p I es of Ass.~ 
Because the object in analysing faecal porphyrins was to detect , 
the presence of the porphyrin P1 fraction, this being indicative of 
PCT or a PCT-like syndrome(?B, 79 ), it was necessary only to do a quali-
tative analysis. Ttlis was achieved by thin layer chromatography of 
the porphyrin methyl esters. 
( b) Mated al s and Methojj_s 
Faeces were pooled and mixed with a pestle and mortar. To 2g 
of this mixture was added 5 ml 1,5 N HCl after which it was stirred 
for 5 min. with a glass rod. The faecal residue was separated by 
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centrifugation in a Roto-Uni bench centrifuge, and after decanting, 
the pH of the supernatant solution was adjusted to 3,1 with saturated 
sodium acetate. The porphyrins were adsorbed onto talc, esterified 
and the methyl esters analysed as detailed in Section 5.6(II)(b)(i). 
5.7. Other Methods Used in the Experimental. Work 
I. Haemoglobin Determination in Haemolysates 
The haemoglobin concentration in haemolysates was determined by 
the cyanmethaemoglobin method, using Aculute Diluent Pellets and 
Acuglobin Haemoglobin Standard (Ortho Diagnostics, Raritan, N.J.) 
Usually 20 µl of haemolysate was added to 5 ml Aculute Diluent, and 
the absorbance determined after lO min. at 540 nm against Aculute 
Diluent as a blank. Readings were compared to that obtained for 
Acuglobin Haemoglobin Standard against Aculute Diluent, for calcula-
tion of haemoglobin concentrations. 
II. Protein Determinatfons 
These were made by the method of Lowry et al(l?B) using bovine 
serum albumin, fraction V as standard. All protein determinations 
were made so that the amounts measured ranged from 0,05 mg to 0,25mg 
thus falling within the linear range of concentration as measured 
spectrophotometri ca l"ly at 750 nm. 
III. Determination of Total Hepatic Iron 
(a) Principles of Assay 
Ferrozine has been used by Carter(43 ) to spectrophotometrically 
determine serum iron, at the submicrogram level. Furthermore, the 
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method has been adapted slightly by Montgomery et al( 203) to measure 
microsomal iron. In this study, the method had been extended to 
the measurement of total hepatic iron. Ferrozine, or the disodium 
salt of 3-:(2-·pyridyl) -5,6··bis-(4-phenylsulphonic acid)-1,2,4-triazine 
is a bidentate ligand, and with iron forms a stable magenta coloured, 
water soluble iron II complex, which is spectrophotometrically deter-
mined at 562 nm. 
(b) Assay Procedur~ 
Rat liver homogenate, 0,1 ml was oxidised at 100°c for 24 hours 
· with·l.9 ml 10% perchloroacetic acid and 15% hydrogen peroxide. 
0,1 ml of the oxidised-homogenate was added to 0,4 ml deionized 
water in a centrifuge tube and to this solution was added 0,5 ml 
of a reducing solution consisting of 20 mg ascorbic acid and l ,67 
ml concentrated HCl per 100 ml. The solution thus obtained.was 
allowed to stand at room temperature for 5 to 10 min., then 0,5 ml 
of an 11 ,3% trichloracetic acid solution was added to precipitate 
the proteins. After centrifugation in a Roto-Uni Bench centrifuge 
for 5 min. at 1500 rpm, ·1 ,0 ml of the clear supernatant was trans-
ferred to another tube. To this was added 0,4 ml 10% NH4COOH, and 
0,1 ml of colour reagent. The colour reagent was made by dissolving 
75 mg ferrozine and 25 mg neocuproin in 25 ml deionized water containing 
one drop of concentrated HCl. The colour was allowed to develop for 
5 min. before the absorbance was determined at 562 nm against water. 
A blank and a standard were prepared with each set of unknowns 
where the oxidised liver homogenate was respectively substituted by 
deionized water and 0,5 ml of a 1:100 dilution of standard solution. 
This consisted of {NH4)2so4. Feso4. 6H2o, 0,7 O 2g per liter, made up 
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to contain 0,5 ml concentrated sulphuric acid. 
IV. MicroscoQic Studies 
It was an important part of the experimental work to corre-
late microscopic studies with biochemical findings. The microscopic 
studies and their interpretation were performed by Dr. B.L. Webber of 
the Department of Pathology, University of Cape Town Medical School. 
{a) Fluorescence micro~. 
An International Harris Cryostat {Model CTD) was used to obtain 
frozen sections. These sections were examined in an Olympus FLMP 
2 fluorescence microscope, with a mercury vapour lamp as the light 
source with a UV excitor and 0-54 barrier filters. The samples were 
exposed to artificial lighting for the minimum period of time, i.e. 
less than 10 min. 
{b) Light Microscop,l_ 
Tissues fixed in formalin were examined after staining with 
haemotoxylin and eosin(53 ). Tissue was stained also for reticulin 
by the method of Gordon and Sweet( 53 ), as well as for haemosiderin, 
using Perls Prussian Blue stain with heated reagents( 53 ). 
{ c) Electron MJs_roscoe_y 
Tissues that were fixed immediately after biopsy in 5% phos-
phate buffered glutaraldehyde were po.st-fixed in Palade's osmium 
fixative. The tissues were embedded in Spurr's resin and cut on 
an LKB automatic ultrarnicrotome with glass knives. Sections were 
stained with uranyl acetate and lead citrate, then examined on a 




The 38 patients selected as controls for biochemical studies 
admitted to excessive alcohol intake and had clinical, biochemical 
or histologic evidence of ethanolicliver damage. They exhibited 
no biochemical evidence of dera.nged porphyrin metabolism, as 
assessed by screening tests for urinary and faecal porphyrins( 75 ) . . 
The screening tests, which were performed in the Porphyrin Diag-
nostic Laboratories, Groote Schuur Hospital, proved to be negative 
in each case. 
Sixteen of the 19 patients with clinical symptoms of PCT 
admitted to excessive alcohol intake. In one patient, H.G., 
there was no history of alcohol, and another was taking oral contra-
ceptives. In patient B.H., aged 8, there was no history of alcohol; 
nor was there any evidence that the patient had ingested any por-
phyrogenic toxin. On liver biopsy, the only abnormality was fatty 
change. Hepatic siderosis could not be demonstrated. 
6. l.(a) Porphvrin_Excretion and Accumulation in PCT 
Quantitat·ive analysis by the Porphyrin Diagnostic Laboratory of 
porphyrins present in the excreta of the 19 patients with clinical 





Porphyrin _Excretion in 19 Patients with PCT 
Urine (119Ll i ter.:J Faeces (µg/g) 
URO COP HO --- COP RO PROTO 
2356 569 129 91 
262-5279 86-1262 11-597 11-253 
In all cases the quantity of urinary URO was elevated above 
that of urinary COPRO. The separation of urinary porphyrins 
as their methyl esters by thin layer chromatography yielded a 
profile similar to that shown in Fig. 11 for all patients with 
PCT. The faecal porphyrin profiles invariably revealed the 
presence of the porphyrin P1 fraction, i.e. isocoproporphyrin and 
de-ethylisocoproporphyrin (Fig. 11). Liver biopsy samples fluoresced 
strongly under ultra-violet light, and the characteristic hepatic 
porphyrin profile, i.e. almost exclusively URO and 7-COOH porphyrin, 
was noted in every case (Fig. 11). 
(b) Porphyrin Excretion and Accumulation· in HCB: and HCB plus 
~ Jectofer-treated Rats. 
(i) Vrinary Por£hyrins 
Urinary excretion of URO and COPRO at 15 day 
intervals .up to 60 days in HCB- arid HCB plus Jectofer-
treated rats is shown in Fig. l2a,b. 
At 15 days, both groups showed no substantial in-
crease in porphyrin excretion. A rise in the output 
of URO was manifested at 30 days in the HCB plus Jectofer-
treated animals which increased to a mean value of 80,94µg/ml 
~ An iron-sorbitol-citric acid complex 








4-COOH 5-COOH 6-COOH 8-COOH 
4-COOH 5-COOH 7-COOH 
2-COOH P1 6-COOH 8-COOH 
7-COOH 8-COOH 
2-COOH 1.-COOH 8-COOH 
Porphyrin composition in urine, faeces and liver in a 
patient with PCT. Porphyrins were extracted, esterified, 
chromatographed, and the fluorometric scans obtained 
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15 30 60 
Days Treatment with HCB 
Uri nary excretion of URO and COP RO as determined by 
the method of Rimington and Sveinsson (241) at 15 day 
intervals in rats treated simultaneously with HCB and 
Jectofer and in rats treated with HCB alone. The 
height of the bars is the mean value of porphyrin 
excretion observed in 3 rats: (a) simultaneously treated 
with HCB and Jectofer; (b) treated with HCB. 
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at 45 days, then dropped to·a mean value of 33,94µg/ml 
at 60 days. The mean level of COPRO in this group did 
not rise appreciably at 30 days, reaching a mean of 
9,69µg/m1 at 45 days, and decreasing slightly to a mean 
of 6,55µg/ml at 60 days. The rats treated with HCB 
alone did not show significant porphyrinuria at 30 days 
but at 45 days both URO and COPRO excretion was elevated 
to mean values of 30,35µg/ml and ll,55µg/ml respectively. 
At 60 days mean URO excretion was 36,67µg/ml and mea·n 
COPRO excretion was 12 ,67µg/ml. 
Thin layer chromatographic analyses of the methyl 
esters of extracted urinary porphyrins from rats on both 
treatment schedules are shown in Fig. 13. The trend of 
urinary porphyrin excretion in both. groups followed that 
indicated in Fig. 12 a,b. At 30 days treatment with HCB 
plus Jectofer there was a shift from mainly COPRO excretion 
to URO excretion, as judged by the areas under the peaks, 
and the presence of 7-, 6- and 5-COOH porphyrins was de-
tected. Note that at 30 days treatment with HCB alone, 
the shift from COPRO to URO was less evident. The shift 
towards the higher carboxylated porphyrins became increas-
. ingly pronounced at 45 and 60 days for both treatments, at 
which times the intermediate 7-, 6- and 5-COOH porphyrins 
were present in significant quantities. 
(ii) .f!leca l Po.rQhXri n§_ 
QualH.at·ive assessment by thin layer chromatography of 
methyl esters of extracted faecal porphyrins from rats 
treated for 45 days with HCB showed the presence of a 
signif'icant quantity of the porphyrin P1 fraction (Fig.14). 
No porphyrin P1 was detected in the faeces of untreated rats. 
(iii) fl.:.SQatic PorQhyrins 
Hepatic porphyrins were not measurable in the livers 
of control animals (Figs. 15,16). After 15 days treatment 
of rats with either HCB or HCB plus Jectofer, small 'in-
creases in the levels of URO and COPRO were observed (Figs. 
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Figure 13 Urinary porphyrin composition at 15 day intervals in 
rats treated simultaneously with HCB and Jectofer and 
in rats treated ~·Ii th HCB. Porphyrins were extracted, 
esterified, chromatographed, and the fluorometric 
scans obtained using a Vitatron VLD 100 densitometer 
are shown. 
ORIGIN 






2COOH l.COOH SCOOH 6COOH 7COOH 8COOH 
SCOOH 
2COOH L.COOH 8COOH 
Faecal porphyrin composition in a rat treated for 45 
days with HCB, compared to that in an untreated rat. 
Porphyrins were extracted, esterified, chromatographed, 
and the fluorometric scans obtained using a Vitatron 
VLD 100 densitometer are shown. 
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Hepatic porphyrin composition at 15 day intervals in 
rats, treated simultaneously with HCB and Jectofer and 
in rats treated with HCB. Porphyrins were ex.tracted, 
esterified, chromatographed and the fluorometric scans 
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0 15 60 
Days Treatment 
Hepatic URO content at 15 day intervals in rats treated 
with HCB alone and in rats treated simultaneously with 
HCB and Jectofer. Liver porphyri ns were directly 
esteri fied, chromatographed and scanned fluorometri cal ly 
using a Vitatron VLD JOO densitometer fitted with an 
integrating recorder. URO was quantitated by comparison 
of the area under each peak corresponding to URO with 
that of a standard quantity of URO III octamethyl ester 
applied to the thin layer chromatography plate. The 
height of the bars is the mean value of URO content in 
the liver of 3 rats. 
Days 
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tected. At 30 days, the excess hepatic porphyrins in both 
_groups were almost entirely URO and 7_-COOH porphyrin (Fig. 
15), the mean URO levels at this time were 3,74µg/g liver 
and 4,12µg/g liver for the HCB- and HCB plus Jectofer-
treated groups respectively (Fig. 16). A dramatic increase 
was observed in the amount of URO to a mean value of 55,92 
µg/g liver at 45 days simultaneous treatment with HCB and 
Jectofer, wh"ich diminished somewhat to 33,45µg/g liver 
at 60 days (Fig. 16). In the HCB-treated group increased 
levels of URO were noted at 45 days, the mean being 20,01 
µg/g liver, but after 60 days treatment there was _a further 
jncrease to a mean value of 39,27µg URO/g liver (Fig. 16). 
When there was increased URO storage in both groups of 
animals, a concomitant increase in 7-COOH porphyrin was noted 
(Fig. 15). The quantity of 7-COOH porphyrin at these times 
was approx·imately 40% of the total porphyrins. This obser-
vation held true for both treatment schedules {Table 4). 
TABLE 4 
Mean Percentage Composition of Liver Porphyrins in Rats 
Treat~~jth HCB and HCB ..E_lus Jectofer 
{Mean values for 3 observations in each case) 
Treatment [ ___ 
HCB HCB plus Jectof er f 8-COOH % 7-COOH % 8-COOH % 7-COOH 
15 83 17 87 13 . 
30 60 40 55 45 
45 63 37 61 39 




Following 30, 45 and 60 days treatment with either HCB or HCB plus 
Jectofer, livers fluoresced strongly when viewed under ultraviolet light. 
(c) Total Hepatic Iron in HCB- and HC~~lus Jectofer-treated 
Rats 
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HCB treatment did not significantly affect total liver iron 
during the course of the experiment (Fig. 17). Simultaneous 
treatment with HCB and Jectofer resulted in an increase at 15 days 
to a mean value of 5,32 µg iron/mg protein. There was no appreciable 
change from this increased value at 30, 45 and 60 days administration 
(Fig. 17). 
6.2. Validit~ of ALA-S Activity De~~rm·i~~tions QY. the Radiochemical 
Microassay 
(a) Choice of Radioactive Label for ALA _Isolated by the Tr.:_]Jl]JL 
Column Technigue __ 
The complete incubation mixture for assay of ALA-S, including 
0,010 ml rat liver homogenate (100 mg/ml), but where radioactive 
succinate was rep.laced by either{14c} - ALA or'{31-n - ALA, was 
subjected to the triple iolumn technique for isolation of ALA, 
after addition of 0,020 ml trichloracetic acid and 0~050 ml ALA/ 
succinate carrier solution. As shown in Table 5 recoveries of radio-
activity were very much lower in the case of {3H} - ALA when compared 
14 3 to· { C} - ALA. This low recovery may be caused by { H} exchanging 
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15 30 60 
' 
Days Treatment 
Total hepatic iron content at 15 day intervals in 
rats treated with HCB alone and in rats treated 
simultaneously with HCB and Jectofer. The height 
of the bars is the mean value of total liver iron 
in three rats. 
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TABLE 5 
Recoveries of Radio label l_ed ALA from Triple Columns 
Label Total D.P.M. Applied Total D.P.M. Recovered 















H-ALA 7,64 1,36 18 
7 ,64 0,63 8 
11, l l ,32 12 
11'1 l ,58 14 
Mean 13 
In view of these results, 14c was used as a label in all ensuing experi-
ments for determinatfon of ALA-S activity. 
(b) Determ·ination o~Jl.~.tivity of Bacterial Succinyl-CoA Synthetas~ 
.Used in th_g_ALA:~~ /\ssay_ 
Succinohydroxamic acid formation, when determined as the ferric 
complex at 540 nm, is not proportional to enzyme concentration except 
at very low enzyme concentrations (37 ,4o). For this reason, the least 
amount of enzyme which gave an absorbance reading at 540 nm in the range 
0,13 to 0,20 was used for calculation of the activity( 40). The single 
preparation of purif'ied, freeze-dried bacteria 1 succi nyl -Co A synthetase 
used in the ALA-S assays over six months showed no significant change in 
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activity, as shown in Table 6. 
TABLE 6 





Vol. Enzyme (10 









Absorbance µmol Succinyl-CoA formed/ 
at 540 nm 30 min. . 








'i 30 0,83 
(c) 8LA-S Activity Determination by the R~iochernical Bssay Method 
in AIA-treated Rats 
It has been shown by a number of investigators that AIA stimulates 
the activity of hepatic ALA-Sin the rat( 2,20,l 9l, 249 ), with maximal 
activity of the enzyme reached 8 hours after injection with AIA. It 
was further demonstrated that the activity of ALA-S remained signifi-
cantly elevated for at 1east 24 hours( 191 ). The activity of ALA-S 
in the liver of each of 6 control rats ~nd 6 AIA-treated rats was 
determined using the radiochemical rnicroassay for this enzyme. As 
shown in Fig. 18, the hepatic ALA-S activity, expressed as nmol ALA 
formed per gram liver per hour, was more than 3-fold greater 16 hours 
I 
after treatment with AIA, being 719 '!: S.E. 131,8 against 221 :!: S.E. 
66,0 in untreated animals. The increase is significant with P<0
5
005. 
























CONTROL RATS AIA-TREATED RATS 
Hepatic ALA-S activity in untreated rats and rats 
treated with 300 mg/kg AIA. Rats were starved for 
24 hours, injected intraperitoneally with AIA, then 
killed 16 hours 1 ater. Control rats were starved 
for 40 hours before killing. The standard assay was 
performed as described .in Section 5. 1. 
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(d) Linearity of the Radiochemicai Assay Method for ALA-S 
Homogenates containing 50, 75, 100, 150 and 200 mg liver/ml were 
prepared from the liver of an untreated rat and the activity of ALA-S 
in ,010 ml of each of these preparations was determined. From Fig. 19 
it can be seen that ALA production was linear when up to 2,0 mg liver 
was used in the mic~oassay. 
6.3. Hepatic ALA-S Activi_!y in PCT and in Non-Porphyries 
No significant difference was found in the activity of hepatic 
ALA.:.s between patients wHh. active PCT and non-porphyri c patients 
{Ftg. 20). The mean activity of the enzyme, expressed as nmol ALA 
formed per g liver per hour was 136 :t S. E. 16 in the PCT group and 
107 ± S.E. 14 in the control group. 
6. 4. He_pati c Cl!_ochrome P450 
(a) L"inearity of the Assay Method for Cytochrome P450 in 
Liver Homogenates 
A 100 mg/ml liver homogenate from one untreated rat 
was diluted to concentrations between 2 and 10 mg/ml. An 
increase in the concentration of cytochrome P450 proportional 
to the concentration of liver in the samples was noted (Fig.21). 
(b) _tie pa tic C,rtochrome P450 in Humans 
During the course of this investigation the opportunity 
arose to measure cytochrome P450 in whole liver homogenates 
not only in the livers of 38 non-porphyric patients and 19 
patient~ with PCT, but also in those of 6 patients with VP 





















Relationship of ALA formation to the amount of liver 
tissue present. Assay was performed as described in 
Section 5.1., using homogenates containing 50; 75; 
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Hepatic 6-aminolaevulinic acid synthetase {ALA-S) 
activity as determined by a radiochemical assay in PCT 
and ·in matched non-porphyri cs (patients with normal 
porphyrin metabolism). __ =Mean; ....... = S.E. 
Each point represents the mean of triplicate determina-
tions which agreed to within 10%. 
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Rel at'ionshi p of rat hepatic cytochrome P450 to content 
of 1 i ver wet weight per mi 11 il it re homogenate assayed. 
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and in Fig. 22, the levels of hepatic P450 were increased only 
in the PCT group. The 4-fold increase in cytochrome P450 found 
in this group when compared to the non-porphyric group was signi-
ficant, with. P<0,001. 
TABLE 7 
Levels of __ Hepatic Cxtochrome P450 in Controls, Vari_egate Porphyria
2 
Erotoporph~ria and PCT. + Results are expressed - S.E. 
Hepatic cytochrome P450 
(nmol/g liver) 
Controls (non- 15,5 :t l ,3 
porphyric) 
Variegate Porphyria 21 ,7 ± 4,0 
Protoporphyr-i a + 20,6 - 5,6 
PCT 63,l ± 9,3 
(c) _tiepatic Cytochrome P450 in HCB-treated Rati 





Hepatic leve·ls of cytochrome P450, measured in whole liver homo-
genates, "in rats treated with HCB up to 60 days is shown in Fig. 23. 
After 20 days treatment an increase was noted in the hepatic cytochrome 
P450 levels to a mean value of 57,5 nmol/g liver, compared with a mean 
of 33,6 nmol/g liver in untreated rats. A further increase was noted 
after 30 days treatment to a mean value of 68,5 nmol/g liver. The 
leveis of cytochrome P450 were found to be increased by· a factor of 
approximately 2,5 after 45 days, the mean value being 81,6 nmol/g liver 
at this time. Sixty days after commencement of HCB-treatment the mean 
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_Days HCB Treatment 
Levels of hepatic cytochrome P450 at various times 
in rats treated with HCB. The mean values together 
with the range obtained for the levels of the haemo-
protein in 3 animals is shown in case. 
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(d) Siderotic Rat Liver Cytochrome P450 Determined in the Presence 
of Excess URO III 
To test whether excess URO I could be bound to excess hepatic 
iron to form a compound wHh spectral characteristics similar to 
that of cytochrome P450, the levels of this cytochrome were measured 
in 10 mg/ml homogenates of liver from rat treated for 60 days with 
Jectofer alone, the homogenising fluid containing from 0 to 5µg/ml 
URO I. Hepatic cytochrome P450 measured in the presence of the 
various concentrations of URO I was not found to be significantly 
different from the value of 38,0 nmol/g liver found in the absence 
of URO I. Histological examination of the liver after staining with 
Prussian blue showed massive deposition of haemosiderin throughout 
the sample, confirming that the rat used in this experiment was 
indeed siderotic. 
(e) Cytochrome P45~ Oete_rminations in Liver Homogenates and in Liver 
Microsomes of Untreated Rats, HCB-treated Rats and Phenobarbital-treated 
Rats. 
Hepatic cytochrome P450 was measured in groups of untreated rats, 
rats treated for 45 days with HCB and phenobarbital-treated rats using 
the whole homogenate technique {Section 5.2. I.) and the microsomal tech-
nique (Section 5.2.II.). A group of animals that had been treated with 
phenobarbital was included, since it has been shown that this pretreat-
ment increased cytochrome P450 in rat hepatic microsomes(l27,215,237). 
In each experiment cytochrome P450 was measured in 1-iver homogenates 
and microsomes prepared from the pooled livers of the same 3 animals. 
The levels of hepatic cytochrome P450 as determined by both methods 
in the three groups of animals are compared in Table 8. 
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TABLE 8 
Hepat_i c Cytochrome P450 in Untreated Rats, HCB-treated Rats and_ 


































(Mean values are given in parentheses) 
Microsomal Cy to-















As shown in Table 8, significant increases in the levels of homo-
genate cytochrome P450 were found in the groups of rats treated with 
/ 
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HCB and phenobarbital, when compared with the control group. These 
increases were reflected in the levels of microsomal cytochrome P450 
in the HCB- and phenobarbita 1-treated groups. 
From Table 8 it will be observed that consistently low values 
for the amount of hepatic cytochrome P450 were obtained when compared 
to those shown in Fig. 23. This may be due to a different batch of 
sodium dithionite being used as a reducing agent, which may have 
undergone a certain amount of decomposition, thus affecting the 
determination of the levels of the haemoprotein. 
6.5. ·The Type of HeQatic Cytochrome P450 Present in PCT and in 
HCB-treated Rats 
(a) CO Difference Spe~tr~ 
It was shown in Section 6.4.(b) that levels of hepatic cytochrome 
P450 were increased about 4-fold in patients with PCT. Further, it 
was shown in Section 6.4.(c) that cytochrome P450 levels were increased 
by a factor of about 2,5 in rats which had been treated with HCB for 
45 days. Examples of the difference spectra obtained by the homogenate 
method of measurement of cytochrome P450 are shown in Fig. 24. In the 
non-porphyric control patient L.M. the peak at 450 nm is separate from 
the cytochrome b5 peak at 428 nm (Fig. 24). In the case of patient 
R.M. who had act-ive PCT, an approximate 5-fold increase in the height 
of the peak attributable to cytochrome P450 can be seen. A slight 
shoulder can be observed in the range 420 to 430 nm which may reflect 
the incorpora.ti on of the cytochrome b5 spectrum into that of cytochrome 
P450. The spectral peak of the CO-binding pigment in patients with 
PCT was shifted to about 448 nm, which is similar to the shift which 
occurs in rodents after treatment with 3-rnethylcholanthrene(6). In 
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Figure 24 
430 L.50 470 490 nm 430 450 470 490 nm 
CONTROL RAT RAT WITH H.C.B. 
INDUCED PORPHYRIA 
Cytochrome P450 levels in human and rodent liver. 
Difference spectra ( 1 i ver homogenate pl us carbon 
monoxide plus sodium dithionite) minus (liver homo-
genate plus carbon monoxide), using approximately the 
same concentration of liver, are shown. The carbon 
monoxide-binding pigment (cytochrome P450), when com-
pared to non-porphyric controls, is increased in PCT 
and in the rat with HCB porphyria. In the porphyric 
situation the spectral peak occurs at a lower wave-
length than 450 nm. 
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peak is at 450 nm. After 45 days treatment with HCB, at which 
time urinary, faecal and hepatic porphyr-in analysis indicate that 
the rats are porphyric (Figs l2b, l3,l4,15,l6), there is an approxi-
mate 2,5 fold increase in the level of cytochrome P450 when compared 
to untreated rats, and furthermore there is a shift of the peak in 
the difference spectrum to about 448 nm (Fig. 24). From the dif-
ference spectra it becomes apparent that there is similarity in the 
spectral characteristics of hepatic cytochrome P450 in non-porphyric 
states in man and rat, and in porphyria, both in PCT and in the HtB-
i ntoxi cated rat. 
(b) Ethyl Isoc,.YE.Dj de DHference Spectra 
I 
The ethyl isocyanide-binding haemoprotein of liver microsomes from 
untreated rats and rats treated with HCB .for 45 days, was examined 
according to the method of Imai and Sato( 133 ). Three experiments 
were performed in each case, using microsomal preparations derived from 
3 groups of 3 animals. When the ratio of the heights of 455 nm peaks 
to the heights of the 430 nm peaks were plotted against pH of the 
microsomal suspension (Fig. 25), the ratio was found to be 1 (i.e. the 
heights of the two peaks were equal) at a mean pH value of approximately 
7,52 for untreated rat liver microsomes and at a mean pH value of 
approximately 7,28 for HCB-treated rat liver microsomes. The lower pH 
i.e. 7,28, at which the heights of the 430 nm and 455 nm peaks were equal 
in mi crosomes from rats treated with HCB for 45 days, is interpreted to 
indicate the presence of a form of cytochrome P450 with a different pH 
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Figure 25 Dependence of the ratio of the height of the 455nm 
peak to the height of the 430nm peak on pH in the 
ethyl i socyani de difference spectrum using mi crosomes 
from untreated rats and microsomes from rats which had 
been treated for 45 days with HCB. Each point is the 
mean of 3 determinations, each determination having been 
made using microsomes prepared from livers pooled from 
3 rats. 
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6. 6. The Fun_ctj_g_@l. Ca~cij:y_ of ~.to_fhrome_ P450 as Assessed by 
Deterrnina ti on of Ami nopyrine _N-D~methyl ati on and 3 ,4-MBenzpyrene 
Hydroxyl at ion 
{a) Product Recoveries and Linearit,x of Product Formation 
(i) Aminopyrine N-Demethylation 
In a series of 12 experiments, the percentage recovery 
of radioactivity from incL~bation mixtures containing 14c-
formaldehyde but no· foimethylamino-14c} aminopyrine was 
J.. 
determined to be 55,34 (~ S.E.M. 2,75). 
As shown in Fig. 26a, where increasing quantities of 
homogenates from an untreated rat were used as enzyme 
source, and aminopyrine including· {dimethylamino-14c} amino-
pyrine concentration was kept constant at 1 ,052 mM,formalde-
hyde formation increased linearly when between 3 and 7 mg 
liver was present in the assay mixture. 
(ii) 3,4-BenzPYrene Hydroxylatio.!l. 
In 6 experiments, 50 ng 3-hydroxy-3,4-benzpyrene con-
tained in 0,05 ml acetone was added to complete assay mix-
tures and immediately extracted. By comparison of spectro-
photofl uorometer readings to that obtained for a 10 ng/ml 
solution of 3-hydroxy-3,4-benzpyrene in lN NaOH, the per-
centage recovery was 17,65 ± S.E.M. 3,82. 
It was demonstrated that 3-hydroxy-3,4-benzpyrene forma-
tion was linear when from 1 to 8 mg liver from an untreated 
rat was used as enzyme source (Fig. 26b). Substrate con-
centration was 6,61 x l0- 5M (0,1 ml of a 500µg/ml solution 
of 3,4-benzpyrene per assay). 
{b) Kinetics of Aminopyrine N-Demethylation and 3,4-Benzpyrene Hydroxy: 
lation in PCT and Non-Porph~rics 
Data obtained for cytochrome P450-mediated N-demethylation of amino-
pyrine and hydroxylation of 3,4-benzpyrene by liver tissue from 9 patients 
with PCT and from 13 non-porphyric patients, were plotted according to 
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Relationship of the formation of the products of arnino-
pyrine N-demethylation and 3,4-benzpyrene hydroxylation 
to the quantity of rat liver present in the respective 
incubation systems. Liver from an untreated rat was 
used as a source of the mixed function oxidase system 
in each experiment: (a) Aminopyrine N-demethylation; 



























Plots of v versus s for the hydroxylation of 3,4-
benzpyrene and the N-demethylation of aminopyrine. 
Velocities are given as nanograrn 3-hydroxy - 3,4-
benzpyrene formed per milligram liver and nanomoles 
formaldehyde formed per hour per µg liver; substrate 
concentrations are in moles per litre. Lines were 
fitted by calculation of linear regression coefficients. 
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. l l 
points in the plots of v vs{S} followed an essentially linear re-
lationship, and linear regression curves were fitted by calculation 
of the liver regression coefficient a and b in the equation y = a + bx, 
using a Hewlett Packard 97 programmable calculator. The coefficient of 
determination r2 , was determined in each case (Table 9). The apparent 
. K and V values were derived from the calculated linear r.egression ·m max . . . 
curves (Table 9). As shown in Figs. 28 and 29 and Table 9, there 
were no significant differences .in the apparent K and V values for ·m max 
both aminopyrine N~·demethy1at'ion and 3,4-benzpyrene hydroxylation between 
the two groups of pat"ients studied, when related to levels of hepatic 
cytochrome P450. 
(CJ
\ , l Kinetics of Aminopyrine N-demethy ation and 3,4-Benzpyrene Hydroxy-
lation in HCB-treated and Control Rats. 
The apparent ~and Vmax values for aminopyrine N-demethylation and 
3,4-benzpyrene hydroxylation by pooled liver homogenates from 3 groups 
of 3 rats treated with HCB for 45 days and by pooled liver .homogenates 
from 3 groups of 3 untreated rats were calculated as described in section 
l l 
6.6.(b) above {Table 10). Further plots constructed of s vs vmean 
aminopyrine N·Nclemethylat"ion and 3,4-benzpyrene hydroxylation by liver 
from both groups of animals, as shown in Figs. 30, 31, where each poi~t 
represents the mean value from 3 different experiments, and with each 
experiment performed ·on pooled liver homogenate from 3 rats. The mean 
apparent~ for aminopyrine N-demethylation in liver of rats treated with 
HCB for 45 days (3,0lmM) v.ias about 3-fold increased above that obtained 
in livers from untreated rats {l,04 mM), whilst the mean maximal velocity 
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Figure 29 Comparison of the hepatic levels of cytochrome P450 and 
Km and Vmax for 3, 4-benzpyrene hydroxylation in liver 
tissue obtained from non-porphyric controls (open 
squares) and pa ti en ts with PCT (closed squares). Km BP · 
and Vmax BP respectively are the Km and Vmax values for 
3, 4-benzpyrene hydroxylation, with Vmax expressed as 
nanogram 3-hydroxy-3,4-benzpyrene formed per hour per milligra1 
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Plots of v versus s for the N-demethyl ati on of 
aminopyrine by liver from untreated rats and rats 
treated for 45 days with HCB. ·.Velocities are given 
as nmol formaldehyde formed per hour per mg liver; 
substrate concentrations are in moles per litre. Each 
point represents the mean value of three different 
experiments. Each experiment was performed using 
pooled liver homogenates from three rats. Lines were 
fitted by calculation of linear regression coefficients. 
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Plots of v versus~ for the hydroxylation of 3,4-benz-
pyrene by liver from untreated rats and rats treated for 
45 days with HCB. Ve loci ti es are given as ng 3-hydroxy-
3, 4-benzpyrene formed per hour per mg liver:; substrate 
concentrations are in moles per litre. Each point 
represents the mean value of three different experiments. 
Each experiment was performed using pooled liver homogenates 




The mean apparent~ for3,4-benzpyrene hydroxylation was found to 
be 0,15 x l0-5M in untreated.rats~ whereas a value of 0,56 x 10-S M 
was obtained in the case of rats that had been treated with HCB for 
45 days (Fig. 31). An almost 25 fold increase in the mean maximal 
velocity of 3,4-benzpyrene hydroxylation was observed in the case of 
rats treated with HCB for 45 days (Vmax(mean) = 1986 ng 3-hydroxy-
3,4-benzpyrene formed/hr/mg liver) when compared to the mean maximal 
velocity observed in the case of the control animals (Vmax(mean) = 
80 ng 3-hydroxy-3,4-benzpyrene formed/hr/mg liver) (Fig. 31). 
Table 9/ ... 
TABLE . 9 
Apparent Km and Vmax Values for Aminopyrine N-demethylation and 3,4-Benzpyrene Hydroxylation in Non-Porphyric Controls and Patients 
"th PCT Wl . 
JIJ'vlINOPYRINE N-DEMETHYLATION 3,4-BENZPYRENE HYDROXYLATION 
Patient ~ v 
r2 ~ ,-21 v 2 r )TlaX max . 
. {mM} (nmol semicarba- (M x 1~5 ) ng 3-hydroxy-3,4-
zone formed/hr/ benzpyrene formed 
mg liver) /hr/mg liver ·-
Non-Porphyric M.K. 3,497 0,86 0,8514 4,500 572 0,9856 
PCT 
R.B. 8,400 31 '11 0,9805 0,243 108 0,8628 
H.M. . 0,763 8,64 0,9877 0,636 182 0,9965 
M.G. I, 761 0,44 0 ,9801 - - -
A.L. 3,010 4,90 0,9877 0,475 l 00 0,9932 
P.O. 0,916 4,98 0,8602 0, 160 127 0,9922 J.P. - - - 0,062 41 0,8763 
A.S. 24,460 51 ,63 0,9943 0,062 22 0,8418 
A.Si. - - - 0,220 37 0,7973_ 
P.T. 4,961 32,93 0,9908 0,273 169 0,9584 
C.P. l ,049 38,29 0,9966 0,262 9 0,8967 
E.Y. 2,833 12,32 0,9844 0,291 6 0,8052 
B.S. 2,150 7 ,79 0,9142 - - -
D.S. 0' 156 4, 12 0,8183 0' 135 25 0,8984 
S.M. - - - 0,686 42 0,9152 
T.B. 1,578 2,38 0,9822 16,940 984 0,9774 H.L. - - - l,367 393 0,9937 P.S. 5,253 2,63 0,9625 0,465 352 0,8210 H.P. 3,011 1,08 0,9847 - - -N.E. - - - l '180 17 0,8762 J.C. 2,993 10,77 0,9437 0,269 59 0,9221 J.H. 19,092 62,07 0,9937 0,761 156 0,9578 
(The apparent ~ and Vmax were derived from plots of ! vs ~ where linear regression curves were fitted to the 





Apparent ~ and Vmax Values for Aminopyrine N-Demethylation and 3,4-Benzpyrene Hydroxylation in Untreated 
Rats and Rats Treated with HCB for 45 Days 
I 
AMINOPYRINE N-DEMETHYLA TI ON 3,4-BENZPYRENE HYDROXYLATION .. 
Treatment of Experiment I ~ v 2 K Vmax r2 max r 
(M x m 1:US) Rats no. . {rnM} (nmol semicarba- ng 3-hydroxy-3,4-
zone formed/hr/ benzpyrene formed 
mg liver) /hr/mg liver 
Controls 1 l ,914 18,63 0,9721 0'178 97 ,69 0 ,9781 
2 0,507 9,54 0,6370 0, 113 72, 12 0,7054 
3 0,916 10 ,23 0,9291 0, 174 74,90 0,9437 
. 
45 Days 4 2,322 18,07 0,9185 l ,263 3205 0 ,9778 
with HCB 5 3,597 26,55 0,8726 0,486 1824 0,9948 
6 3,492 31 ,74 0 ,9871 0,283 1535 0,9670 
\ 
(In each experiment homogenates from each of 3 rats were pooled. The apparent Km and V ax were derived from plots.!. vs l 
~ m s v -' 
0 
where linear regression curves were fitted to the data. The coefficient of determination of the computed l_inear regression -i::. 
is given by r2). 
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Figure 28 Comparison of the hepatic levels of cytochrome P450, 
and Kmax and Vmax for a.minopyrine N-demethylation in 
liver tissue obtained from non-porphyric controls (open 
squa~es) and patients with PCT (closed squares). 
Km AP and Vmax AP respectively are the Km and Vmax 
values for aminopyrine N-demethylation. 
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6.7. Histological Findings 
Light, fluorescence and electron microscopy was performed by 
a histopathologist, Dr. B.L. Webber of the Department of Pathology, 
University of Cape Town and the findings have been reported in detail 
elsewhere{23 ). 
(a) Human Hepati.£..1~ 
Light microscopy revealed significant abnormalities of hepatic 
morphology in all patients with PCT. Haemosiderin was demonstrable 
in 18 of the PCT patients. Fluorescence microscopy showed fluores-
cence to be patchy and diffuse in all the samples examined from PCT 
patients. On electron microscopy of liver biopsy samples, there 
appeared to be no significant increase in hepatic smooth endoplasmic 
reticulum in cases of PCT when compared to cases of VP and protoporphyria. 
This might have been expected in view of increased levels of cytochrome 
P450 found in PCT and not in VP or protoporphyria (Section 6.4.(b)). 
An important finding from electron microscopic studies wp.s that the 
quantity of smooth endoplasmic reticulum varied greatly from one cell 
to another. For the interested reader, electron micrographs obtained 
by Dr. Webber of PCT liver and protoporphyric liver may be found in 
previously published papers {23 ,223) 
(b) Rat Hepatic Tissue 
No stainable iron in the form of haemosiderin (Prussian blue 
staining) was present in the livers of rats that had been treated with 
HCB and Jectofer simultaneously for 30 days. In a control group given 
Jectofer without HCB, at the same dosage schedule, abundant stainable 
iron was present on histological examination. 
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6.8. UROGEN-I Decarboxylase - Preliminary Experiments 
(i) Extinc.:lliw_Coefficjent for URO-I at 560 nm under the 
Conditions of Assay for UROGEN-I DecaJ:Qox~lq~~ 
Enzymati ca 1 ly generated UROGEN-I substrate for the 
decarboxy1ase was measured as URO-I in all the experiments 
by determination of the absorbance of band II shown in Fig. 
32. The absorbance of varying concentrations of URO-I was 
measured at 560 nm in the presence of the incubation mixture 
for UROGEN-I decarboxylase (Fig. 33). A linear increase 
in absorbance with increasing URO-I concentrations was ob~ 
served. From the slope of the calculated linear regression 
curve, whose coefficient of determination was 0,997, the 
millimolar extinction coefficient for URO-I at 560 nm was 
7,554 cm- 1mM-l, under the conditions of assay. 
(ii) Enzymatic Generation of UROGEN-I Enzyme and Substrate 
.Conditions for the Generation of 25 - 30 nm.Ql. UROGEN-I 
The quantity of UROGEN-I generated from various 
quantities of a 2 mg/ml solution of the 14c-PBG preparation 
purchased from Porphyrin Products by UROGEN-I synthetase 
in a total volume of l ml is shown in Table 11. 
TABLE 11 
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Figure 32 Absorption spectrum (Soret band omitted) of URO-I (20µM) 
in the assay mixture used for the determination of 




























Relationship of the absorbance of URO-I at 560nm in the 
incubation mixture for UROGEN-I decarboxylase to the 
concentration of URO-I. The line was fitted by calcu-
lation of linear regression, coefficients. 
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(Each sample contained ~ 4c~PBG, O,lml 0,066M L-cysteine, 
0, 1 ml 7 mg/ml UROGEN-I synthetase and O, lM tris:H.Cl pH 
7,65 to a total volume of 0,5 ml. Samples were incubated 
in the dark for 30 min. at 37°c, at which time O,l ml 0,4M 
KH2Po4 and 0,4 ml 0,1 M tris:HCl were added~ After a 
further 1ncubation period of 30 min. at 37°c in the dark, 
the UROGEN-I formed was oxidised to URO, and absorbance 
at 560 nm determined. URO concentration was calculated 
. . -1 -l usrng EmM == 7 ,554 cm mM ) • 
From the result of this experiment, in the ensuing 
experiments, 0,15 ml of a 2 mg/ml solution of 14c-PBG 
in O,lM t~is:HCl, pH 7,65 and 0,1 ml of a 7 mg/ml solution 
of UROGEN-I synthetase in O,lM t~is~HCl, pH 7,65, were 
present in the assay mixture. 
The amount of UROGEN-I generated from various quan-
tities of a 5 mg/ml solution of 14c-ALA by a preparation 
of bacterial ALA dehydratase and UROGEN-I synthetase in 
a total volume of 1 ml is shown in Table 12. 
TABLE 12 
Formation of UROGEN-I by a mixture of ALA Dehydratase and UROGEN-I 
synthetase from 14c-ALA 
Sample number Volume of 5 mg/ml solution nmol 14C-UROGEN- I 
14c-ALA formed 
1 0,02 20,28 
2 0,03 24,88 
3 0,04 26,77 
4 0,05 27,31 
5 0, 10 29,32 
6 0,15 27,30 
(Each sample contained 14c-ALA, O,lrnl 0,066M L-cysteine, 0,1 ml 
7mg/ml ALA dehydratase/UROGEN-I synthetase and O,lM tris:HCl pH 7,65 
to a total volume of 0,5 ml. Incubation conditions and UROGEN-I 
determinations were as for those described for Tab·le 11). 
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In the experiments where UROGEN-1 was generated by this 
latter method,· 0,05 ml of a 5mg/ml s.olution of 14c-ALA 
in 0,1M tris:HCl, pH 7,65 and 0,1 ml of a 7 mg/ml solution 
of the ALA dehydration/UROGEN-I synthetase preparation 
were used 'in the assay mixture. 
It was found, usfog either method for production of 
UROGEN-I substrate, that from 7 to 10% of the UROGEN-I 
produced was autooxidised under the incubation conditions 
by spectrophotometric determination before and after 
oxidation with iodine. 
6.9.UROGEN-I Decarboxy1ase in Human Red Blood Cells. 
In all the assays for determination of the activity of red blood 
cell UROGEN-I decarboxylase, UROGEN-I substrate was generated from 
14
c-PBG by UROGEN-I synthetase. The amount of haemoglobin present 
per assay ranged from 23,44 mg to 66,00 mg. 
Red cell UROGEN-I decarboxylase activity in 3 large families is 
shown in Fig. 34. There appeared to be no obvious genetically-deter-
mined deficiency of this enzyme in the progeny· of the 2 patients with 
PCT. Furthermore, no significant differences were noted in the activity 
of red cell UROGEN-I decarboxylase between male or female patients with 
PCT and sex-matched non-porphyric controls (Fig. 35). By application 
of the students t test, P values between non-porphyric males and PCT 
males are >0,05; P vaiues between non-porphyric females and PCT females 
are >0,2. These differences were not considered significant. 
6.10 J}ROGEN-I Oecarboxylase in Livers of Rats Treated with HCB anq 
HCB plus Jectof~r. 
\ 
The activity of hepatic UROGEN-I decarboxylase expressed as nmol 
UROGEN-I decarbo.xylated/hr/mg protein at 15 day intervals up to 60 days 
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Red blood cell UROGEN-I decarboxylase activity in 
three unrelated families. In two families the 
father had overt PCT. The activity of UROGEN-I 
decarboxylase is expressed as nanomoles UROGEN-I 
decarboxylated per hour per milligram. 
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Red blood cell UROGEN-I decarboxylase activity in un-
related non-porphyric controls and in unrelated PCT 
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15 30 ' 45 60 
Days Treatment 
Hepatic UROGEN-I decarboxylase activity at 15 day 
i nterva 1 s in rats treated with HCB a 1 one and in rats 
treated simultaneously with HCB and Jectofer. The 
heights of the bars represent the mean activity of 
the enzyme in the livers of 3 rats. 
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For up to 30 days, the activity of the enzyme did not appear to 
be affected by either treatment schedule. However, after 45 days 
treatment, the mean activity of the enzyme decreased to 0,45 in the 
case of the HCB-treated rats, arid to 0,33 in the case of the HCB plus 
Jectofer-treated rats. This decrease in the activity was highly sig-
nificant, with P<0,00·1 in both cases, when compared to the activity 
in untreated rats where the mean activity was l,88. At 60 days, 
hepatic UROGEN-I decarboxylase activity increased somewhat to a mean 
value of 1,07 in the group treated with HCB alone, but this activity 
was still significantly different from that of the untreated group, 
with P<0,05. In rats treated with HCB together with Jectofer, a 
slight decrease in the activity of ·the enzyme to a mean value of 0,30 
was noted, and again the difference was s_i gni fi cant when compared to 
the control group with P<0,001. 
6.11. Effect of in vitro Addition of Iron on UROGEN-I Decarboxyl as~ 
i n Rat Li ve;c. 
· The effects of in vitro additions of iron as ferrous ammonium 
sulphate and ferritin, and an iron chelator, l,10-phenanthroline, on 
hepatic UROGEN-I decarboxylase in untreated rats and rats treated for 
45 days with HCB are shown in Table 13. As demonstrated in Section 
6. 10, a significant diminution of the activity of the enzyme was again 
noted in HCB-treated rats when compared to the untreated group of 
animals. The addition of ferrous ammonium sulphate to the assay mix-
ture for UROGEN-I decarboxylase resulted in a significant increase in 
the activity both in control and HCB-treated rat liver, whereas ferritin 
en 
had no such effects (Table 12). 1,10-Pliknthroline did not significantly 
influence the hepatic UROGEN-I decarboxylase. 
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TABLE 13 
UROGEN-I Decarboxylase Activity in Rat Liver. Effects of In Vitro 
Additions of Iron (Ferrous A1l1Tlonium Sulphate and Ferritin) and 
..LlQ.-Phenanthrol ine 
nmol UROGEN-I Decarboxylated/hr/mg Protein 
Additives Controls HCB 
(no treatment) (45 days) 
None· 4,9' (4,4 - 5,7) 0,8 (0,4 - l ,4) 
Fe ++ ( lrnM) 1051 {8,4 - 12,4) 2'1 (l,4 - 2,7) 
Ferritin(lmM Fe) 3,8 (2,9 - 4,6) 0,5 (0,2 - 0,9) 
l,10 Phenanthroline(3mM) I 6,4 (5,7 - 7,1) l ,8 {l,2-2,4) 
(Three animals were used in each study and values are expressed as 
a mean with the range for individual data in parenthesis. It was 
assumed ~hat 23% of the ferritin was iron). 
The in vitro effect of increasing concentrations of ferrous iron 
(as ferrous ammon"ium sulphate) up to 0,25mM on rat liver UROGEN-I 
decarbo.xylase is shown in Fig. 37. It was found that maximal activity 
was manifested at concentrations of ferrous iron from 0,10 mM. Further, 
the activity remained elevated at this level up to the highest concen-
tration used, viz. 2mM (Table 14). 
n mol Uroporphyrinogen J 















The effect of added in vitro iron as ferrous ammonium 
su1 phate on the activity of he pa tic UROGEN decarboxyl ase. 
The 32000xg supernatant of a liver homogenate from an 
untreated rat was used as enzyme source. Each point 
is the mean of two observations. 
lll 
TABLE 14 
Effect. of In Vitro Addition of Ferrous Ammonium Sulphate on 
Rat Liver UROGEN-I Decarboxylase 

































(The mean value for two determinations of UROGEN-I decarboxylase 
activity at each concentration of Fe2+ is given. Liver from an 
untreated rat was used as enzyme source). 
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6.12. UROGEN-I DecarboxylaseAssay - Extraction of Reaction Product~. 
The activity of UROGEN-I decarboxylase is calculated from the 
radioactivity of the decarboxylated porphyrin esters expressed as a 
fraction of total radioactivity of the URO and 7-,6-,5- and 4-COOH 
porphyrin esters (Appendix A). If different proportions of the par-
phyrin esters are extracted by the method; described in Section 5.5.(b) 
and (c), either from the talc or from the esterification mixture, a true 
value for the activity of the enzyme will not be obtained. An experi-
ment was thus designed to test the possibility of differential extraction 
of reaction products. With the pooled post-mitochondrial supernatants 
from the-livers of 3 rats as enzyme source, UROGEN-I decarboxylase activity 
was determined in triplicate for increasing protein concentrations in two 
parallel experiments where two methods were used for the extraction of 
the reaction products. 
In both sets of determinations, incubations and termination of the 
reactions were performed as in Section 5.5.(b) and (c), with 14c-ALA 
and a mixture of ALA dehydratase and UROGEN-I synthetase used to generate 
UROGEN-I substrate. The reaction products in one set of assay tubes 
were adsorbed onto ta·1 c, esterified, extracted and chromatographed as 
detailed in Section 5.5.(b) and (c). 
In an attempt to overcome the possibility of differential desorbtion 
of porphyrin esters from talc, a different method was used to oxidise and 
esteri fy the reaction products from the second set of assay tubes. After 
term"ination of the reactions the samples were left in the light, but 
screened from direct sunlight,for l hr to allow oxidation of the porphyrino-
. gens to porphyri ns ( 
162
). The porphyri ns were converted to their methyl 
esters by addition of 50 ml 5% H2so4 in methanol, and left overnight at 
room temperature in the dark. 
A modified procedure was used to extract the porphyrin esters from 
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the esterification mixture. The esterification mixture was neutral-
ised with 10% NH40H and extracted repeatedly with 10 ml aJiquots of 
CHC1 3, until no further fluorescence was visible in the CHC1
3 
layer 
when viewed under ultraviolet light. The CHC1
3 
extracts were pooled, 
washed twice with distilled water, then filtered through CHC1
3
-wetted 
filter paper (Whatman no. 1) into beakers. Chromatographic analysis 
and scintillation counting of the porphyrin esters was as described 
in Section 5.5.(b) and (c). 
The above method was used for the extraction of porphyrin esters 
from the esterification mixture since it was found in a preliminary 
experiment, performed in triplicate, where 4,7 nmol URO III octamethyl 
ester and 6,3 nmol COPRO-III tetramethyl ester were added to 50 ml 
aliquots of 5% H2so4 in methanol and extracted by this method, the 
recoveries of URO-III ester and COPRO-III ester (determined spectro-
photometrically as in Section 5.6.I{b)) were 89.6% (Range 88,3 - 91,1) 
and 90,8% (Range 88,7 - 93,4) respectively. In a similar experiment, 
where the esters were recovered as described in Section 5.5.(b) and (c), 
recoveries were 61,7% (Range 58,5 - 64,2) and 82,4% (Rang~ 81,9 ~ 83,2) 
respectively for the methyl esters of URO and COPRO. 
Fig. 38 compares the activities of rat liver UROGEN-I decarboxylase 
with increasing protein concentration obtained where the two methods 
were used to extract the products of the reaction. The activities as 
determined where the reaction products were adsorbed and oxidised on 
talc, esterifi~d and extracted as in Section 5.5.(b) and {c) were 39% 
. greater than the activities as determined where the reaction products 
were oxidised by light, directly esterified and extracted from a neutral-
ised esterification mixture with CHC13• This result indicates that a 
differential exists in the extractability of the products of the UROGEN-I 
10 
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Re·lationship of the activity of rat liver UROGEN-I 
decarboxylase to the quantity of protein present in the 
assay. Each point is the mean of 3 observations. 
Pooled 32000xg supernatant prepared from the 1 i vers of 
three untreated rats was used as enzyme source. Incuba-
tion conditions were as described in Section 5.5. 
Line A was obtained when the reaction products were 
adsorbed on talc, esterified,extracted and chromatographed 
as detailed in Section 5.5. Line B was obtained when the 
reaction products were oxidised by light, directly 
esterified, exhaustively extracted into chloroform at 
neutral pH and chromatographed, as described in Section 
6.12. Lines were fitted by calculation of linear re-
gression coefficients. 
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decarboxylase assay when these are extracted by.the method as described 
in Section 5.5~(b) and (c). By this method of extraction, it appeared 
that URO-I as URO-I octarnethyl ester was the most incompletely extrac-
ted ester, with a consequent overestimation of the activity of UROGEN-I 
decarboxylase. 
A further finding was that 17857 to 27373 dpm remained in the 
talc after extraction with 5% H2so4 in methanol in those assay samples 
extracted as described in Section 5.5.(b) and (c). By calculation, 
if the specific activity of 14C-ALA is 0,42 µCi/pmol, the specific 
activity of UROGEN-I formed will be 8 x 0,42 = 3,36 µCi/µmol. In the 
experiment, 26,3 nmol UROGEN-I was generated, corresponding to 194410 
dpm. Thus 9,18% to 14,08% of the radioactive porphyrin esters remained 
on the talc. 
The above findings do not invalidate the results obtained for the 
activity of UROGEN-I decarboxylase where the reaction products were 
extracted as described in Section 5.5.(b) and (c) for 3 reasons: 
(i) Using either method of extraction, reproducibility 
to within 15% was obtained (Fig. 38) 
(ii) Using both methods of extractJon,,there was an 
essentially linear increase of activity with in-
creasing protein concentration to 3,5 mg protein 
(Fig. 38) 
(iii) The results obtained for the activity of UROGEN-I 
decarboxy1ase have been used in co~parative studies 
only 
6.13. Effect of Haemoglobin on UROGEN-I Decarbo~ylase Activity. 
(a) fktivity of Human Red Blood Cell UROGEN-I Decarboxvlase with 
Increasing Concentration of Enzyme Source. 
The activity of UROGEN-I decarboxylase was determined in human red 
blood cells using as enzyme source from 0,1 to 0,4 ml haemo"Jysate derived 
115 
from 14 the author of this thesis. C-UROGEN-I substrate was generated 
14 . . 
C-PBG by UROGEN-I synthetase, and reaction products of the de-from 
carboxylation were extracted by the method as described in Section 
5.5.(b) and (c). A linear increase in the activity was not observed 
with increasing amounts of haemolysate as shown in Fig. 39. 
(b) Activity of Rat Liver UROGEN-I Decarboxylase in the Presence of 
Increasing Concentrations of Haemoglobin. 
With a constant quantity of post-mitochondrial supernatant pre-
pared from a 1:5 w/v liver homogenate from an untreated rat as enzyme 
source, the activity of UROGEN-I decarboxylase was determined in the 
presence of increasing concentrations of electrophoretically pure 
human haemoglobin prepared by Mr. J. Rees of the Provincial Blood 
Grouping Laboratories, University of Cape Town Medical School, Cape 
Town. 
14
c-UROGEN substrate was generated from 14c-ALA using a mixture 
of ALA dehydratase and UROGEN-I synthetase. At the start of the second 
30 min,. incubation, from 10 to 56 mg haemoglobin contained in 0,3 ml 




and 0,1 ml post-mitochondrial supernatant. After termination of the 
reaction, the products were isolated by the alternative method described 
in Section 6.12. The activity of UROGEN-I decarboxylase relative to 
the protein concentration of the 32000 x g supernatant was not found to 
be constant in the presence of haemoglobin (Table 15). 
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mg haemoglobin 
Rel ati onshi p of the activity of human red blood ce 11 
UROGEN-I decarboxyl ase to the quantity of haemoglobin 
present in the assay. The 32000 xg supernatant of an 
haemolysate prepared from red blood cells of a non-
porphyric subject was used as enzyme source. 
TABLE 15 
iffect of Added Haemoglobin on the Activity of Rat Hepatic_ 
UROGEN-I Decarboxylase 
Quantity Haemoglobin added 





nmol UROGEN-I decarboxylated 
/hr/m Protein 






(The activity in the absence of haemoglobin is given as the mean 
of four determinations, with the range given in parenthesis. In 
view of the limited quantity of electrophoretically pure haemoglobin 
available for this experiment, all other values given are from single 
observations). 
(c) Activity of Rat Red Cell UROGEN-I Decarboxylase with Increasing 
CQncentration of Enzyme Sour~ 
Blood was obtained from an untreated anaesthetised female rat 
by cardiac puncture and an haemolysate was prepared as for human red 
blood cells. The activity of UROGEN-I decarboxylase was determined 
in rat erythrocytes using as enzyme source 0,02, 0,07 and 0,13 ml 
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haemolysate, with 
1 ~c;..UROGEN-I substrate generated from 14c-PBG 
by UROGEN-I synthetase~ Reaction products were extracted as detailed 
in Section 5.5.(b) ~nd (c). 
A linear increase in the activity was observed with increasing 
amounts of haemolysate containing up to 4 mg haemoglobin as shown in 
Fig. 40. Rat red blood cell haemolysates were found to have a low 
~ 
haemoglobin content when compared to human red cell haemolysates due 
to the fact that rat haemoglobin can be crystallised at pH 6,8(l 9) 
which is the pH of the buffer added before haemolysis. 
The observations detailed in (a)~(b) and (c) immediately pre-
ceeding indicate that high concentrations of haemoglobin may inter-
fere non-specifically in the assay for human red cell UROGEN-I 
decarboxy"lase activity. It is recognised that no definite conclusions 
can be made from merely 3 points. However the proportional increase 
in enzyme activity observed with increasing amounts of rat red blood 
cell haemolysate indicates that it may be possible to overcome the 
non-specific interference by haemoglobin on human red blood cell 
UROGEN-I decarboxyl ase by determination of the activity of the enzyme 
in haemolysates where haemoglobin concentration is low. 
(d) Human Red Blood C~ll UROGEN-I Decarboxylase Activity in Haemo-
q lob i tl-Free Haemo l.Y.s ate...! 
Haemoglobin-free haemolysates were prepared essentially according 
to the method of Hennessey et a1( 126 ). 
An haemolysate was prepared from 20 ml of the author 0s blood 
as detailed in Section 5.1£2.but the buffer used was 0,003M potassium 
phosphate, pH 7 ,0. The stroma-free haemolysate was divided equally 






























Relationship of the activity of rat red blood cell 
UROGEN-I decarboxylase to the quantity of haemoglobin 
present in the assay. The 32000xg supernatant of an 
haemolysate prepared from red blood cells of an un-
treated rat was used as enzyme source. 
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represents the treatment of one of the 5 ml sru~ples carried out at 
4°C. To 5 ml of haemolysate ·was added 5 ml of an aqueous suspension 
of Whatman DE 52 (diethylaminoethyl cellulose anion exchange resin, 
40g/liter, pH 7,0), and the mixture was allowed to stand at 4°c for 
20 min.~ with manual stirring approximately every 4 min. The unad-
sorbed material in the supernatant,principally haemoglobin which has 
an isoelectric point near neutrality, was separated by centrifugation .. 
for 15 min at 5000 x g, and residual haemoglobin was removed by wash-
ing the adsorbant 8 times with a total of 200 ml 0,003M phosphate 
buffer, pH 7,0. The final wash was colourless. 
The .enzyme protein fraction was desorbed from the DE 52 resin by 
adding 10 ml 0,5M KC1 and gently stirring the mixture magnetically for 
l hr in an ice bath. The supernatant fluid was collected by centri-
fugation at 5000 x g for 15 min. The adsorbant was washed twice more 
with 5 ml aliquots of 0,5M KCl. The combined supernatant from all 
three washes was dialysed overnight against O,lM tris:HCl, pH 6,8, 
following which the dialysate was concentrated to about 5 ml by plac-
ing the dialysis bag in concentrated polyethylene glycol 6000 solution. 
The activity of human red blood cell UROGEN-I decarboxylase 
was measured using as enzyme source from 0,1 to 0,4 ml of each of the 
four haemogfobin-free preparations. The 14c-UROGEN-I substrate was 
prepared by the action of a mixture of ALA dehydratase and UROGEN-I 
14 
synthetase on C-ALA. Analysis of the reaction products was performed 
by the alternative method described in Section 6. 12. As shown in Table 
16, considerable variation in the activity of red blood cell UROGEN-I 
decarboxylase, expressed as nmol UROGEN-I decarboxylated/hr/mg protein, 
was observed, both within a group where the same haemolysate preparation 
was used as enzyme source, and between the groups where different haemo-
119 
_ globin-free enzyme preparations from the Sillne original haemolysate 
were used as enzyme source. The former variation may be due to 
loss of enzyme stability in the dilute haemoglobin-free preparations, 
the protein concentration of which was found to range from 0,3 to 
0,5 mg/ml in the 4 preparations. The variation between groups might 
be due to varying recoveries of UROGEN-I decarboxylase from the anion 
exchange resin. 
JABLE 16 
Human Red Blood Cell UROGEN-I Decarboxylase Activity as Determined in 
Haemoglobin-Free Haemolysate 
Haemolysate I Volume of Haemolysate 






































D I S C U S S I 0 N 
In each of the 19 patients with clinical symptoms of PCT, 
investigations of their urinary, faecal and hepatic porphyrins 
fulfilled all the established diagnostic criteria for a positive 
unequivocal diagnosis of PCT(23,64,65,69,73,75,77,78,79,83,288). 
The controls who all had clinical and histological evidence of 
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ethanolic liver disease, simiiar to that present in patients with 
PCT, had negative screening tests for urinary and faecal porphyrins, 
and quanti tati on tests were therefore not performed. 
HCB is a known porphyrogenic compound which has produced an 
acquired PCT syndrome "in man ( 57 ' 251 ), and an experimenta 1 porphyri a 
in rats( 2l0, 252 ,253 ,255 ) which biochemically resembles PCT. The 
development of HCB porphyria in female rats over a period of 60 days 
at 15 day intervals was studied by analysis of urinary, faecal and 
he pa tic porphyri ns. 
Female rats were used throughout the study, since it has been 
shown that these are more susceptible to HCB than male rats{ll 2, 246 ). 
It was found that after 30 days treatment with HCB, the animals 
showed no significant porphyrinuria (Fig. 12b). After 45 days treatment 
it was found that there was a si gni fi cant increase in the excretion of 
urinary porphyrins, and furthermore, at this stage, the level of URO 
was about 3-fold greater than the level of COPRO. This finding corro-
borates that of Taljaard et al( 294 ), but is at variance with that of both 
Elder et al{SO) and Ockner and Schmid(2lO), who found that URO excretion 
exceeded that of COPRO only after approximately 60 days. The disparity 
may be caused by differences in the strain of rat, a different treatment 
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schedule or the age of the rat. In the studies of Ockner and 
Schmid(
2
l0) a male rat was used which ma,y account in part for the 
difference between their findings and those reported in this thesis. 
Hepatic URO accumulation in HCB-treated rats over the 60 day 
treatment period reflected the urinary URO excretion pattern. After 
30 days treatment with HCB, an increase was noted in the amount of 
URO accumulated in the livers, with further increases observed at 45 
and 60 days. Concomitantly, increases in he pa tic 7-COOH porphyri n 
content was observed, such that at these times the excess porphyrins 
were almost entirely URO and 7-COOH porphyrin. 
Hepatic porphyrins were not measurab'le in untreated rats by the 
methods used to quantitate hepatic porphyrins in the porphyric animals, 
but by using larger quantities of liver tissue, an indication of the 
pattern and quantity of hepatic porphyrins present in untreated rats 
might be obtained. 
/ 
Analysis of faecal porphyrins after 45 days treatment with HCB, 
i.e. at a time when the rats were porphyric, with the urinary porphyrin 
excretion pattern and the he pa tic porphyri n accumulation pattern c 1 ose ly 
resembling that found in human PCT, indicated the presence of a signifi- · 
cant quantity of the porphyrin P1 fraction, which is in agreement with 
the findings of Elder( 7s, 79 >. 
Iron appears to play a central role in the genesis of the PCT 
syndrome, since hepatic siderosis is an almost invariable finding in 
PCT{l43, 144, 161, 164, 186,250,307,311). Moreover, porphyrin excretion is 
decreased when removal of storage iron by venesection is used to effect 
clinical remission(B
9





) by oral iron ingestion. In the experimental porphyrias, iron 
has been observed to influence porphyrin biosynthesis at different levels 
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in the biosynthetic pathway. Iron as ferric citrate administered 
orally exerts a synergistic effect on AIA induction of ALA-S in 
rodent porphyria( 281 ), emphasising the importance of iron in the 
regulatory control of porphyrin biosynthesis. Kushner et al(lGl) 
have shown that in vitro ferrous iron inhibits UROGEN cosynthetase, 
which has been regarded as a possible explanation for the excess 
production and excretion of URO I in patients with PCT. 
Experimental hepatic siderosis in the rat due to dietary iron 
overload has been shown to result in urocoproporphyrinuria{ 266 ) which 
was further aggravated by concurrent drinking of ethanol. Further, 
rats ·previously rendered siderotic by intraperitoneal administration 
of i ron-Dextran deve 1 oped ·HCB-induced he pa tic porphyri a more rapidly 
than rats fed HCB alonJ294 , 295 ) and the porphyrin profile in the liver 
and urine resembled that seen in PCT. 
In the work presented here, a study was made of the effect of 
simultaneous treatment of rats with HCB and iron on the development 
of HCB porphyria. It was found after 30 days simultaneous treatment 
there was already significant uroporphyrinuria, but at this time the 
level of hepatic URO was very similar to that found in rats treated 
with HCB alone {Figs. l2a, 16). After 45 days treatment with HCB and 
iron, the large increase in hepatic URO was mirrored by a large in-
crease in ur"inary URO. The increase in urinary and hepatic URO at 
this time was more than tvrice that seen in rats treated with HCB alone. 
Kalivas et a1( 145 ), found that a single intraperitoneal injection of 
iron-dextran either before or after the onset of porphyria in HCB-
treated rats did not result in porphyrinuria of greater degree than that 
found in HCB-fed uninjected animals, although the rats were siderotic 
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after approximately 56 days treatment with the toxin. Similar ob-
servations to those reported in this thesis as regards the effect of 
HCB and iron on urinary porphyrin excretion have been made by Taljaard 
et a.1(294). 
A puzzling feature was noted in that in rats treated with HCB 
and iron simultaneously for 30 days, there was no stainable iron in 
the liver at a time at which rats given iron alone are markedly haemo-
1siderotic on light microscopy. A similar observation was made by 
Taljaard et al (294 ) who showed that in rats rendered siderotic before 
HCB feeding, there was a uniform distribution throughout the liver 
lobules, whereas following HCB ingestion, hepatic iron was depleted 
in the centri"lobular regions which are the first areas to show intense 
red porphyrin fluorescence. Further, it was observed in the present 
study that after 30 days total hepatic iron was increased more than 
two-fold in rats treated simultaneously with HCB and iron when compared 
with untreated rats, with no change from the increased level up to 
60 days treatment. A similar increased level of hepatic iron was ob-
served in a rat treated with iron alone. No significant increase in 
total hepatic iron content was observed in rats treated with HCB alone, 
which is at variance with the findings of Saunders et a1(250 ), who 
reported that HCB feeding resulted in the accumulation of iron in the 
1 i ver. 
There appear to be tv10 possible explanations to account for the 
absence of stainable iron in the livers of rats treated simultaneously 
with HCB and iron, at a time when the total hepatic iron content is 
elevated. Firstly, it is possible that HCB or HCB metabolites inter-
fere with the stain. The possible interference of HCB could be checked 
in vitro by addition of the staining reagents to a suspension of HCB in 
I 
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aqueous Tv1een 20 containing ferric iron. Interference by HCB 
metabolites would be more difficult to ascertain, since it is quite 
possible that these may be strongly bound in the liver. Secondly, 
he pa tic iron may be in the form of ferr·i tin and thus not detected 
after staining with Prussian blue. This could be checked by sub-
jecting the liver to electron microscopy, which might reveal the 
presence of ferritin. This second possibility lends itself to an 
attractive hypothesis to explain the absence of haemosiderin when 
total hepatic iron is elevated in HCB and iron-treated rats. 
Ferritin appears to be the precursor of haemosiderin that is formed 
when the rate of iron deposition exceeds the rate of apoferritin 
formation( 225 ). HCB or a metabolite might act in two ways, firstly 
to increase the rate of synthesis of apoferritin such that no haemo-
siderin is deposited, and secondly to increase mobilisation of stain-
able iron. The finding of Taljaard et al( 294 )of stainable hepatic 
iron depletion in the centrilobular areas in the !·!CB-fed rats pre-
viously rendered siderotic, might well be explained on ·this basis if 
some further cons·i derati ons are taken into account. It was demonstrated 
by Burger and Herdson(l7) that in the case of phenobarbital-induced 
rat liver, the centrilobular hepatocytes were the f1rst to be affected 
by the drug, with the characteristic cellular changes consisting of pro-
liferation of the smooth endoplasmic reticulum progressively involving 
more peripheral cells, such that after 3 days phenobarbital administra-
tion, the inner half of the liver lobule is profoundly transformed 
whereas the outer half is virtually unchanged( 199 ). HCB has been shown 
to cause an increase in smooth endoplasmic reticulum in rats treated 
with this toxin( 290). If the induction of microsomal proteins such 
as hepatic cytochrome P450 is taken to be indicative of proliferation 
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of smooth endoplasmic reticulum(45, 49,87,93,140,141,215~ 236) 
then HCB exerts its inductive effect more slowly, if it is considered 
that only after 20 days intoxication is there any marked increase in 
the levels of this haemprotein, as sho1tm in Section 6~4(e) of this 
thesis. Thus it might be expected that if HCB or a metabolite acted 
in such a way as to increase the mobilisation of stainable iron in 
the liver, the centrilobular areas would be the first areas to show 
a depletion in the quantity of stainable iron i.e. the quantity of 
haemosiderin, once th~ more readily available stored iron as ferritin 
became utilised in haem synthesis. It is recognised that in the treat-
ment ·of rodents simultaneously with HCB and iron in the long term, a 
maximal rate of synthesis of apoferritin might be attained, such that 
iron deposition as haernosiderin might occur. It is suggested that in 
view of the above considerations, further research into the effect of 
HCB on iron metabolism is warranted in order to understand more com-
pletely the mode of action of the toxin. 
The excessive hepatic synthesis and urinary excretion of URO and 
7;COOH porphyri n in the HCB-treated rat is highly i ndi ca ti ve of an 
impaired ability to decarboxylate UROGEN to COPROGEN, a reaction cata-
lysed by UROGEN decarboxylase. Previously, Taljaard et al (295 , 296 ) 
found no diminution in the activity of this enzyme in HCB-treated rats, 
whereas in rats previously rendered siderotic with iron-Dextran, 55 
days feeding almost abolished hepatic UROGEN decarboxylase activity. 
In the present investigation, it was found that 30 days treatment with 
HCB or HCB si rnultaneous ly with iron did not si gni fi cantly affect the 
activity of the enzyme, but at 45 days and at 60 days there was a si g-
ni fi cant decrease in the activity of UROGEN-I decarboxylase in both 
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groups of rats when compared to control animals. Recently, other 
workers have similarly found a decrease in HCB-fed rats(BO,Bl, 245 ). 
Elder et al(BO,Bl)have reported a progressive decrease in the activity 
of UROGEN decarboxylase during feeding with HCB, using as substrate 
5-COOH porphyrinogen on the assumption that a single enzyme is re-
sponsible for the 4 successive decarboxylations of UROGEN( 95 , 3oi)_ 
·In the present investigation, on comparing the activity of 
UROGEN-I decarboxylase (Fig. 36) with urinary porphyrin excretion 
(Figs. 12a,b), it appears that the activity of the enzyme is inversely 
related to porphyr"in excretion. Furthermore, if a single enzyme 
·is responsible for the stepvdse decarboxylation of UROGEN to COPROGEN, 
as the activity of UROGEN decarboxylase decreases, it was found in 
both the HCB- and HCB plus iron-treated rats, the porphyrins corres-
ponding to the substrate for, and intermediate:; of:Jthef~, reaction cata-
lysed by. the enzyme become more prominent in the urine (Fig. 13). 
From these results, it is suggested that the !-!CB-induced porphyri a 
is due to the decrease in the activity of this enzyme. 
The failure of Taljaard et al (295 , 296 ) to demonstrate a decrease 
in UROGEN decarboxyl ase "in rats treated with HCB for 55 days is at 
variance with the results presented in this thesis. These workers 
emphasised the focal nature of early HCB porphyria and suggested that 
the normal enzyme activity they observed in HCB-treated rats might 
represent the sum of decreased activity in porphyri c hepatocytes and 
compensatory increased activity in surrounding unaffected cells( 143 ). 
Alternatively, the differences bebJeen the present findings and those 
of Taljaard et a1(295 •296 ) may be related to differences in sensitivity 
of the methods employed for the measurement of UROGEN-I decarboxyl ase. 
Furthermore, these workers were unab 1 e to measure the activity of the 
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enzyme in their HCB and iron-treated rats( 295 , 296 ) whereas the 
present investigation revealed reduced enzyme activity. This may 
well be due to the fact that in the method used for the assay of 
UROGEN-I decarboxylase in this study, reaction products other than 
COPRO can be demon$trated, viz. 7-, 6- and 5-COOH porphyrinogens. 
It was found in this study that large amounts of URO and 7-COOH 
porphyrin accumulated in the livers both of rats treated with HCB 
and those treated simultaneously with HCB and iron. A decrease in 
the activity of he pa tic UROGEN-I decarboxyl ase would be expected to 
lead to an accumulation of porphyrinogens. If the rate and pattern 
of urinary and faecal porphyri n excretion is compared to the rate 
and pattern of hepatic porphyrin accumulation in the HCB-treated rat, 
then it becomes apparent that the liver selectively retains a pro-
portion of the more hydrophilic porphyrins. Thus, the maximum com-
bined rate of he pa tic URO and 7-COOH accumulation found in this study 
was approximately 28µg/g liver/15 days, or about l9µg/24 hours (Fig.16, 
Table 4), if the weight of rat liver is taken to be lOg. If the 
method used for the recovery of URO and 7-COOH porphyrin from the 1 i ver 
wereonly 10% efficient, instead of the 60% efficiency of recovery of 
URO found (Section 6.12), the maximum combined rate of accumulation 
of these por~hyrins would be about 190µg/24 hours. Elder et al{BO) 
have indicated that in HCB-treated rats, total urinary and faecal 
porphyrin excretion amounts to some 1,3 to 1,9 mg/24 hours, which in-
cludes large quantities of 4-, 5- and 6-COOH porphyrins, as well as URO 
and 7-COOH porphyrin. Thus it is clear that the porphyrins stored in 
the liver do not represent the pattern of overproduction of inter-
mediates in HCB-induced porphyria in the rat. Moreover, storage of 
porphyrin is compatible with initial accumulation as porphyrinogens 
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followed later by oxidation. 
On the basis of the observation that there is little difference 
in the decreased activity of hepatic UROGEN I decarboxylase after 45 
and 60 days of treatment \'Jith either HCB alone or HCB simultaneously 
with iron {Fig. 36), it appears unlikely that iron accelerates the on-
sc~t of porphyri a in the rat if the mani festati ans of HCB porphyri a are 
attributed to a decreased activity of UROGEN decarboxyl ase. It is 
suggested that i ran potenti ates the effect of HCB as evidenced by 
increased urinary porphyrin excretion and increased hepatic porphyrins 
in rats treated simultaneously with HCB and iron, when compared to rats 
treated with HCB alone (Figs. 12, 16). Yet there are other considera-
tions to be taken into account. Kushner and associates( 161 ) have re-
ported that when iron is added to mitochondria-free crude liver 
extracts in vitro, an increased amount of porphyrin is synthesised, 
and in a later investigation, Kushner et al( 162 ) found the activity 
of he pa tic UROGEN decarboxyl ase to be decreased in liver extracts 
preincubated with ferrous i ran. Further, the findings of Shanley 
et a1(
266
) of urocoproporphyrinuria in experimental siderosis in the 
rat is indicative of increased porphyrin production. As shown in the 
present study, there appears to be a delay before the onset of porphyria 
in the HCB-fed rat. ihis might represent the time taken to accumulate 
a toxic dose of HCB, if this is indeed the porphyrogenic agent, or 
alternatively, the time taken for the formation of porphyrogeni c 
metabolites of HCB(lB3) if it is considered that HCB appears to be a 
slowly metabolised toxin which has been reported to be virtually inert 
in rabbits( 217 ). It is possible then that at an early stage of HCB 
intoxication in rats treated simultaneously with iron, a very low con-
centration of HCB metabolite(s) may potentiate the effect of iron on 
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porphyrin synthesis in vivo, and conversely, iron might potentiate 
the porphyrogenic effect of very low concentrations of HCB metabolite(s). 
If the liposome model of K6sz6 et al(lSS) is invoked, where HCB in-
creases membrane permeability, loss of intermediates in haem synthesis 
might occur, so that initially on treatment with HCB together with 
iron, increased excretion of porphyrin might be observed when compared 
to the case of rats treated with HCB alone. 
If the manifestations of HCB porphyria are direct consequences of 
decreased UROGEN decarboxylase activity, it may be important to esta-
blish the mechanism whereby HCB or porphyrogenic metabolites exert 
their effects. The simplest explanation of the results presented here 
would be that a metabolite of HCB directly inhibits the activity of 
UROGEN decarboxylase. 
Reports have been published which suggested that overproduction 
of ALA is the primary defect accounting for the biochemical abnormalities 
. . . (109 147 205 3051' rn all the hepatic porphyrias ' ' , . Thus, it was possible 
that diminished haem biosynthesis, with derepression of the rate-limiting 
enzyme ALA-S, might account for the elevated levels of URO and COPRO 
excreted in patients vv-ith PCT( 219 ). However, it may also be expected 
that a modest, barely d·iscernable increase in ALA-S activity would 
similarly account for porphyrin overproduction in PCT, according to the 
deductions of Kaufman and Marver( 149 ), in which case another enzymatic 
step may become rate-limiting, i.e. at the UROGEN synthetase level. The 
activity of hepatic ALA-Sin patients with PCT has been measured by a 
number of investigators( 66 ' 149 , 168 ,204 , 283 ,285 ,328)but conflicting re-




), the enzyme assay used was limited by the small quantity of 
liver obtained, resulting in an inability to separate enzymatically 
' 
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generated ALA quantitatively from another enzymatically generated 
aminoketone, aminoacetone. Further characterisation of ALA is 
crucial since normal and porphyric liver mitochondria contain amino-
acetone synthetase, with the product of the reaction, ami noacetone, 
giving the same colour reaction with Ehrlichs reagent as ALA( 3o5, 3lo). 
Moreover, under the con di ti ons of the assay used, human liver produces 
about five times more aminoacetone than it does AL1A (3o5), and it has 
been found that in nonporphyric subjects there is a substantial varia-
tion in the activity of aminoacetone synthetase( 3o5). It is possible 
then, that under certain physiological or pathological conditions, the 
activity of this enzyme may be elevated. It is for these reasons that 
on measuring the activity of ALA-S in liver, it is absolutely impera-
tive that ALA and aminoacetone are separated before quantitation. 
In view of the contradictory results obtained for the activity of 
hepatic ALA-S in PCT, a highly specific radiochemical assay which dis-
cri mi nates ALA from other ami noketones 1i ke ami noacetone, was adapted 
from the method of Strand et a 1 (285 ) to measure ALA-S activity in the 
livers of patients with PCT and nonporphyrics. Two modifications to 
the method of Strand et a1( 285 ) were made. Firstly, dithiothreitol was 
used in place of glutathione in the incubations since better reproduci-
bility was obtained with the former .. It is possible that the commercial 
gl utathi one preparation used in some of the pre 1 iminary experiments con-
tained an impurity v1hi ch interfered in the assay. Secondly, a 1 ower 
concentration of succinate including {1,4 - 14c} - succinate was employed, 
resulting in a high specific activity succinate as substrate. It is 
recognised that this may not be the optimal substrate concentration for 
maximal incorporation of radioactive succinate into ALA( 134 , 285 ), but 
use of a lower specif'ic activity substrate under the conditions of the 
assay employed in this study resulted in radioactivity recovered as 
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14c-ALA being only slightly greater than that found in the succinate 
blanks, using both human and rat liver as sources for ALA-S. In 
a comparative study, such as that in the present investigation, low 
radioactive counts may have resulted in data that might have been di f-
fi cult to interpret. The assay method used in this work was valid on 
three counts: . Firstly, the production of 14c-ALA increased linearly 
·with increasing amounts of rat liver up to 2 mg. Secondly, repro-
ducible results are obta.ined as evidenced by triplicate a~alysis in 
close agreement (within 10%). Thirdly, using the radiochemical 
microassay, it was demonstrated that the activity of ALA-S was increased 
in rats treated with AIA, which is in agreement with the findings of 
other investigators( 2, 20,l 9l, 249 ) who in general measured ALA produc-
tion from approximately 250 mg liver using colorimetric methods. 
The activity of hepatic ALA-S was not found to be significantly 
different in PCT and nonporphyric controls. This supports the data 
of Strand et al( 283, 285 ) and Kaufman and Marver(l 49 ), but is at 
variance with the results of Dm\ldle et a1( 66 ), Levere( 168), Moore et 
al( 204) and Zail and Joubert( 328 ). Three possible explanations for 
the disparity of results have been considered. Firstly, the difference 
may be due to the . fact that ·different methods of assay were used: 
in this study, those of Strand et al (283 , 285 ) and Kaufman and Marver(l 49 ) 
ALA was discriminated from aminoacetone. In other reports, total 
ami noketone production \'las assumed to represent ALA. The selection 
of nonporphyric controls may offer a second explanation for the dis-
parity as the majority of patients in this group had alcoholic liver 
disease. Alcohol has been shown to stimulate ALA-S activity in rodents 
(265 , 266 ), which may explain in part why the hepatic ALA-S activity 
in the non-porphyri c patients was greater than that observed by other 
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investigators. Indeed, Shanley et al {265 ) have intimated that 
ALA-S activity may be normal in patients with PCT if they have not 
recently imbibed alcohol. Finally, a modest increase in hepatic 
ALA-S, not si gni fi cantly greater than norma 1, may adequately account 
for increased porphyrin excretion in PCT, according to the calculations 
of Kaufman and Marver(l 49 ). 
An unexpected finding in PCT was the highly significant elevation 
of the levels of hepatic cytochrome P450, when compared to those found 
in nonporphyric controls and in other hepatic porphyrias such as 





in PROTO and haem biosynthesis might account for the 
pattern of porphyrin excretion in this condition. PCT is the only 
pathological condition "in which the levels of hepatic cytochrome P450 
are significantly elevated. 
There appear to be three possible explanations to account for the 
elevated levels of cytochrome P450 in PCT. Firstly, the result may be 
due to ah artefact. Secondly, increased amounts of cytochrome P450 
may reflect increased hepatic synthesis of haem and cytochrome P450 
apoprotein, or increased formation of cytochrome P450 apoprotein with 
diversion of an already depleted haem pool to apoprotein. The third 
possibility is that there may be stabilisation of cytochrome P450 
with decreased degradation. 
It appears unlikely that the elevated levels of cytochrome P450 
found in PCT are due to an artefact. If the increase in the levels 
of the haemoprotein was due to the formation of a complex which resembled 
cytochrome P450 in spectral properties, then it might be surmised that 
in view of the hepatic accumulation of, principally, UR0( 23 , 64 , 65 ) and 
the almost invariable finding of hepatic siderosis in PCT{l 43 , 144, 16l, 
164, 186,250,307,311) 
URO might combine with haemosiderin to yield 
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that complex. However on testing this possibility by measuring 
cytochrome P450 levels in siderotic rat livers in the presence of 
URO I, such that the URO I concentration corresponded to up to 
SOOµg/g liver, the levels of this cytochrome were not increased. 
The possibility that the measurement of levels of hepatic cyto-
chrome P450 in whole liver homogenates, the technique used in the 
studies on PCT and nonporphyric livers, does not give a true reflection 
of mi crosoma 1 1eve1 s of this haemoprotei n, was discounted by a number 
of observations. In the first place, levels of hepatic cytochrome 
P450 \'/ere compared between patients with PCT and nonporphyric controls, 
using approx·irnately the same concentrations of liver in the determin-
ations. Secondly, using rat liver homogenates, a linear increase in 
levels of the haemoprotein \Vere found with increasing concentrations 
of liver, up to 10 mg. Al"I determinations of levels of hepatic cyto-
chrome P450 were made within this linear range. Thirdly, consistent 
results using liver homogenates were obtained. Finally, it has been 
reported that the levels of cytochrome P450 are elevated in the hepatic 
microsomes of rats treated with HCB{l?S, 231 , 282 , 290, 3oa) and in those of 
rats treated with phenobarbita1{1 27 , 2·i 5, 237 ). In the present investi-
gation, levels of hepatic cytochrome P450 as measured in microsomes and 
in homogenates from the same rats which were either untreated, treated 
with HCB for 45 days, or treated with phenobarbital, were compared. Sig-
nificant increases in the levels of the haemoprotein in rats treated with 
HCB and phenobarbi tone when compared to untreated rats were found in 
both microsomes and in homogenates and furthermore, these increases were 
of the same order of magnitude by both methods of determination (Table 8). 
It \\las observed that in rats treated with HCB, levels of cytochrome 
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were significantly increased after 20 days with an increase after 
30 days, then further increases were noted at 45 and 60 days treat-
ment. Stanard and Nenov( 282 ) have reported an initial fourfold 
rise in levels of cytochrome P450 after 10 days HCB treatment followed 
by a decrease with the levels increased about twofold above that of 
the controls at 15 days. The cytochrome P450 content remained at 
this level up to 30 days. Rajantanick-am et, al (231 ) showed a striking 
increase in the amount of cytochrome P450 during the initial 3 days 
of HCB treatment with a smaller increase over and above this after 15 
days. These workers found that the level of the haemoprotein remained 
constant for the remainder of the treatment period, i.e. up to 29 days. 
Lissner et al {l
75
) have studied the effect of HCB-feeding for up to 100 
days on he pa tic cytochrome P450 and have observed similar results to 
those reported in this th1;sis, i.e. an initial increase, a plateau where 
the levels remained re 1 ati ve ly constant, fo 11 mved by a further increase 
in the levels of the haemoprotein. 
In this investigation it was observed that 45 days feeding with 
HCB resulted in elevated levels of cytochrome P450 (Fig. 23), decreased 
UROGEN decarboxylase activity (Fig. 36), elevated urinary porphyrin 
excretion, with more URO than COPRO excreted by this route (Fig. 12), 
significant levels of the porphyrin P1 fraction in the faeces (Fig. 14) 
and the accumulation of virtually exclusively URO and 7-COOH porphyrin 
in the liver {Fig. 15). These data are consistent with the findings of 
increased hepatic cytochrome P450 {Fig 22, Table 7), the porphyrin ex-
cretory and accumulation pattern (Fig. 11, Table 3), and the diminished 





);n human PCT. The observations that levels of hepatic cyto-
chrome P450 were increased in both PCT and in HCB-treated rats despite 
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the deficiency in the liver of UROGEN-I decarboxylase{1 59 ,l60,this 
thesis) suggest that the haem pool in these conditions is initially 
not rate limiting in the format·ion of the microsomal haemoprotein. 
This would correlate well i-1ith data{ 52 ) which imply that the primary 
and rate-limiting event during induction of cytochrome P450 is the 
induction of its apoprotein, and moreover that apo-cytochrome P450 
may control the rate of haem biosynthesi s under these conditions (219 ). 
Thus in a situation in which apo-cytochrome P450 might have accumu-
lated, haem precursor overproduction and excretion could be expected 
to accompany accelerated formation of cytochrome P450 when haem syn-
thesis is impaired. 
Yet there are other data that should be considered. It has been 
' shown in this thesis that the activity of hepatic ALA-S in PCT was 
not si gni fi cant1.Y different from that found in nonporphyri c controls, 
although leve·ls of cytochrome P450 were significantly elevated in 
PCT. There have been reports which have indicated con di ti ans where 
amounts of cytochrome· P450 increase without any change in ALA-S 
activity: in neotatal rats adrninistrat·ion of phenobarbital increases 
the levels of cytochrome P450 without affecting ALA-S activity{ 278 ); 
in fed adult rats, phenobarbital brings about a similar effect( 24 ). 
Further, Rajamanickam et al{ 231 ) have reported that initially on feeding 
rats with HCB, the rate of cytochrome P450 synthesis is greater than 
that of total haem synthesis, which indicates that even under conditions 
where an enhanced rate of total haem synthesis is not discernable, there 
may be a significant channelling of the available haem tO\•tards cyto-
chrome P450. It was suggested that the primary effect of HCB was to 
enhance the rate of apo-cytochrome P450 synthesis( 231 ). The above 
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situations where the levels of cytochrome P450 increase without any 
change in ALA-S activity were in rats that were non-porphyric. Hhen 
the animal becomes porphyric, it may be expected that the liver is 
required to synthesise more porphyrins to achieve the same level of 
haem, and a modest increase in ALA-S activity might be anticipated. 
Rajamanickam et al(
231
) have found this to be the case and have re-
ported a sma 11 i ncreaSE! in the activity of ALA-S, as HCB porphyri a in 
the rat develops. 
If in both PCT and HCB-porphyria there is accumulation of apo-
cytochrome P450, a situation might arise where thereis an increase 
in the levels of cytochrome P450 as haem is drawn from the regulatory 
haem pool. If the postulates of Bissell and Hammaker( 20) are con-
s·; de red, where the regulatory hepatic haem pool is fed by both endoge-
nous haem synthesis and di ssoci ati on of haem from cytochrome P450 
prior to its degradation, then initially there may be derepression of 
ALA-S, leading to an increase in the activity of the enzyme. This 
increase need be only modest to account for increased haem synthesis. 
With enhanced haem synthesis the regulatory haem pool would become 
augmented and further haem would be provided for cytochrome P450 syn-
thesis. The overall result would be a further increase in cytochrome 
P450, assuming there is st"ill excessive apocytochrome P450 present. 
The haem moiety of cytochrome P450 would feed the regulatory haem pool 
with concomittant repression of ALA-S activity. The possibility exists 
that in PCT and HCB-porphyria there may be continual induction of apo-
cytochrome P450, so that the pattern outlined above is repetitive, which 
may account for the increased cytochrome P450 levels noted in PCT and 
the continual increment of the haemoprotein observed in HCB-treated rats. 
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It is unlikely that as suggested'recently by Elder et al(Bl), the 
fall in UROGEN decarboxylase activity in HCB-treated rats initially 
. limits the rate of haem synthesis to decrease hepatic haem concentra-
tions, so that there is a derepression of ALA-S activity, with con-
. 
sequent increased production of haem precursors to maintain haem syn-
thesis at the required ·ievel. The increasing levels of cytochrome 
P450 during HCB-feeding found in this study and that of Lissner et al {1?5) 
suggests that there is in fact accelerated haem synthesis. It is sug-
gested that in both PCT and HCB-porphyria, the decrease in UROGEN de-
carboxyl ase activity·is an event vvhich follows accelerated haem synthe-
sis. ·Thus, under these conditions there may be overproduction of the 
i ni ti a 1 and intermediate substrates for UROGEN decarboxyl ase to main-
tai n the rate of COPROGEN formation - and hence haem synthesis - at an 
elevated level when the activity of UROGEN decarboxylase is decreased. 
Recently, Elder et al (S
2
) have emphasised the importance of the con-
sideration of the probable relative activities of the enzymes of haem 
bi osynthesi s. These workers have suggested that 'in hereditary copro-
porphyri a, where the activity of COPROGEN oxidase is decreased, that 
normal rates of hepatic haem synthesis would be maintained if the con-
centration of substrate i.e. COPROGEN III, normally lower than the 
apparent Km va 1 ue, is increased, so that the rate of formation of pro-
duct approached its max·imum. The required increase in COPROGEN III 
concentration may be achieved at the expense of increased 1 oss of this 
intermediate from the pathway. It is suggested that in this situation 
the activity of UROGEN·-I synthetase may become rate limiting, if it is 
considered that the activity of the enzyme is so low in human liver 
(0~018 nmol porphyrin formed/h/mg protein( 283 ) compared \'lith the basal 
rate of haem synthesis of 0,016 nmol/h/mg protein(82 )) that the rate of 
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UROGEN formation prevents compensation of the COPROGEN oxi dase de-
fect by substrate accumulation when the demand for haem synthesis is 
increased. It has been suggested(82 ) that three factors determine 
whether an enzyme defect di sta 1 to UROGEN synthetase can be compen-
sated by an increase in substrate concentration when hepatic haem 
synthesis is stimulated: the activity of the defective enzyme, the 
. relationship between the substrate concentration and the Km value, 
and the extent to which substrate concentration can be increased with-
out enhancing loss from the pathway. If it is considered that in 
PCT the activity of the defective enzyme, UROGEN decarboxylase, is 
high (0,2 - 1,0 nmol porphyrin formed/h/mg protein( 159 ,l 60)) relative 
to the requ·irement for haem synthesis, with a slow rate of loss of 
UROGEN from the hepatocyte( 273 ), increases in substrate concentration 
can occur, so that the rate of formation of product is increased. 
On spectral analys·i s, the carbon monoxide-binding haemoprotein 
in both PCT and HCB-porphyri a showed apparent peaks at 448 nm (Section 
6.5.), which is similar to the microsomal cytochrome induced by the 
polycyclic aromat"ic hydrocarbon 3-methylcho l anthrene ( 6, 274 ). Further 
definitive spectral characterisation of the haemoprotein in PCT was 
hampered by the limited amount of liver tissue available for study. 
Study of the ethy'I i socyani de.binding spectra of he pa tic mi crosomes 
from untreated and HCB·-treated rats revealed that the 455 nm and 430 
nm peaks were of equal hei gilt at pH 7 ,52 for the untreated rats and 
at pH 7, 28 for the HCB··treated rats. . Lui et a 1 ( 183) have reported 
a value of pH 7,52 in phenobarbital-treated rodents, and pH 7,42 in 
rats treated w·i th HCB for 35 days. The results obtained in the present 
study are interpreted to indicate a greater admixture of a spectrally 
distinct haemoprotein, cytochrome P448, which is formed during induction 
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with HCB. The carbon-monoxide difference spectra in PCT suggest 
the possibility of a similar greater admixture of P448. 
The functional nature of the increased cytochrome P450 was 
explored by examination of the ability of liver tissue from patients 
with PCT and rats treated with HC8 for 45 days, a time at which HCB 
porphyria in the rodents closely resembled,biochemically, human PCT 
(Figs. 11, 12b, 13,14, 15, 16,22,23,24) to metabolise drugs in vitro. 
The metabolism of aminopyrine and 3,4-benzpyrene were studied, since 
it has been shown that cytochrome P450, which is ·induced by pheno-
barbi ta 1, enhances the metabolism of both ami nopyri ne .and 3,4-benz-
pyrene, whereas cytochrome P448 which is induced by 3-methyl chol an-
threne) enhances the metabolism of 3,4-benzpyrene but not that of 
aminopyrine(
105
). In vitro drug metabolism studies were performed 
using liver homogenates in place of hepatic microsomes as the source 
of the hepatic m·ixed function oxidase system. These studies were 
performed with quantities of liver which were within the range where 
the rate of product formation increased linearly \·Jith increasing liver 
concentration (Section 6.6.(a)). 
In rats fed with HCB for 45 days, the mean apparent Km for 
aminopyrine N-demethylation was about 3-fold with an approximate 2-fold 
increase in the maximal velocity, when compared to that observed in 
untreated animals. The apparent Km for 3,4-benzpyrene hydroxylation 
was found to be increased about 4-fold and the maximal velocity in-
creased approximately 25-fo 1 d in the HCB-treated rats when compared to 
the control animals. Alvares et al( 5) have reported that in 3-methyl-
cholanthrene-treated rodents, the apparent Km for 3,4-benzpyrene hydroxy-
lation by liver microsomes is decreased, whereas the maximal velocity 
for the reaction rises about 3-fold \'Jhen compared to the values obtained 
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in control animals. The lower Km obtained by these workers{ 5) 
suggests that the induced cytochrome p44g{lOS) has a higher affinity 
for 3,4-benzpyrene, thereby differing· from the naturally occurring 
cytochrome P450. The greater Km values found for both aminopyrine 
N-demethyl ati on and 3,4-benzpyrene hydroxylation in HCB-treated rats 
suggests the presence of an induced haemoprotein which has a lower 
affinity for both substrates. However, the ~ values are apparent 
~values and may be influ(:rnced by non-specific binding to proteins 
{l0
2
), which may be an important consideration as it has been shown 
(
3os) that in HCB-treated rats hepatic microsomal protein levels 
are increased. Moreover, nonspecific binding may in part account 
for the lmiJer Km for 3,4-benzpyrene hydroxylation found in this study 
in untreated animals v1hen compared to that found by Alvares et al (S). 
These investigators performed determinations using liver microsomes, 
whereas in the present investigation, liver homogenates were used. 
The increased maxima·! velocity values for both aminopyrine N-demethyla-
tion and 3,4-benzpyrene hydroxylation found in HCB-treated rats are 
not inconsistent with the induction of both cytochromes P450 and P448. 
The latter might be ·induced to a greater extent to account for the 
greater elevation in the maximal velocity for 3,4-benzpyrene hydroxyla-
tion in these animals and furthermore, studies of ethyl isocyanide-
binding to the haemoprotei n "in HCB-fed rats indicate a greater amount 
of the spectrally distfoct cytochrome P448. 
An alternative possibility which might explain the kinetics of 
e 
he pa tic ami nopyri ne tf-derdthyl ati on and 3, 4-benzpyrene hydroxylation in 
HCB-fed rats may be that the toxin is responsible for the induction of 
a different form of cytochrome P450, \-Jhich has different catalytic 
propert"ies to those of either cytochrome P450 or cytochrome P448. 
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This mecha~i~m has been proposed to account for the inductive 
( 181) 
effect of pregnenolone-16-a-carbonitrile pretreatment of rats 
In the studies on PCT liver tissue, however, no significant 
differences were observed in Km on maximal velocity for hepatic 
3,4-benzpyrene hydroxylation and ami nopyrine N-demethyl ati on when 
compared to similar in vitro data in non-porphyric controls (Figs. 
28,29). The interindividual differences in enzyme kinetics exhibited 
a wide range, which is consistent with other sfudies(~ 5 , 3 1 2 , 313 ). 
Large differences "in the rates of oxi dat·i on of ethyl morphine by human 
l ·i ver mi crosomes derived from different pa ti en ts were reported by 
Davies et al(
55
). It was further suggested by these investigators(55 ) 
that interindividual diffe1~nces in the pl~sma half-lives of lipid 
soluble drugs such as ant·ipyrine, phenylbutazone and oxyphenbutazone 
may be due at least in part to the varying activities of the cyto-
throme P450-dependent drug oxidising systems. Vesell and Page< 312 ' 
313 )ob~erved larger differences in the metabolic dispositions of phenyl-
butazone and antipyr"ine in fraternal twins when compared to that seen 
in monozygotic twins. Thus, genetic factors might make it impossible 
to distinguish small yet significant correlations betvJeen hepatic 
cytochrome P450 levels and drug metabolism in patients with PCT, varie-
gate porphyria and protoporphyria. Indeed, Al~ares et al( 4) were unable 
to detect the expected retardation of the metabolism of phenyl butazone 
or antipyrine in lead-poisoned children, where haemsynthesis is inhibited, 
when compared to randomly selected controls. This was demonstrable only 
when the patients were used as their own controls i.e. by removal of 
the genetically determined variables. Treatment which reversed lead 
inhibition of haem synthesis resulted in an increase in the rate of 
plasma disappearance of the two drugs. 
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From the above observations it becomes evident that when 
studies are performed in a heterogeneous, unrelated group of people, 
difficulty is encountered when relating in vitro drug metaboli~m to 
increased hepatic levels of, or a different form of, cytochrome P450. 
It might be possible to use patients with PCT as their own controls 
to correlate drug metabolism with levels of cytochrome P450 by investi-
gation of the parameter before and after phlebotomy, when no distur-
bance of porphyrin rr.etabolism is evident. However, repeated biopsy 
cannot be justified under any circumstances in patients who have re-
covered and do not require liver biopsy for diagnostic purposes. 
Jt might be expected that in view of the elevated levels of 
hepatic cytochrome P450 found in patients with PCT, proliferation of 
the smooth endoplasmic reticulum would be observed, since in experi-
w.ental animals, induction of microsomal haemqproteins by HCB, pheno-
barbital, progesterone or other compounds, is associated with a 
marked proliferat·ion of liver microsomes(45 , a7, 93 , 140,141,142,215, 
236,290) 
However, on comparing the amounts of smooth endoplasmic 
reticulum in the hepatocytes of patients with PCT with those found in 
variegate porphyri a and protoporphyri a, where there was no elevation 
in the levels of hepatic cytochrome P450 (Table 7, Fig. 22), no signi-
ficant difference was observed( 22 , 23). The finding that the quantity 
of hepatic smooth endoplasmic reticulum in PCT varied from cell to cell, 
suggests that differences in the amounts found in this syndrome and in 
variegate porphyri a and protoporphyri a might become more apparent by 
electron microscopic mapping of large sheets of cells. 
Light microscopy of the livers of patients with PCT showed simi-
lar damage to that which has been previously described( 164 , 298 , 299 , 31 1). 
Fluorescence microscopy indicated a patchy and diffuse distribution of 
porphyrins in the liver samples, which confirms the findings of 
other investigators(BB,l 43 , 279 ). 
In the literature, there appears to be little evidence that 
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PCT may be a purely inherited form of porphyria. The family study 
by Holt·i and associates( 132 ), referred to in a review by Beattie and 
Goldberg(l
6
) represents on closer scrutiny a typical instance of 
variegate porphyri a and thus cannot be quoted to support the existence 
of hereditary PCT. It was suggested by Redeker( 233 ) that cutaneous 
symptoms could be hereditary but this was d·iscounted by Schmid in the 
same discussion on the basis of stool porphyrin analysis not being 
available. Later, t4elland et al (324 ) described PCT in only one mem-
ber of a pair of homozygous twins. Haegar-Aronson( 120 ) has reported 
PCT in 3 members of one family, and another family in which 4 members 
were affected. Investigations by Eales( 74 ) of 133 relations of 22 
PCT patients revealed only one case of familial PCT involving a father 
and daughter, both alcoholics, and prior to this survey only 4 other 
instances of familial involvement have been documented in South Africa 
(
74
) Of note in these i nvesti gati ons was the fact that no more than 
-2 members of one family were cases of PCT. 
In 1974, it was suggested by Kushner{lSB) that idiosyncratic PCT 
might be an overt manifesti:'ltion of an autosomal dominantly inherited 
defect in UROGEN decarboxylase activity. Diminished levels of activity 
of this enzyme were observed in hepatic tissue( 159 ) and in red blood 
cells{lSS) of patients with PCT. In a more recent report, Kushner 
et al{l
6
0) have extended their studies in that multiple examples of de-
creased · erythrocyte UROGEN decarboxyl ase activity were detected in 
asymptomatic members of families of patients with PCT. In addition
9 
these workers ( 160) reported that the mean erythrocyte enzymatic activity 
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was greater in males than in females in both patients and in normal 
subjects. In the present investigation using similar assay condi-
tions to those of Kushner et a1(1SB,l 60) it was found that red blood 
cell UROGEN-I decarboxyiase was not significantly different in non-
porphyric controls when compared with patients with active PCT (Fig. 
35). In the two fam"ily studies presented in this thesis where the 
proposi ti had overt PCT, there did not. appear to be defi ni ti ve evi-
dence of a genetically determined deficiency of UROGEN decarboxylase 
(Fig. 34). In addition, the activity of the enzyme in erythrocytes 
did not appear to be influenced by the sex of the patients (Fig. 35). 
In the assay for red blood cell UROGEN decarboxylase the activity 
of the enzyme is measured in the presence of a large excess of haemo-
globin. Hennessey ·et a1(1 26 ) have found an approximate 20-fold ex-
cess of haemoglobin over other soluble proteins in human red blood 
ce 11 haemolysates. Thus, the excess of haemoglobin over UROGEN de-
carboxylase will be many-fold greater than this. It was considered 
that haemog"lobin might interfere with the determination of red cell 
UROGEN decarboxy1ase. This possibility was checked in two ways. 
Firstly, the effect of increasing quantities of haemolysate,derived 
from the red blood ce 11 s of the author of this thesis, on the activity 
of erythrocyte UROGEN~·I decarboxylase was investigated. A linear . 
increase in enzyme activity was not observed (Fig. 39). Secondly, 
the effect of increasing quantities of electrophoretically pure 
human haemoglobin on the activity of rat liver UROGEN-I decarboxylase 
was investigated using a constant quantity of post-mitochondrial super-
natant as enzyme source. The activity of the enzyme was not found to 
be constant under these conditions (Table 15). Thus it is suggested 
that under the con di ti ons of assay for red blood ce 11 UROGEN-I de car-
boxylase, there is non-specific interference by haemoglobin, and in view 
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of this both the results presented here and those of Kushner et 
al(l 60) should be interpreted with this in mind. Idiosyncratic 
PCT appears to occur sporadically in patients with common hepatic 
disorders( 219 ) so that the proposal by Kushner et al(l 60) based on 
studies of the activity of erythrocyte UROGEN-I decarboxylase in the 
presence of an excess of haemoglobin, that PCT may be due to an 
inherited defect "in UROGEN decarboxyl ase re qui res confirmation. 
An attempt was made to measure human red blood cell UROGEN-I 
decarboxylase in haemolysates in which the haemoglobin was removed 
by the method of Hennessey et al (1 26 ) .. However the results obtained 
were not consistent (Table 16). It must further be pointed out 
that when comparative stud·ies of UROGEN-I decarboxylase activity 
are to be carried out in PCT and in nonporphyric patients on haemo-
g"lobin-free 32000xg supernatants, there may be varying recoveries 
of UROGEN decarboxylase after separation, so that definitive con-
clusions as to the activity of the enzyme may be di ffi cu·1 t to reach. 
The observation, albeit on only 3 points, that the activity of rat 
red blood cell UROGEN-I decarboxylase increased in a linear fashion 
with increasing amounts of haemolysate {Fig. 40) indicates that the 
activity of the enzyme could be measured in highly diluted haemoly-
sates. Tht~ haemoglobin content of rat liver haemolysates was low, 
owing to the fact that rat haemoglobin largely crystallizes out at 
pH5,8( 19 ), the pH of the buffer added before haemolysis. If human 
red b 1 ood ce 11 UROGEN-I decarboxyl ase were to be measured in di 1 uted 
haemolysates using 14c-UROGEN-I as substrate and in a range where the 
activity increased linearly with increasing enzyme concentration, the 
initial substrate concentration should be similar to that used in the 
present work, i.e. 25 - 30 µmol/litre. Dilution of the haemolysate 
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would result in very much reduced decarboxylation of UROGEN-I, so 
that decarboxylation in reagent blanks would of necessity have to 
be as close to zero as possible to detect small yet significant de-
carboxy1 ati on of the substrate by the erythrocyte UROGEN decarboxy-
lase. Furthermore, in order to detect the anticipated reduced 
level of decarboxylation, the use of substrate of much greater 
specific activity would be necessitated. It is suggested that it 
might be possible to measure the enzyme act·ivity in diluted haemo-
lysates with no interference by haemoglobin, and moreover, to detect 
significant changes in activity in different situations by using 
pure synthetically prepared 14c-:UROGEN-I of high specific activity 
as substrate, rather than to generate 14c-UROGEN-I just prior to 
use. 
The augmentation of rat liver UROGEN-I decarboxylase activity 
in vitro by ferrous iron from concentrations of 0,01 to 2,00 mM 
has not been previously described {Fig. 37, Table 14). In addition, 
an increase in the activity of enzyme in the presence of 1,00 mM 
ferrous ammonium sulphate of a similar order of magnitude was ob-
served in the livers of rats treated for 45 days with HCB, i.e. a 
situation where the activity of UROGEN-I decarboxyl ase is decreased 
{Table 13). The observed increase in enzyme activity was real, 
si nee corrections were made in each observation for the effects of 
the same concentrations of ferrous i ran on non-enzymatic decarboxy-
1 ati ons and on the production of 14c-UROGEN-I substrate. 
It is probable that ferrous iron added in vitro directly acti-
vates UROGEN-I decarboxylase. Neither the biologically occurring 
iron compound, ferritin, nor 1, 10-phenanthroline, a ferrous chelator 
of high speci fi ci ty_( 275 ), had any si gni fi cant effect on the activity 
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of rat liver UROGEN-1 decarboxylase both in untreated rats and rats 
treated for 45 days with HCB. 
The finding that added iron in vitro enhances the activity of 
hepatic UROGEN-I decarboxylase is at variance with the findings of 
Kushner et a1( 162 ) who have reported inhibition of the enzyme in 
porcine liver extracts preincubated with ferrous ammonium sulphate. 
The disparity between the results reported here and those of Kushner 
et a1( 162 ) may be due to a different methodological approach since 
in the present work, ferrous iron was added at the beginning of the 
assay, and furthermore, these investigators( 162 ) did not indicate 
whether further substrate generation occurred during the course of 
incubation with crude liver extracts in the presence of ferrous 
iron. 
Results obtained dur"ing the course of i nves ti gati ons into the 
ac;tivity of hepatic UROGEN-I decarboxylase indicated that the meas-
ured activity when reaction products are extracted onto ta 1 c does 
not yi e 1 d an absolute- va 1 ue for the activity of the enzyme, owing to 
a differential in the extractability of porphyrin esters from talc. 
In the alternate method described in section 6.12 where the reaction 
products of UROGEN decarboxylation were first oxidised by light, 
followed by ester·ification with a large volume of 5% sulphuric acid 
in methanol with subsequent exhaustive extracticin of the porphyrin 
methyl esters from the esterification mixture of chloroform, two 
assumptions were made. First, it was assumed that equal proportions 
of each porphyrinogen were oxidised to the corresponding porphyrin 
by the action of light._ Second, it was assumed that equal proportions 
of the porphyrins in aqueous samples were esterified in the presence 




in PCT{lSS, 159 ) was not confirmed by investigation of the activity 
of the enzyme in red blood cells; neither was a deficiency in the 
activity of the enzyme detected in red blood ce 11 s of pa ti en ts with 
PCT. However, the assay system for the determination of UROGEN-I 
decarboxylase activity in red blood cells suffers a serious short-
coming in that the 1 arge excess of haemoglobin interferes in the 
assay in a non-specific manner. It is suggested that the activity 
of the enzyme should be reinvestigated in PCT, either in haemoglo-
bin-free haemolysates, or in diluted haemolysates along the lines sug-
gested previously,or in other extra-hepatic tissue e.g. skin fibro-
blast~, before any definitive statements can be made about an inherited 
defect. 
The role of iron in the genesis of PCT is a complicated one. 
It is possible that in PCT,as suggested from the studies on the devel-
opment of porphyri a "in the rat treated with HCB and i ran, the effect 
of i ran may be to potenti ate the porphyri c process. Hepatic iron 
may interfere with UROGEN cosynthetase activity, and additionally more 
UROGEN might be synthesised, if the in vitro findings of Kushner et 
a1{ 161 ) are extrapolated to the in vivo situat·ion. It is further 
possible that the effect of mobilisation of storage iron by venesection 
may be to remove this effect and addi ti ona lly increase the concentra-
tion of ferrous iron. The latter might activate UROGEN decarboxylase 
which has been found to be decreased in PCT(l 59 ,l 60), if the in vitro 
finding of au9mentati on of the activity of the enzyme by ferrous iron 
reported in this thesis is extended to man, such that biochemical re-
mission occurs. It may be worthwhile to investigate the effect of 
bleeding on the activity of hepatic UROGEN decarboxylase and porphyrin 
overproduction in rats treated simultaneously with HCB and intramus~ular 
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iron to test this possibility Additionally, if hepatic iron 
inhibits UROGEN cosynthetase activity{l 6l), the overproduction of 
predominantly the isomer series I porphyrins would be expected, so 
that it may be important to establish the nature of the isomer type 
in siderotic rats treated with HCB. 
The development of PCT should be viewed in relation to the levels 
of hepatic cytochrome P450, which are increased in this disease(this 
thesis, 22,23,220,221,222) 
It is an interesting possibility that the 
primary event in the genesis of the syndrome may be the induction of 
apo-cytochrome P450 which may be consequential to liver insult or injury. 
This ·would lead to increased cytochrome P450 formation and increased 
haem synthesis, as haem from the regulatory pool is channelled towards 
cytochrome P450. Moreover, there may be an over-response for the in-
creased demand for haem, resulting in haem precursor overproduction and 
excretion. Spectral studies on the binding of carbon monoxide to the 
induced hepatic cytochrome P450 tentatively suggest that both in PCT 
and in HCB-treated rats a similar alternative form of the haemoprotein 
may be induced. Further definitive studies were possible only in the 
HCB-i ntoxi cated rat, where ethyl ·i socyani de-binding studies indicated 
a greater admixture of a spectrally distinct haemoprotein. If the 
same form of cytochrome P450 is induced in PCT as in the HCB-fed rat, 
then by inference the induction of a different apoprotein to that found 
in untreated rats and in control patients, is indicated. It is interest-
ing to speculate that this induced apocytochrome may directly inhibit 
UROGEN decarboxylase or inhibit its synthesis, to result in the porphyrin 
overproduction pattern seen in PCT. Hepatic i ran may serve to poten-
ti ate porphyrin overproduction to produce the overt symptoms. 
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If the manifestations of PCT are considered secondary to the 
induction of a different form of apocytochrome P450, then it is 
possible that only in some susceptible patients will this apoprotein 
be induced when there is injury or insult to the liver. This may 
form a basis for explanation of the sporadic occurrence of PCT. 
Finally, it is hoped that this thesis has contributed towards 
the understanding of the metabolic basis for PCT, and will stimulate 




METHODS OF CALCULATION 
1. Hepatic ALA-S Activity 
nmol ALA forrned/h/g liver = [-abg- x 106 
1, 1 x 105 (c-a) efh 
Where a = counts per min in sample without internal standard 
b = disintegrations per min of added internal standard 
( i ) 
(ii ) 
~Jhere 
c = counts per min in sample after addition of internal standard 
e = volume (ml) of final eluate taken for counting 
f = absorbance at 556 nm of final eluate with Ehrlich mercury 
reagent 
g = absorbance at 556 nm of standard ALA-pyrrole with Ehrlich 
mercury reagent 
h = specif·ic activity of {l,4 - 14c} - succinic acid 
j = mg liver tissue present in assay 
k = abg for succinate blanks 
1,1 x l05(c-a)efh 
nmol P450/g liver = 6 (A450 - 8450) - (A490 - 8490) x lO 
91 x a 
nmol P450/mg protein = (A450 - B450 ) -
-~~~~~~~~~~~~~~~~-
91 x b 
A450 = absorbance at 450 nm in the difference spectra 
8450 = absorbance at 450 nm in the baseline 
A 490 :-:: absorbance at 490 nm in the difference spectra 
B490 = absorbance at 490 nm in the baseline 
a = concentration of liver in cuvettes (mg/ml) 
b = concentration of protein in cuvettes (mg/ml) 
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3. Hepatic Aminopyrine N-Demethylation 
nmol formaldehyde semicarbazone formed/hr/mg liver 
= 
Where 
4,9282 x 10-3 r {h ~ g) ] 
l- g J k 
a = counts per min in sample without internal standard 
b = di s·i ntegrati ans per min of added internal standard 
c = counts per min in sample after addition of internal 
standard 
d =volume {ml) of aqueous phase 
e = volume {ml) of aqueous phase taken for counting 
f = abd \ for sample blank 
~-- ( c-a)} 
g = nmol {dimethylamino - 14c} aminopyrine in incubation 
mixture 
h ·- nmol non-radioactive arninopyrine in incubation mixture 
j ==specific activity of {dimethylamino - 14c} aminopyrine 
k =mg liver tissue present in assay 
4. Hepatic 3,4-Benzpy.rerye Hydroxylation 




T1 =transmission reading for sample on 0,1 scale 
T2 =transmission reading for sample blank on 0,1 scale 
ui =mg liver tissue used in assay 
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5. UROGEN-I Decarboxylase Activity 
(i) nmol UROGEN-I decarboxylated/hr/mg haemoglobin 
) 
d = 2e 
c + d f 
(ii) nmol UROGEN-I decarboxylated/hr/mg protein 
= 
Hhere 
( ~b~ ) d 2e 
c + d g 
a =- counts per min in URO ester spot 
b = total counts per min in 7-, 6-, 5- and 4- COOH 
porphyrin ester spots 
c = counts per min in URO ester spot for blank 
d = total counts per min in 7-, 6-, 5- and 4-COOH 
porphyrin ester spots for blank 
e = nrnol UROGEN-I produced during assay = Absorbance at 560nm 
.007554 
f = mg haemoglobin present in assay 
g = mg protein present in assay 
6. C~ncentrati on of Porp!:Y-!i n Esters in Chloroform 
g porphyrin ester/1-iter = Dcorr x M.W. 
Where 
k. E: , x 
Dcorr = 2 Amax - (A380 + A430 ) with Amax the absorbance 
maxi mum between 400 and 410 nm, A380 the absorbance 
at 380 nm and A430 the absorbance at 430 nm. 
M.W. =molecular weight of porphyrin ester 
k. = absorbance correction factor , 
E = molar extinction coefficient 
Values used for M.W., ki and E are given in Table 17 for the esters 
in chloroform( 289 ). 
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TABLE 17 
FACTORS USED FOR CALCULATION OF PORPHYRIN ESTER CONCENTRATION 
IN CHLOROFORM 
~~~-~~~~~..;:...;..;.--.::.;..;.:: ·-~~~~~~~~~~~~~ 
Ester M.W. k. £ l 
" 
URO 943 1 '91 2,15 x 10 5 
COP RO 711 1,496 1,8 x 105 
PROTO 590 ls4043 l '71 x 105 
--·· 
7. Uri nary COP RO at!d URO (289 ) 
8. 
(i) µg COPRO/ml = [ 2 Amax - {A380 + A430 ) J x 0,932a 
b 
(ii) µg URO/ml 
Where 
= [ 2 Amax - (A380 + A430) J x 0,837 c 
b 
Amax = absorbance maximum between 400 and 410 nm 
A380 = Absorbance at 380 nm 
A430 = Absorbance at 430 nm 
a = total volume{ml)of 1,5N HCl extracts 
b = volume (ml) of urine taken for analysis 
c = total volume (ml) of 2% HC1 extracts 
Statistical Methods (277 ) 
( i) The mean (x) is given by 
(x) = E X -n 
\~here EX -- sum of all observati ans in the sample population 
n = number of observations 
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the sum of square of a 11 observat"i ans in 
the sample population 
square of the sum of all observations in 
the sample population 
(iii) Standard Error (S.E.) is given by 
S.E. s 
(iv) The signif'icance of difference between two mean values was 
Where 
ascertained using Student's t in a two-tailed test, with 
n1 + n2 - 2 degrees of freedom. 
x1 = mean value of observations in first sample 
population 
-x2 - mean value of observation in second sample 
population 
51 = standard deviation for first sample population 
S2 = standard deviation for second sample population 
n1 = number of observations in first sample population 
n2 = number of observations in second sample population 
The value of P was ascertained from tables. 
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, 
(v) The coefficients of regression (a and b) in the regression 
line whose equation is y = a + bx and the coefficient of 
2 
















Chemi ca·1 · Reagents and S12ecia 1 Items Used. in the Experimenta 1 Work_, 
together with Suppliers 
(All reagents were of the highest grade available, except where 
otherwise stated). 
Afrox, Maitland, Cape: 
Carbon Monoxide 
Beckman Instruments: 
Semi-microcuvettes, 1,5 ml capacity 
Biorad Laboratories, 32nd and Griffin Avenue, R"ichmond, California: 
Disposable polyethy"lene columns, 5,5 cm x l,O cm inside diameter, 
with reservoir 3,5 cm x 1,9 cm inside diameter. 





EDTA (ethylene d"iamino tetra-acet"ic acid, disodium salt) 
Ether (Laboratory Reagent) 








Talc fine powder 
Tris (Tris(hydroxymethyl)rnethylarnine) 
Eastman Kodak Company, Rochester, N.Y. 14650 U.S.A. 
Hexachlorobenzene {practical grade) 
Hach Chemical Company, P.O. Box 907, Ames, Iowa, 50010, U.S.A. 
Ferrozine 
Hopkin and Williams Ltd., Chadwell Heath, Essex, England: . 
DL-Malic Acid 
May and Baker, Dagenham, England: 
Acetic Acid (Glacial) 
Acetone 
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Ammonia Solution S.G. 0,9 27% w/w Jl.rrnnonia (Laboratory Reagent) 
Ascorbic Acid 
Carbon Tetrach"loride {Laboratory Reagent) 
Chloroform 
Cyclohexanone (Laboratory Reagent) 
Ethyl Iodide 
Ferrous Ammonium su·1 phate Hexahydrate 
Gardenal (Phenobarbitone Sodium) 
n-Hexane (Laboratory Reagent) 
Hydrochloric Acid 
_Hydrogen Peroxide 
Hydroxyl amine Hydro ch 1 ori de 
Magnesium c11 ·1 ori de 
Methanol (Laboratory Reagent) 









Sulph,ur·ic Acid (Laboratory Reagent) 
Trichloracetic Acid 
E. Merck, Darmstadt, Germany: 
p-Dimethylaminobenzaldehyde 
Dipotassium Hydrogen Phosphate 
Ethyl Propionate 
Neocuproin 
Potassium Dihydrogen Phosphate 
Potassium Iodide 
TLC Aluminium Sheets, Silica Gel 60, Layer Thickness 0,2 m.m. 
(without fluorescence indicator) 
Miles Laboratories, Epping, Cape: 
Bovine Serum Albumin (fraction V) 
Coenzyme A 
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Nutritional Biochemicals Corporation, Cleveland, Ohio, 44128, U.S.A.: 
Antimycin A 
Ortho Diagnostics, Raritan, New Jersey, 08869, U.S.A.: 
Aculute Diluent Pellets 
Acuglobin Hemoglobin Standard 
Packard Instrument Company 9 Inc., 220Q Warrenville Road, Downers Grove~ 
Illinois 60515, U.S.A.: 
Instagel Scintillator Fluid 
Porphyrin Products, P.O. Box 31, Logan, Utah, 84321, U.S.A.: 
Coproporphyrin III tetramethyl ester 
14c-Porphobilinogen 
Protoporphyri n IX dimethyl ester 
Uroporphyri n I 
Uroporphyrin III octamethyl ester 
Bacterial Uroporphyrinogen I synthetase 
Mixture of Bacterial Uroporphyrinogen I synthetase and 
ALA Dehydratase 
The Radiochemical Centre, Amersham, Buckinghamshfre, England: 
a-· {4 - 14c} Jl.minolaevulinic Acid Hydrochloride 
{dimethylamino - 14c} Aminopyrine 
{14c} Formaldehyde 
{14c} n-Hexadecane Reference Standard 
{l ,4 ·· 14C} Sucdn-Jc Acid 
Riedel de Haen, Seelze bei Hanover, Germany 
Iodine 
Saphar ML Laborator"ies (Pty) Ltd., Stephen Road,Ophirton,Johannesburg: 
Jectofer 
Sodium Chlor-ide Injection B.P. 0,9% (m/v) (Normal Saline) 
Sigma Chemical Company, P.O. Box 14508, St. Louis, Missouri, 63178,U;.S.A.: 
a-Amino l evu"li ni c Acid Hydro chloride 
ATP 
3,4-Benzpyrene 
Dithiothreitol (Clelands Reagent) 
( 
Dowex - l x 8 400 Chloride Form 
Dowex - 50 x 4 200 Acid Form 
Ferritin (100 mg/ml in 0,15M NaC~) 
Glucose"-6-Phosphate (disodium salt) 
Glucose-6-Phosphate Dehydrogenase (Torula Yeast XI) 
Malanie Acid (disodium salt) 
N A D 
NADP 







Amir:iopvr'in~ was a gift from Mr. N.M. Shapiro, Groote Schuur. 
Hospital and 3-Jl..Y~.Y_-:l:i..4-benzpyrene was a gift from Dr. H.V. Gelboin, 
National Cancer Institute, National Institutes of Health, Bethesda, 
Maryland, 20014, U.S.A. Dr. Bruce Burnham supplied a gift of 
. purified .bacterial suc~iD.il coenzY.J]l~~L .. 8 .. ~mthetase,. Allylisoprop.Y]-
acetamide was a gift from Roche Products, 4 Brewery Street, Isando, 
Transvaal. 
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